Method for the Production of Commercial Nanoparticle and Microparticle Powders

ABSTRACT

The present invention relates to methods for producing nanoparticle and microparticle powders of a biologically active material which have improved powder handling properties making the powders suitable for commercial use using dry milling processes as well as compositions comprising such materials, medicaments produced using said biologically active materials in particulate form and/or compositions, and to methods of treatment of an animal, including man, using a therapeutically effective amount of said biologically active materials administered by way of said medicaments.

RELATED APPLICATIONS

This application is a continuation of U.S. application Ser. No.15/387,541, filed on Dec. 21, 2016, which is a continuation of U.S.application Ser. No. 14/279,185, filed on May 15, 2014, which is acontinuation of U.S. application Ser. No. 13/265,933, filed on Mar. 9,2012, which is a U.S. national stage under 35 USC § 371 of InternationalApplication Number PCT/AU2010/000467, filed on 23 Apr. 2010, whichclaims priority to AU Application No. 2009901747, filed on 24 Apr. 2009and U.S. Application No. 61/172,300, filed on 24 Apr. 2009, the entirecontents of which applications is hereby incorporated by reference.

FIELD OF THE INVENTION

The present invention relates to methods for producing nanoparticle andmicroparticle powders of a biologically active material using drymilling processes, as well as compositions comprising such materials,medicaments produced using said biologically active materials inparticulate form and/or compositions, and to methods of treatment of ananimal, including man, using a therapeutically effective amount of saidbiologically active materials administered by way of said medicaments.Compositions of the present invention have unexpectedly improved powderhandling properties relative to compositions made by conventionaltechniques, making them advantageous for use in commercial applications.

BACKGROUND

Poor bioavailability is a significant problem encountered in thedevelopment of compositions in the therapeutic, cosmetic, agriculturaland food industries, particularly those materials containing abiologically active material that is poorly soluble in water atphysiological pH. An active material's bioavailability is the degree towhich the active material becomes available to the target tissue in thebody or other medium after systemic administration through, for example,oral or intravenous means. Many factors affect bioavailability,including the form of dosage and the solubility and dissolution rate ofthe active material.

In therapeutic applications, poorly and slowly water-soluble materialstend to be eliminated from the gastrointestinal tract before beingabsorbed into the circulation. In addition, poorly soluble active agentstend to be disfavored or even unsafe for intravenous administration dueto the risk of particles of agent blocking blood flow throughcapillaries.

It is known that the rate of dissolution of a particulate drug willincrease with increasing surface area. One way of increasing surfacearea is decreasing particle size. Consequently, methods of making finelydivided or sized drugs have been studied with a view to controlling thesize and size range of drug particles for pharmaceutical compositions.

For example, dry milling techniques have been used to reduce particlesize and hence influence drug absorption. However, in conventional drymilling the limit of fineness is reached generally in the region ofabout 100 microns (100,000 nm), at which point material cakes on themilling chamber and prevents any further diminution of particle size.Alternatively, wet grinding may be employed to reduce particle size, butflocculation restricts the lower particle size limit to approximately 10microns (10,000 nm). The wet milling process, however, is prone tocontamination, thereby leading to a bias in the pharmaceutical artagainst wet milling. Another alternative milling technique, commercialairjet milling, has provided particles ranging in average size from aslow as about 1 to about 50 microns (1,000-50,000 nm).

There are several approaches currently used to formulate poorly solubleactive agents. One approach is to prepare the active agent as a solublesalt. Where this approach cannot be employed, alternate (usuallyphysical) approaches are employed to improve the solubility of theactive agent. Alternate approaches generally subject the active agent tophysical conditions that change the agent's physical and or chemicalproperties to improve its solubility. These include process technologiessuch as micronization, modification of crystal or polymorphic structure,development of oil based solutions, use of co-solvents, surfacestabilizers or complexing agents, micro-emulsions, super-critical fluidand production of solid dispersions or solutions. More than one of theseprocesses may be used in combination to improve formulation of aparticular therapeutic material. Many of these approaches commonlyconvert a drug into an amorphous state, which generally leads to ahigher dissolution rate. However, formulation approaches that result inthe production of amorphous material are not common in commercialformulations due to concerns relating to stability and the potential formaterial to re-crystallize.

These techniques for preparing such pharmaceutical compositions tend tobe complex. By way of example, a principal technical difficultyencountered with emulsion polymerization is the removal of contaminants,such as unreacted monomers or initiators (which may have undesirablelevels of toxicity), at the end of the manufacturing process.

Another method of providing reduced particle size is the formation ofpharmaceutical drug microcapsules, which techniques include micronizing,polymerisation and co-dispersion. However, these techniques suffer froma number of disadvantages including at least the inability to producesufficiently small particles such as those obtained by milling, and thepresence of co-solvents and/or contaminants such as toxic monomers whichare difficult to remove, leading to expensive manufacturing processes.

Over the last decade, intense scientific investigation has been carriedout to improve the solubility of active agents by converting the agentsto ultra fine powders by methods such as milling and grinding. Thesetechniques may be used to increase the dissolution rate of a particulatesolid by increasing the overall surface area and decreasing the meanparticle size. U.S. Pat. No. 6,634,576 discloses examples of wet-millinga solid substrate, such as a pharmaceutically active compound, toproduce a “synergetic co-mixture”.

International Patent Application PCT/AU2005/001977 (NanoparticleComposition(s) and Method for Synthesis Thereof) describes, inter alia,a method comprising the step of contacting a precursor compound with aco-reactant under mechanochemical synthesis conditions wherein asolid-state chemical reaction between the precursor compound and theco-reactant produces therapeutically active nanoparticles dispersed in acarrier matrix. Mechanochemical synthesis, as discussed in InternationalPatent Application PCT/AU2005/001977, refers to the use of mechanicalenergy to activate, initiate or promote a chemical reaction, a crystalstructure transformation or a phase change in a material or a mixture ofmaterials, for example by agitating a reaction mixture in the presenceof a milling media to transfer mechanical energy to the reactionmixture, and includes without limitation “mechanochemical activation”,“mechanochemical processing”, “reactive milling”, and related processes.

International Patent Application PCT/AU2007/000910 (Methods for thepreparation of biologically active compounds in nanoparticulate form)describes, inter alia, a method for dry milling raloxifene with lactoseand NaCl which produced nanoparticulate raloxifene without significantaggregation problems.

Critical to the successful commercialization of such technology is theability to easily and cheaply process the materials into finalformulations such as tablets or hard gelatin capsules. Many of thetechnologies discussed above require the particles to be produced in aliquid suspension such that expensive and complicated further processingis needed to make common dry formulations such as tablets.

Some technologies such as micronization do produce material in a dryform, but the particles have inherently high cohesiveness and highstatic charge. This leads to poor product flow and high aggregationproperties. The product fails to flow smoothly into containers (such ascapsules) and aggregates significantly when poured. It also adheressignificantly to process equipment and containers, thus resulting in asignificant loss of product. One solution adopted by the prior art is tobind the material to a carrier product or to dissolve the material in asolution to improve product handling, but these steps add to the overallexpense of any process. Fukami et al (Fukami et al. A nanoparticleprocessing in solid state dramatically increases the cell membranepermeation of a cholesterol lowering drug, Probucol. Mol. Pharmaceutics,accepted Apr. 1, 2009) describe a process for manufacturingnanoparticles of probucol which has a number of limitations. Firstly,the nanoparticles produced by the Fukami process are sticky anddifficult to handle. Secondly, to overcome this problem the particleshad to be dispersed in water and spray coated onto a carrier particle.The spray coating process, which uses significant amounts of energy, isexpensive and adds to the overall cost of the manufacturing.

The present invention provides methods for overcoming the problemsidentified by the prior art by providing a milling process that producesnanoparticles or microparticles of a biologically active material withpowder handling characteristics superior to powders made by conventionalsize reduction processes.

One limitation of many of the prior art processes is that they are notsuitable for commercial scale.

The present invention provides methods for overcoming the problemsidentified by the prior art by providing a milling process that producessmall particles easily and economically even at high volume commercialscale.

One example of a therapeutic area where this technology could be appliedin is the area of acute pain management. Many pain medications such asmeloxicam (marketed as Mobic® by pharmaceutical company BoehringerIngelheim) provides pain relief for chronic pain, but must be taken on adaily basis to maintain an effective therapeutic level.

Meloxicam is a poorly water soluble drug which is only slowly absorbedby the body (Tmax is 4-5 hours), so a method such as the presentinvention which provides for improved dissolution, will likely providemuch faster absorption resulting in a more rapid onset of thetherapeutic effect. Meloxicam also has a long half life (15-20 hours)that means it only need be taken once a day. By using a method such asthe present invention, which provides faster absorption, a drug such asmeloxicam, could be transformed from a chronic pain drug to an acutepain drug. For meloxicam this would provide a medication that couldprovide therapeutic relief for acute pain, with the advantage ofsustained pain relief over 24 hours.

Meloxicam also has sub-optimal bioavailability at 89% for an oralcapsule, compared with an IV dosage form. A component of this suboptimal bioavailability is also likely due to the poor water solubilityof this drug. If the low solubility does contribute to this sub optimalbioavailability, the improvement of the dissolution of this drug with amethod such as the present invention could provide scope to produce adosage form with a lower active dose whilst still providing theeffective therapeutic dose.

Although the background to the present invention is discussed in thecontext of improving the powder handling characteristics of biologicallyactive materials that are poorly or slowly water soluble, theapplications of the methods of the present invention are not limited tosuch, as is evident from the following description of the invention.

Further, although the background to the present invention is largelydiscussed in the context of improving the powder handlingcharacteristics of therapeutic or pharmaceutical compounds, theapplications of the methods of the present invention are clearly notlimited to such. For example, as is evident from the followingdescription, applications of the methods of the present inventioninclude but are not limited to: nutraceutical and nutritional compounds,complementary medicinal compounds, veterinary therapeutic applicationsand agricultural chemical applications, such as pesticide, fungicide orherbicide.

Furthermore an application of the current invention would be tomaterials which contain a biologically active compound such as, but notlimited to a therapeutic or pharmaceutical compound, a nutraceutical ornutrient, a complementary medicinal product such as active components inplant or other naturally occurring material, a veterinary therapeuticcompound or an agricultural compound such as a pesticide, fungicide orherbicide. Specific examples would be the spice turmeric that containsthe active compound curcumin, or flax seed that contains the nutrientALA an omega 3 fatty acid. As these specific examples indicate thisinvention could be applied to, but not limited to, a range of naturalproducts such as seeds, cocoa and cocoa solids, coffee, herbs, spices,other plant materials or food materials that contain a biologicallyactive compound. The application of this invention to these types ofmaterials would enable greater availability of the active compound inthe materials when used in the relevant application. For example wherematerial subject to this invention is orally ingested the active wouldbe more bioavailable.

SUMMARY OF THE INVENTION

In one aspect, the present invention is directed to the unexpecteddiscovery of a dry milling process for producing small particles of amaterial, wherein the powders made by the dry milling process of thepresent invention have powder handling characteristics that are superiorto those of powders made by conventional size reduction processes. In apreferred form of the invention, the material is a biologically activematerial. In one surprising aspect this can be done at commercial scale.In one surprising aspect the particle size produced by the process isequal to or less than 10,000 nm. In one surprising aspect the particlesize produced by the process is equal to or less than 5,000 nm. In onesurprising aspect the particle size produced by the process is equal toor less than 2000 nm. In another surprising aspect the particle sizeproduced by the process is equal to or less than 1000 nm. In anothersurprising aspect the crystallinity of the active material is unchangedor not substantially changed.

Thus in a first aspect, the invention comprises a method for producingnanoparticle and/or microparticle biologically active material withpowder handling characteristics superior to powders made by conventionalsize reduction processes wherein the said method comprises the steps ofdry milling a solid biologically active material and a millable grindingmatrix in a mill comprising a plurality of milling bodies, for a timeperiod sufficient to produce particles of the biologically activematerial dispersed in an at least partially milled grinding material.Preferably the biologically active material has a particle size lessthan 10,000 nm Preferably, the powder handling characteristics of thebiologically active material produced by this invention are superior tothe powder handling characteristics of a biologically active materialwith the same, similar or larger particle size manufactured using aconventional process. Preferably, the biologically active materialsubject to this invention has superior product flow characteristiccompared to the product flow characteristic of a biologically activematerial with the same, similar or larger particle size manufacturedusing a conventional process. Preferably, the the biologically activematerial subject to this invention has a lower static charge compared tothe static charge of a biologically active material with the same,similar or larger particle size manufactured using a conventionalprocess. Preferably, the biologically active material subject to thisinvention has a lower cohesiveness profile compared to the cohesivenessprofile of a biologically active material with the same, similar orlarger particle size manufactured using a conventional process.Preferably, the biologically active material subject to this inventionhas a lower propensity for aggregation compared to the propensity foraggregation of a biologically active material with the same, similar orlarger particle size manufactured using a conventional process.Preferably, the biologically active material subject to this inventionhas a lower propensity for adherence to other materials compared to thepropensity for adherence of a biologically active material with thesame, similar or larger particle size manufactured using a conventionalprocess. Preferably, the biologically active material subject to thisinvention has increased uniformity compared to a biologically activematerial with the same, similar or larger particle size manufacturedusing a conventional process. Preferably, the biologically activematerial subject to this invention has reduced levels of dust comparedto a biologically active material with the same, similar or largerparticle size manufactured using a conventional process. Preferably, thebiologically active material subject to this invention has improvedrheology compared to a biologically active material with the same,similar or larger particle size manufactured using a conventionalprocess. Preferably, the biologically active material subject to thisinvention has reduced segregation compared to a biologically activematerial with the same, similar or larger particle size manufacturedusing a conventional process. Preferably, the biologically activematerial subject to this invention has increased bulk density or tappedbulk density compared to a biologically active material with the same,similar or larger particle size manufactured using a conventionalprocess. Preferably, the biologically active material subject to thisinvention has superior powder flow as defined by the Hausner ratio orCarr's index compared to a biologically active material with the same,similar or larger particle size manufactured using a conventionalprocess. Preferably, the biologically active material subject to thisinvention has lower compressibility compared to a biologically activematerial with the same, similar or larger particle size manufacturedusing a conventional process. Preferably, the biologically activematerial subject to this invention has increased permeability comparedto a biologically active material with the same, similar or largerparticle size manufactured using a conventional process. Preferably, thebiologically active material subject to this invention has a higherminimum ignition energy compared to a biologically active material withthe same, similar or larger particle size manufactured using aconventional process. Preferably, the biologically active materialsubject to this invention has higher hopper flow rates compared to abiologically active material with the same, similar or larger particlesize manufactured using a conventional process. Preferably, thebiologically active material subject to this invention has smallercritical orifice diameter compared to a biologically active materialwith the same, similar or larger particle size manufactured using aconventional process. Preferably, the biologically active materialsubject to this invention has smaller angle of repose compared to abiologically active material with the same, similar or larger particlesize manufactured using a conventional process. Preferably, thebiologically active material subject to this invention has smallerdynamic angle of repose compared to a biologically active material withthe same, similar or larger particle size manufactured using aconventional process.

In a second aspect, the invention comprises a method for producing ablend containing nanoparticle and/or microparticles of biologicallyactive material with powder handling characteristics superior to a blendmade by conventional methods, wherein the said method comprises thesteps of dry milling a solid biologically active material and a millablegrinding matrix in a mill comprising a plurality of milling bodies, fora time period sufficient to produce particles of the biologically activematerial dispersed in an at least partially milled grinding material. Inone embodiment, the blend has a median particle size, determined on aparticle volume basis, equal or greater than a size selected from thegroup consisting of: 20,000 nm, 15,000 nm, 10,000 nm, 8000 nm, 6000 nm,5000 nm, 4000 nm, 3000 nm and 2000 nm. In another embodiment, the blendhas a median particle size, determined on a particle volume basis equalor less than 50 micron. In another embodiment, the blend has a volumeweighted mean (D4,3) equal or greater than a size selected from thegroup consisting of: 40,000 nm, 30,000 nm, 20,000 nm, 15,000 nm, 10,000nm, 8000 nm, 6000 nm and 5000 nm. In another embodiment, the blend has avolume weighted mean (D4,3) equal or less than 70 micron. In anotherembodiment, the percentage of particles in the blend, on a particlevolume basis, is selected from the group consisting of: greater than 2micron (%>2 micron) is selected from the group 50%, 60%, 70%, 80%, 85%,90% and 95%; greater than 10 micron (%>10 micron) is selected from thegroup 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 85%, 90% and 95%; equal toor less than 20 micron (%<20 micron) is selected from the group 10%,20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95% and 100%.

In another preferred embodiment, the average particle size of thebiologically active material, determined on a particle number basis, isequal to or less than a size selected from the group consisting of,10,000 nm, 8000 nm, 6000 nm, 5000 nm, 4000 nm, 3000 nm, 2000 nm, 1900nm, 1800 nm, 1700 nm, 1600 nm, 1500 nm, 1400 nm, 1300 nm, 1200 nm, 1100nm, 1000 nm, 900 nm, 800 nm, 700 nm, 600 nm, 500 nm, 400 nm, 300 nm, 200nm and 100 nm. Preferably, the average particle size is equal to orgreater than 25 nm.

In another preferred embodiment, the particles of the biologicallyactive material have a median particle size, determined on a particlevolume basis, equal or less than a size selected from the groupconsisting of 20,000 nm, 15,000 nm, 10,000 nm, 8000 nm, 6000 nm, 5000nm, 4000 nm, 3000 nm, 2000 nm, 1900 nm, 1800 nm, 1700 nm, 1600 nm, 1500nm, 1400 nm, 1300 nm, 1200 nm, 1100 nm, 1000 nm, 900 nm, 800 nm, 700 nm,600 nm, 500 nm, 400 nm, 300 nm, 200 nm and 100 nm. Preferably, themedian particle size of the biologically active material is equal to orgreater than 25 nm. Preferably, the percentage of particles, on aparticle volume basis, is selected from the group consisting of: 50%,60%, 70%, 80%, 90%, 95% and 100% less than 20,000 nm (%<20,000 nm).Preferably, the percentage of particles, on a particle volume basis, isselected from the group consisting of: 50%, 60%, 70%, 80%, 90%, 95% and100% less than 10,000 nm (%<10,000 nm). Preferably, the percentage ofparticles, on a particle volume basis, is selected from the groupconsisting of: 50%, 60%, 70%, 80%, 90%, 95% and 100% less than 5000 nm(%<5000 nm). Preferably, the percentage of particles, on a particlevolume basis, is selected from the group consisting of: 50%, 60%, 70%,80%, 90%, 95% and 100% less than 2000 nm (%<2000 nm). Preferably, thepercentage of particles, on a particle volume basis, is selected fromthe group consisting of: 50%, 60%, 70%, 80%, 90%, 95% and 100% less than1000 nm (%<1000 nm). Preferably, the percentage of particles, on aparticle volume basis, is selected from the group consisting of: 0%,10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95% and 100% less than 500nm (%<500 nm). Preferably, the percentage of particles, on a particlevolume basis, is selected from the group consisting of: 0%, 10%, 20%,30%, 40%, 50%, 60%, 70%, 80%, 90%, 95% and 100% less than 300 nm (%<300nm). Preferably, the percentage of particles, on a particle volumebasis, is selected from the group consisting of: 0%, 10%, 20%, 30%, 40%,50%, 60%, 70%, 80%, 90%, 95% and 100% less than 200 nm (%<200 nm).Preferably, the Dx of the particle size distribution, as measured on aparticle volume basis, is selected from the group consisting of lessthan or equal to 10,000 nm, 5000 nm, 3000 nm, 2000 nm, 1900 nm, 1800 nm,1700 nm, 1600 nm, 1500 nm, 1400 nm, 1300 nm, 1200 nm, 1100 nm, 1000 nm,900 nm, 800 nm, 700 nm, 600 nm, 500 nm, 400 nm, 300 nm, 200 nm, and 100nm; wherein x is greater than or equal to 90.

In another preferred embodiment, the crystallinity profile of thebiologically active material is selected from the group consisting of:at least 50% of the biologically active material is crystalline, atleast 60% of the biologically active material is crystalline, at least70% of the biologically active material is crystalline, at least 75% ofthe biologically active material is crystalline, at least 85% of thebiologically active material is crystalline, at least 90% of thebiologically active material is crystalline, at least 95% of thebiologically active material is crystalline and at least 98% of thebiologically active material is crystalline. More preferably, thecrystallinity profile of the biologically active material issubstantially equal to the crystallinity profile of the biologicallyactive material before the material was subjected to the method asdescribed herein.

In another preferred embodiment, the amorphous content of thebiologically active material is selected from the group consisting of:less than 50% of the biologically active material is amorphous, lessthan 40% of the biologically active material is amorphous, less than 30%of the biologically active material is amorphous, less than 25% of thebiologically active material is amorphous, less than 15% of thebiologically active material is amorphous, less than 10% of thebiologically active material is amorphous, less than 5% of thebiologically active material is amorphous and less than 2% of thebiologically active material is amorphous. Preferably, the biologicallyactive material has no significant increase in amorphous content aftersubjecting the material to the method as described herein.

In another preferred embodiment, the milling time period is a rangeselected from the group consisting of: between 10 minutes and 2 hours,between 10 minutes and 90 minutes, between 10 minutes and 1 hour,between 10 minutes and 45 minutes, between 10 minutes and 30 minutes,between 5 minutes and 30 minutes, between 5 minutes and 20 minutes,between 2 minutes and 10 minutes, between 2 minutes and 5 minutes,between 1 minutes and 20 minutes, between 1 minute and 10 minutes, andbetween 1 minute and 5 minutes.

In another preferred embodiment, the milling medium is selected from thegroup consisting of: ceramics, glasses, polymers, ferromagnetics andmetals. Preferably, the milling medium is steel balls having a diameterselected from the group consisting of: between 1 and 20 mm, between 2and 15 mm and between 3 and 10 mm. In another preferred embodiment, themilling medium is zirconium oxide balls having a diameter selected fromthe group consisting of: between 1 and 20 mm, between 2 and 15 mm andbetween 3 and 10 mm. Preferably, the dry milling apparatus is a millselected from the group consisting of: attritor mills (horizontal orvertical), nutating mills, tower mills, pearl mills, planetary mills,vibratory mills, eccentric vibratory mills, gravity-dependent-type ballmills, rod mills, roller mills and crusher mills. Preferably, themilling medium within the milling apparatus is mechanically agitated by1, 2 or 3 rotating shafts. Preferably, the method is configured toproduce the biologically active material in a continuous fashion.

Preferably, the total combined amount of biologically active materialand grinding matrix in the mill at any given time is equal to or greaterthan a mass selected from the group consisting of: 200 grams, 500 grams,1 kg, 2 kg, 5 kg, 10 kg, 20 kg, 30 kg, 50 kg, 75 kg, 100 kg, 150 kg, 200kg.

Preferably, the total combined amount of biologically active materialand grinding matrix is less than 2000 kg.

In another preferred embodiment, the biologically active material isselected from the group consisting of: fungicides, pesticides,herbicides, seed treatments, cosmeceuticals, cosmetics, complementarymedicines, natural products, vitamins, nutrients, nutraceuticals,pharmaceutical actives, biologics, amino acids, proteins, peptides,nucleotides, nucleic acids, additives, foods and food ingredients andanalogs, homologs and first order derivatives thereof. Preferably, thebiologically active material is selected from the group consisting of:anti-obesity drugs, central nervous system stimulants, carotenoids,corticosteroids, elastase inhibitors, anti-fungals, oncology therapies,anti-emetics, analgesics, cardiovascular agents, anti-inflammatoryagents, such as NSAIDs and COX-2 inhibitors, anthelmintics,anti-arrhythmic agents, antibiotics (including penicillins),anticoagulants, antidepressants, antidiabetic agents, antiepileptics,antihistamines, antihypertensive agents, antimuscarinic agents,antimycobacterial agents, antineoplastic agents, immunosuppressants,antithyroid agents, antiviral agents, anxiolytics, sedatives (hypnoticsand neuroleptics), astringents, alpha-adrenergic receptor blockingagents, beta-adrenoceptor blocking agents, blood products andsubstitutes, cardiac inotropic agents, contrast media, coughsuppressants (expectorants and mucolytics), diagnostic agents,diagnostic imaging agents, diuretics, dopaminergics (anti-parkinsonianagents), haemostatics, immunological agents, lipid regulating agents,muscle relaxants, parasympathomimetics, parathyroid calcitonin andbiphosphonates, prostaglandins, radio-pharmaceuticals, sex hormones(including steroids), anti-allergic agents, stimulants and anoretics,sympathomimetics, thyroid agents, vasodilators, and xanthines.Preferably, the biologically active material is selected from the groupconsisting of: indomethacin, diclofenac, naproxen, meloxicam,metaxalone, cyclosporin A, progesterone and estradiol or any salt orderivative thereof.

In another preferred embodiment, the grinding matrix is a singlematerial or is a mixture of two or more materials in any proportion.Preferably, the single material or a mixture of two or more materials isselected from the group consisting of: mannitol, sorbitol, Isomalt,xylitol, maltitol, lactitol, erythritol, arabitol, ribitol, glucose,fructose, mannose, galactose, anhydrous lactose, lactose monohydrate,sucrose, maltose, trehalose, maltodextrins, dextrin, Inulin, dextrates,polydextrose, starch, wheat flour, corn flour, rice flour, rice starch,tapioca flour, tapioca starch, potato flour, potato starch, other floursand starches, milk powder, skim milk powders, other milk solids andderivatives, soy flour, soy meal or other soy products, cellulose,microcrystalline cellulose, microcrystalline cellulose based co blendedmaterials, pregelatinized (or partially) starch, HPMC, CMC, HPC, citricacid, tartaric acid, malic acid, maleic acid fumaric acid, ascorbicacid, succinic acid, sodium citrate, sodium tartrate, sodium malate,sodium ascorbate, potassium citrate, potassium tartrate, potassiummalate, potassium ascorbate, sodium carbonate, potassium carbonate,magnesium carbonate, sodium bicarbonate, potassium bicarbonate andcalcium carbonate. dibasic calcium phosphate, tribasic calciumphosphate, sodium sulfate, sodium chloride, sodium metabisulphite,sodium thiosulfate, ammonium chloride, Glauber's salt, ammoniumcarbonate, sodium bisulfate, magnesium sulfate, potash alum, potassiumchloride, sodium hydrogen sulfate, sodium hydroxide, crystallinehydroxides, hydrogen carbonates, ammonium chloride, methylaminehydrochloride, ammonium bromide, silica, thermal silica, alumina,titanium dioxide, talc, chalk, mica, kaolin, bentonite, hectorite,magnesium trisilicate, clay based materials or aluminium silicates,sodium lauryl sulfate, sodium stearyl sulfate, sodium cetyl sulfate,sodium cetostearyl sulfate, sodium docusate, sodium deoxycholate,N-lauroylsarcosine sodium salt, glyceryl monostearate, glyceroldistearate glyceryl palmitostearate, glyceryl behenate, glycerylcaprylate, glyceryl oleate, benzalkonium chloride, CTAB, CTAC,Cetrimide, cetylpyridinium chloride, cetylpyridinium bromide,benzethonium chloride, PEG 40 stearate, PEG 100 stearate, poloxamer 188,poloxamer 338, poloxamer 407 polyoxyl 2 stearyl ether, polyoxyl 100stearyl ether, polyoxyl 20 stearyl ether, polyoxyl 10 stearyl ether,polyoxyl 20 cetyl ether, polysorbate 20, polysorbate 40, polysorbate 60,polysorbate 61, polysorbate 65, polysorbate 80, polyoxyl 35 castor oil,polyoxyl castor oil, polyoxyl 60 castor oil, polyoxyl 100 castor oil,polyoxyl 200 castor oil, polyoxyl 40 hydrogenated castor oil, polyoxyl60 hydrogenated castor oil, polyoxyl 100 hydrogenated castor oil,polyoxyl 200 hydrogenated castor oil, cetostearyl alcohol, macrogel 15hydroxystearate, sorbitan monopalmitate, sorbitan monostearate, sorbitantrioleate, Sucrose Palmitate, Sucrose Stearate, Sucrose Distearate,Sucrose laurate, Glycocholic acid, sodium Glycholate, Cholic Acid,Soidum Cholate, Sodium Deoxycholate, Deoxycholic acid, Sodiumtaurocholate, taurocholic acid, Sodium taurodeoxycholate,taurodeoxycholic acid, soy lecithin, phosphatidylcholine,phosphatidylethanolamine, phosphatidylserine, phosphatidylinositol,PEG4000, PEG6000, PEG8000, PEG10000, PEG20000, alkyl naphthalenesulfonate condensate/Lignosulfonate blend, Calcium DodecylbenzeneSulfonate, Sodium Dodecylbenzene Sulfonate, Diisopropylnaphthaenesulphonate, erythritol distearate, Naphthalene SulfonateFormaldehyde Condensate, nonylphenol ethoxylate (poe-30),Tristyrylphenol Ethoxylate, Polyoxyethylene (15) tallowalkylamines,sodium alkyl naphthalene sulfonate, sodium alkyl naphthalene sulfonatecondensate, sodium alkylbenzene sulfonate, sodium isopropyl naphthalenesulfonate, Sodium Methyl Naphthalene Formaldehyde Sulfonate, sodiumn-butyl naphthalene sulfonate, tridecyl alcohol ethoxylate (poe-18),Triethanolamine isodecanol phosphate ester, Triethanolaminetristyrylphosphate ester, Tristyrylphenol Ethoxylate Sulfate,Bis(2-hydroxyethyl)tallowalkylamines. Preferably, the concentration ofthe single (or first) material is selected from the group consisting of:5-99% w/w, 10-95% w/w, 15-85% w/w, of 20-80% w/w, 25-75% w/w, 30-60%w/w, 40-50% w/w. Preferably, the concentration of the second orsubsequent material is selected from the group consisting of: 5-50% w/w,5-40% w/w, 5-30% w/w, of 5-20% w/w, 10-40% w/w, 10-30% w/w, 10-20% w/w,20-40% w/w, or 20-30% w/w or if the second or subsequent material is asurfactant or water soluble polymer the concentration is selected from0.1-10% w/w, 0.1-5% w/w, 0.1-2.5 w/w, of 0.1-2% w/w, 0.1-1%, 0.5-5% w/w,0.5-3% w/w, 0.5-2% w/w, 0.5-1.5%, 0.5-1% w/w, of 0.75-1.25% w/w, 0.75-1%and 1% w/w.

Preferably, the grinding matrix is selected from the group consistingof:

-   -   (a) lactose monohydrate or lactose monohydrate combined with at        least one material selected from the group consisting of:        xylitol; lactose anhydrous; microcrystalline cellulose; sucrose;        glucose; sodium chloride; talc; kaolin; calcium carbonate; malic        acid; trisodium citrate dihydrate; D,L-Malic acid; sodium        pentane sulfate; sodium octadecyl sulfate; Brij700; Brij76;        sodium n-lauroyl sacrosine; lecithin; docusate sodium;        polyoxyl-40-stearate; Aerosil R972 fumed silica; sodium lauryl        sulfate or other alkyl sulfate surfactants with a chain length        between C5 to C18; polyvinyl pyrrolidone; sodium lauryl sulfate        and polyethylene glycol 40 stearate, sodium lauryl sulfate and        polyethylene glycol 100 stearate, sodium lauryl sulfate and PEG        3000, sodium lauryl sulphate and PEG 6000, sodium lauryl        sulphate and PEG 8000, sodium lauryl sulphate and PEG 10000,        sodium lauryl sulfate and Brij700, sodium lauryl sulfate and        Poloxamer 407, sodium lauryl sulfate and Poloxamer 338, sodium        lauryl sulfate and Poloxamer 188; Poloxamer 407, Poloxamer 338,        Poloxamer 188, alkyl naphthalene sulfonate        condensate/Lignosulfonate blend; Calcium Dodecylbenzene        Sulfonate (Branched); Diisopropyl naphthalenesulphonate;        erythritol distearate; linear and branched dodecylbenzene        sulfonic acids; Naphthalene Sulfonate Formaldehyde Condensate;        nonylphenol ethoxylate, POE-30; Phosphate Esters,        Tristyrylphenol Ethoxylate, Free Acid; Polyoxyethylene (15)        tallowalkylamines; sodium alkyl naphthalene sulfonate; sodium        alkyl naphthalene sulfonate condensate; sodium alkylbenzene        sulfonate; sodium isopropyl naphthalene sulfonate; Sodium Methyl        Naphthalene; Formaldehyde Sulfonate; sodium salt of n-butyl        naphthalene sulfonate; tridecyl alcohol ethoxylate, POE-18;        Triethanolamine isodecanol phosphate ester; Triethanolamine        tristyrylphosphate ester; Tristyrylphenol Ethoxylate Sulfate;        Bis(2-hydroxyethyl)tallowalkylamines.    -   (b) lactose anhydrous or lactose anhydrous combined with at        least one material selected from the group consisting of:        lactose monohydrate; xylitol; microcrystalline cellulose;        sucrose; glucose; sodium chloride; talc; kaolin; calcium        carbonate; malic acid; trisodium citrate dihydrate; D,L-Malic        acid; sodium pentane sulfate; sodium octadecyl sulfate; Brij700;        Brij76; sodium n-lauroyl sacrosine; lecithin; docusate sodium;        polyoxyl-40-stearate; Aerosil R972 fumed silica; sodium lauryl        sulfate or other alkyl sulfate surfactants with a chain length        between C5 to C18; polyvinyl pyrrolidone; sodium lauryl sulfate        and polyethylene glycol 40 stearate, sodium lauryl sulfate and        polyethylene glycol 100 stearate, sodium lauryl sulfate and PEG        3000, sodium lauryl sulphate and PEG 6000, sodium lauryl        sulphate and PEG 8000, sodium lauryl sulphate and PEG 10000,        sodium lauryl sulfate and Brij700, sodium lauryl sulfate and        Poloxamer 407, sodium lauryl sulfate and Poloxamer 338, sodium        lauryl sulfate and Poloxamer 188; Poloxamer 407, Poloxamer 338,        Poloxamer 188, alkyl naphthalene sulfonate        condensate/Lignosulfonate blend; Calcium Dodecylbenzene        Sulfonate (Branched); Diisopropyl naphthalenesulphonate;        erythritol distearate; linear and branched dodecylbenzene        sulfonic acids; Naphthalene Sulfonate Formaldehyde Condensate;        nonylphenol ethoxylate, POE-30; Phosphate Esters,        Tristyrylphenol Ethoxylate, Free Acid; Polyoxyethylene (15)        tallowalkylamines; sodium alkyl naphthalene sulfonate; sodium        alkyl naphthalene sulfonate condensate; sodium alkylbenzene        sulfonate; sodium isopropyl naphthalene sulfonate; Sodium Methyl        Naphthalene; Formaldehyde Sulfonate; sodium salt of n-butyl        naphthalene sulfonate; tridecyl alcohol ethoxylate, POE-18;        Triethanolamine isodecanol phosphate ester; Triethanolamine        tristyrylphosphate ester; Tristyrylphenol Ethoxylate Sulfate;        Bis(2-hydroxyethyl)tallowalkylamines.    -   (c) mannitol or mannitol combined with at least one material        selected from the group consisting of: lactose monohydrate;        xylitol; lactose anhydrous; microcrystalline cellulose; sucrose;        glucose; sodium chloride; talc; kaolin; calcium carbonate; malic        acid; trisodium citrate dihydrate; D,L-Malic acid; sodium        pentane sulfate; sodium octadecyl sulfate; Brij700; Brij76;        sodium n-lauroyl sacrosine; lecithin; docusate sodium;        polyoxyl-40-stearate; Aerosil R972 fumed silica; sodium lauryl        sulfate or other alkyl sulfate surfactants with a chain length        between C5 to C18; polyvinyl pyrrolidone; sodium lauryl sulfate        and polyethylene glycol 40 stearate, sodium lauryl sulfate and        polyethylene glycol 100 stearate, sodium lauryl sulfate and PEG        3000, sodium lauryl sulphate and PEG 6000, sodium lauryl        sulphate and PEG 8000, sodium lauryl sulphate and PEG 10000,        sodium lauryl sulfate and Brij700, sodium lauryl sulfate and        Poloxamer 407, sodium lauryl sulfate and Poloxamer 338, sodium        lauryl sulfate and Poloxamer 188; Poloxamer 407, Poloxamer 338,        Poloxamer 188, alkyl naphthalene sulfonate        condensate/Lignosulfonate blend; Calcium Dodecylbenzene        Sulfonate (Branched); Diisopropyl naphthalenesulphonate;        erythritol distearate; linear and branched dodecylbenzene        sulfonic acids; Naphthalene Sulfonate Formaldehyde Condensate;        nonylphenol ethoxylate, POE-30; Phosphate Esters,        Tristyrylphenol Ethoxylate, Free Acid; Polyoxyethylene (15)        tallowalkylamines; sodium alkyl naphthalene sulfonate; sodium        alkyl naphthalene sulfonate condensate; sodium alkylbenzene        sulfonate; sodium isopropyl naphthalene sulfonate; Sodium Methyl        Naphthalene; Formaldehyde Sulfonate; sodium salt of n-butyl        naphthalene sulfonate; tridecyl alcohol ethoxylate, POE-18;        Triethanolamine isodecanol phosphate ester; Triethanolamine        tristyrylphosphate ester; Tristyrylphenol Ethoxylate Sulfate;        Bis(2-hydroxyethyl)tallowalkylamines.    -   (d) Sucrose or sucrose combined with at least one material        selected from the group consisting of: lactose monohydrate;        lactose anhydrous; mannitol; microcrystalline cellulose;        glucose; sodium chloride; talc; kaolin; calcium carbonate; malic        acid; tartaric acid; trisodium citrate dihydrate; D,L-Malic        acid; sodium pentane sulfate; sodium octadecyl sulfate; Brij700;        Brij76; sodium n-lauroyl sacrosine; lecithin; docusate sodium;        polyoxyl-40-stearate; Aerosil R972 fumed silica; sodium lauryl        sulfate or other alkyl sulfate surfactants with a chain length        between C5 to C18; polyvinyl pyrrolidone; sodium lauryl sulfate        and polyethylene glycol 40 stearate, sodium lauryl sulfate and        polyethylene glycol 100 stearate, sodium lauryl sulfate and PEG        3000, sodium lauryl sulphate and PEG 6000, sodium lauryl        sulphate and PEG 8000, sodium lauryl sulphate and PEG 10000,        sodium lauryl sulfate and Brij700, sodium lauryl sulfate and        Poloxamer 407, sodium lauryl sulfate and Poloxamer 338, sodium        lauryl sulfate and Poloxamer 188; Poloxamer 407, Poloxamer 338,        Poloxamer 188, alkyl naphthalene sulfonate        condensate/Lignosulfonate blend; Calcium Dodecylbenzene        Sulfonate (Branched); Diisopropyl naphthalenesulphonate;        erythritol distearate; linear and branched dodecylbenzene        sulfonic acids; Naphthalene Sulfonate Formaldehyde Condensate;        nonylphenol ethoxylate, POE-30; Phosphate Esters,        Tristyrylphenol Ethoxylate, Free Acid; Polyoxyethylene (15)        tallowalkylamines; sodium alkyl naphthalene sulfonate; sodium        alkyl naphthalene sulfonate condensate; sodium alkylbenzene        sulfonate; sodium isopropyl naphthalene sulfonate; Sodium Methyl        Naphthalene; Formaldehyde Sulfonate; sodium salt of n-butyl        naphthalene sulfonate; tridecyl alcohol ethoxylate, POE-18;        Triethanolamine isodecanol phosphate ester; Triethanolamine        tristyrylphosphate ester; Tristyrylphenol Ethoxylate Sulfate;        Bis(2-hydroxyethyl)tallowalkylamines.    -   (e) Glucose or glucose combined with at least one material        selected from the group consisting of: lactose monohydrate;        lactose anhydrous; mannitol; microcrystalline cellulose;        sucrose; sodium chloride; talc; kaolin; calcium carbonate; malic        acid; tartaric acid; trisodium citrate dihydrate; D,L-Malic        acid; sodium pentane sulfate; sodium octadecyl sulfate; Brij700;        Brij76; sodium n-lauroyl sacrosine; lecithin; docusate sodium;        polyoxyl-40-stearate; Aerosil R972 fumed silica; sodium lauryl        sulfate or other alkyl sulfate surfactants with a chain length        between C5 to C18; polyvinyl pyrrolidone; sodium lauryl sulfate        and polyethylene glycol 40 stearate, sodium lauryl sulfate and        polyethylene glycol 100 stearate, sodium lauryl sulfate and PEG        3000, sodium lauryl sulphate and PEG 6000, sodium lauryl        sulphate and PEG 8000, sodium lauryl sulphate and PEG 10000,        sodium lauryl sulfate and Brij700, sodium lauryl sulfate and        Poloxamer 407, sodium lauryl sulfate and Poloxamer 338, sodium        lauryl sulfate and Poloxamer 188; Poloxamer 407, Poloxamer 338,        Poloxamer 188, alkyl naphthalene sulfonate        condensate/Lignosulfonate blend; Calcium Dodecylbenzene        Sulfonate (Branched); Diisopropyl naphthalenesulphonate;        erythritol distearate; linear and branched dodecylbenzene        sulfonic acids; Naphthalene Sulfonate Formaldehyde Condensate;        nonylphenol ethoxylate, POE-30; Phosphate Esters,        Tristyrylphenol Ethoxylate, Free Acid; Polyoxyethylene (15)        tallowalkylamines; sodium alkyl naphthalene sulfonate; sodium        alkyl naphthalene sulfonate condensate; sodium alkylbenzene        sulfonate; sodium isopropyl naphthalene sulfonate; Sodium Methyl        Naphthalene; Formaldehyde Sulfonate; sodium salt of n-butyl        naphthalene sulfonate; tridecyl alcohol ethoxylate, POE-18;        Triethanolamine isodecanol phosphate ester; Triethanolamine        tristyrylphosphate ester; Tristyrylphenol Ethoxylate Sulfate;        Bis(2-hydroxyethyl)tallowalkylamines.    -   (f) Sodium chloride or sodium chloride combined with at least        one material selected from the group consisting of: lactose        monohydrate; lactose anhydrous; mannitol; microcrystalline        cellulose; sucrose; glucose; talc; kaolin; calcium carbonate;        malic acid; tartaric acid; trisodium citrate dihydrate;        D,L-Malic acid; sodium pentane sulfate; sodium octadecyl        sulfate; Brij700; Brij76; sodium n-lauroyl sacrosine; lecithin;        docusate sodium; polyoxyl-40-stearate; Aerosil R972 fumed        silica; sodium lauryl sulfate or other alkyl sulfate surfactants        with a chain length between C5 to C18; polyvinyl pyrrolidone;        sodium lauryl sulfate and polyethylene glycol 40 stearate,        sodium lauryl sulfate and polyethylene glycol 100 stearate,        sodium lauryl sulfate and PEG 3000, sodium lauryl sulphate and        PEG 6000, sodium lauryl sulphate and PEG 8000, sodium lauryl        sulphate and PEG 10000, sodium lauryl sulfate and Brij700,        sodium lauryl sulfate and Poloxamer 407, sodium lauryl sulfate        and Poloxamer 338, sodium lauryl sulfate and Poloxamer 188;        Poloxamer 407, Poloxamer 338, Poloxamer 188, alkyl naphthalene        sulfonate condensate/Lignosulfonate blend; Calcium        Dodecylbenzene Sulfonate (Branched); Diisopropyl        naphthalenesulphonate; erythritol distearate; linear and        branched dodecylbenzene sulfonic acids; Naphthalene Sulfonate        Formaldehyde Condensate; nonylphenol ethoxylate, POE-30;        Phosphate Esters, Tristyrylphenol Ethoxylate, Free Acid;        Polyoxyethylene (15) tallowalkylamines; sodium alkyl naphthalene        sulfonate; sodium alkyl naphthalene sulfonate condensate; sodium        alkylbenzene sulfonate; sodium isopropyl naphthalene sulfonate;        Sodium Methyl Naphthalene; Formaldehyde Sulfonate; sodium salt        of n-butyl naphthalene sulfonate; tridecyl alcohol ethoxylate,        POE-18; Triethanolamine isodecanol phosphate ester;        Triethanolamine tristyrylphosphate ester; Tristyrylphenol        Ethoxylate Sulfate; Bis(2-hydroxyethyl)tallowalkylamines.    -   (g) xylitol or xylitol combined with at least one material        selected from the group consisting of: lactose monohydrate;        lactose anhydrous; mannitol; microcrystalline cellulose;        sucrose; glucose; sodium chloride; talc; kaolin; calcium        carbonate; malic acid; tartaric acid; trisodium citrate        dihydrate; D,L-Malic acid; sodium pentane sulfate; sodium        octadecyl sulfate; Brij700; Brij76; sodium n-lauroyl sacrosine;        lecithin; docusate sodium; polyoxyl-40-stearate; Aerosil R972        fumed silica; sodium lauryl sulfate or other alkyl sulfate        surfactants with a chain length between C5 to C18; polyvinyl        pyrrolidone; sodium lauryl sulfate and polyethylene glycol 40        stearate, sodium lauryl sulfate and polyethylene glycol 100        stearate, sodium lauryl sulfate and PEG 3000, sodium lauryl        sulphate and PEG 6000, sodium lauryl sulphate and PEG 8000,        sodium lauryl sulphate and PEG 10000, sodium lauryl sulfate and        Brij700, sodium lauryl sulfate and Poloxamer 407, sodium lauryl        sulfate and Poloxamer 338, sodium lauryl sulfate and Poloxamer        188; Poloxamer 407, Poloxamer 338, Poloxamer 188, alkyl        naphthalene sulfonate condensate/Lignosulfonate blend; Calcium        Dodecylbenzene Sulfonate (Branched); Diisopropyl        naphthalenesulphonate; erythritol distearate; linear and        branched dodecylbenzene sulfonic acids; Naphthalene Sulfonate        Formaldehyde Condensate; nonylphenol ethoxylate, POE-30;        Phosphate Esters, Tristyrylphenol Ethoxylate, Free Acid;        Polyoxyethylene (15) tallowalkylamines; sodium alkyl naphthalene        sulfonate; sodium alkyl naphthalene sulfonate condensate; sodium        alkylbenzene sulfonate; sodium isopropyl naphthalene sulfonate;        Sodium Methyl Naphthalene; Formaldehyde Sulfonate; sodium salt        of n-butyl naphthalene sulfonate; tridecyl alcohol ethoxylate,        POE-18; Triethanolamine isodecanol phosphate ester;        Triethanolamine tristyrylphosphate ester; Tristyrylphenol        Ethoxylate Sulfate; Bis(2-hydroxyethyl)tallowalkylamines.    -   (h) Tartaric acid or tartaric acid combined with at least one        material selected from the group consisting of: lactose        monohydrate; lactose anhydrous; mannitol; microcrystalline        cellulose; sucrose; glucose; sodium chloride; talc; kaolin;        calcium carbonate; malic acid; trisodium citrate dihydrate;        D,L-Malic acid; sodium pentane sulfate; sodium octadecyl        sulfate; Brij700; Brij76; sodium n-lauroyl sacrosine; lecithin;        docusate sodium; polyoxyl-40-stearate; Aerosil R972 fumed        silica; sodium lauryl sulfate or other alkyl sulfate surfactants        with a chain length between C5 to C18; polyvinyl pyrrolidone;        sodium lauryl sulfate and polyethylene glycol 40 stearate,        sodium lauryl sulfate and polyethylene glycol 100 stearate,        sodium lauryl sulfate and PEG 3000, sodium lauryl sulphate and        PEG 6000, sodium lauryl sulphate and PEG 8000, sodium lauryl        sulphate and PEG 10000, sodium lauryl sulfate and Brij700,        sodium lauryl sulfate and Poloxamer 407, sodium lauryl sulfate        and Poloxamer 338, sodium lauryl sulfate and Poloxamer 188;        Poloxamer 407, Poloxamer 338, Poloxamer 188, alkyl naphthalene        sulfonate condensate/Lignosulfonate blend; Calcium        Dodecylbenzene Sulfonate (Branched); Diisopropyl        naphthalenesulphonate; erythritol distearate; linear and        branched dodecylbenzene sulfonic acids; Naphthalene Sulfonate        Formaldehyde Condensate; nonylphenol ethoxylate, POE-30;        Phosphate Esters, Tristyrylphenol Ethoxylate, Free Acid;        Polyoxyethylene (15) tallowalkylamines; sodium alkyl naphthalene        sulfonate; sodium alkyl naphthalene sulfonate condensate; sodium        alkylbenzene sulfonate; sodium isopropyl naphthalene sulfonate;        Sodium Methyl Naphthalene; Formaldehyde Sulfonate; sodium salt        of n-butyl naphthalene sulfonate; tridecyl alcohol ethoxylate,        POE-18; Triethanolamine isodecanol phosphate ester;        Triethanolamine tristyrylphosphate ester; Tristyrylphenol        Ethoxylate Sulfate; Bis(2-hydroxyethyl)tallowalkylamines.    -   (i) microcrystalline cellulose or microcrystalline cellulose        combined with at least one material selected from the group        consisting of: lactose monohydrate; xylitol; lactose anhydrous;        mannitol; sucrose; glucose; sodium chloride; talc; kaolin;        calcium carbonate; malic acid; tartaric acid; trisodium citrate        dihydrate; D,L-Malic acid; sodium pentane sulfate; sodium        octadecyl sulfate; Brij700; Brij76; sodium n-lauroyl sacrosine;        lecithin; docusate sodium; polyoxyl-40-stearate; Aerosil R972        fumed silica; sodium lauryl sulfate or other alkyl sulfate        surfactants with a chain length between C5 to C18; polyvinyl        pyrrolidone; sodium lauryl sulfate and polyethylene glycol 40        stearate, sodium lauryl sulfate and polyethylene glycol 100        stearate, sodium lauryl sulfate and PEG 3000, sodium lauryl        sulphate and PEG 6000, sodium lauryl sulphate and PEG 8000,        sodium lauryl sulphate and PEG 10000, sodium lauryl sulfate and        Brij700, sodium lauryl sulfate and Poloxamer 407, sodium lauryl        sulfate and Poloxamer 338, sodium lauryl sulfate and Poloxamer        188; Poloxamer 407, Poloxamer 338, Poloxamer 188, alkyl        naphthalene sulfonate condensate/Lignosulfonate blend; Calcium        Dodecylbenzene Sulfonate (Branched); Diisopropyl        naphthalenesulphonate; erythritol distearate; linear and        branched dodecylbenzene sulfonic acids; Naphthalene Sulfonate        Formaldehyde Condensate; nonylphenol ethoxylate, POE-30;        Phosphate Esters, Tristyrylphenol Ethoxylate, Free Acid;        Polyoxyethylene (15) tallowalkylamines; sodium alkyl naphthalene        sulfonate; sodium alkyl naphthalene sulfonate condensate; sodium        alkylbenzene sulfonate; sodium isopropyl naphthalene sulfonate;        Sodium Methyl Naphthalene; Formaldehyde Sulfonate; sodium salt        of n-butyl naphthalene sulfonate; tridecyl alcohol ethoxylate,        POE-18; Triethanolamine isodecanol phosphate ester;        Triethanolamine tristyrylphosphate ester; Tristyrylphenol        Ethoxylate Sulfate; Bis(2-hydroxyethyl)tallowalkylamines.    -   (j) Kaolin combined with at least one material selected from the        group consisting of: lactose monohydrate; xylitol; lactose        anhydrous; mannitol; microcrystalline cellulose; sucrose;        glucose; sodium chloride; talc; kaolin; calcium carbonate; malic        acid; tartaric acid; trisodium citrate dihydrate; D,L-Malic        acid; sodium pentane sulfate; sodium octadecyl sulfate; Brij700;        Brij76; sodium n-lauroyl sacrosine; lecithin; docusate sodium;        polyoxyl-40-stearate; Aerosil R972 fumed silica; sodium lauryl        sulfate or other alkyl sulfate surfactants with a chain length        between C5 to C18; polyvinyl pyrrolidone; sodium lauryl sulfate        and polyethylene glycol 40 stearate, sodium lauryl sulfate and        polyethylene glycol 100 stearate, sodium lauryl sulfate and PEG        3000, sodium lauryl sulphate and PEG 6000, sodium lauryl        sulphate and PEG 8000, sodium lauryl sulphate and PEG 10000,        sodium lauryl sulfate and Brij700, sodium lauryl sulfate and        Poloxamer 407, sodium lauryl sulfate and Poloxamer 338, sodium        lauryl sulfate and Poloxamer 188; Poloxamer 407, Poloxamer 338,        Poloxamer 188, alkyl naphthalene sulfonate        condensate/Lignosulfonate blend; Calcium Dodecylbenzene        Sulfonate (Branched); Diisopropyl naphthalenesulphonate;        erythritol distearate; linear and branched dodecylbenzene        sulfonic acids; Naphthalene Sulfonate Formaldehyde Condensate;        nonylphenol ethoxylate, POE-30; Phosphate Esters,        Tristyrylphenol Ethoxylate, Free Acid; Polyoxyethylene (15)        tallowalkylamines; sodium alkyl naphthalene sulfonate; sodium        alkyl naphthalene sulfonate condensate; sodium alkylbenzene        sulfonate; sodium isopropyl naphthalene sulfonate; Sodium Methyl        Naphthalene; Formaldehyde Sulfonate; sodium salt of n-butyl        naphthalene sulfonate; tridecyl alcohol ethoxylate, POE-18;        Triethanolamine isodecanol phosphate ester; Triethanolamine        tristyrylphosphate ester; Tristyrylphenol Ethoxylate Sulfate;        Bis(2-hydroxyethyl)tallowalkylamines.    -   (k) Talc combined with at least one material selected from the        group consisting of: lactose monohydrate; xylitol; lactose        anhydrous; mannitol; microcrystalline cellulose; sucrose;        glucose; sodium chloride; kaolin; calcium carbonate; malic acid;        tartaric acid; trisodium citrate dihydrate; D,L-Malic acid;        sodium pentane sulfate; sodium octadecyl sulfate; Brij700;        Brij76; sodium n-lauroyl sacrosine; lecithin; docusate sodium;        polyoxyl-40-stearate; Aerosil R972 fumed silica; sodium lauryl        sulfate or other alkyl sulfate surfactants with a chain length        between C5 to C18; polyvinyl pyrrolidone; sodium lauryl sulfate        and polyethylene glycol 40 stearate, sodium lauryl sulfate and        polyethylene glycol 100 stearate, sodium lauryl sulfate and PEG        3000, sodium lauryl sulphate and PEG 6000, sodium lauryl        sulphate and PEG 8000, sodium lauryl sulphate and PEG 10000,        sodium lauryl sulfate and Brij700, sodium lauryl sulfate and        Poloxamer 407, sodium lauryl sulfate and Poloxamer 338, sodium        lauryl sulfate and Poloxamer 188; Poloxamer 407, Poloxamer 338,        Poloxamer 188, alkyl naphthalene sulfonate        condensate/Lignosulfonate blend; Calcium Dodecylbenzene        Sulfonate (Branched); Diisopropyl naphthalenesulphonate;        erythritol distearate; linear and branched dodecylbenzene        sulfonic acids; Naphthalene Sulfonate Formaldehyde Condensate;        nonylphenol ethoxylate, POE-30; Phosphate Esters,        Tristyrylphenol Ethoxylate, Free Acid; Polyoxyethylene (15)        tallowalkylamines; sodium alkyl naphthalene sulfonate; sodium        alkyl naphthalene sulfonate condensate; sodium alkylbenzene        sulfonate; sodium isopropyl naphthalene sulfonate; Sodium Methyl        Naphthalene; Formaldehyde Sulfonate; sodium salt of n-butyl        naphthalene sulfonate; tridecyl alcohol ethoxylate, POE-18;        Triethanolamine isodecanol phosphate ester; Triethanolamine        tristyrylphosphate ester; Tristyrylphenol Ethoxylate Sulfate;        Bis(2-hydroxyethyl)tallowalkylamines.

Preferably, the grinding matrix is selected from the group consistingof: a material considered to be Generally Regarded as Safe (GRAS) forpharmaceutical products; a material considered acceptable for use in anagricultural formulation; and a material considered acceptable for usein a veterinary formulation.

In another preferred embodiment, a milling aid or combination of millingaids is used. Preferably, the milling aid is selected from the groupconsisting of: colloidal silica, a surfactant, a polymer, a stearic acidand derivatives thereof. Preferably, the surfactant is selected from thegroup consisting of: polyoxyethylene alkyl ethers, polyoxyethylenestearates, polyethylene glycols (PEG), poloxamers, poloxamines,sarcosine based surfactants, polysorbates, aliphatic alcohols, alkyl andaryl sulfates, alkyl and aryl polyether sulfonates and other sulfatesurfactants, trimethyl ammonium based surfactants, lecithin and otherphospholipids, bile salts, polyoxyethylene castor oil derivatives,polyoxyethylene sorbitan fatty acid esters, Sorbitan fatty acid esters,Sucrose fatty acid esters, alkyl glucopyranosides, alkylmaltopyranosides, glycerol fatty acid esters, Alkyl Benzene SulphonicAcids, Alkyl Ether Carboxylic Acids, Alkyl and aryl Phosphate esters,Alkyl and aryl Sulphate esters, Alkyl and aryl Sulphonic acids, AlkylPhenol Phosphates esters, Alkyl Phenol Sulphates esters, Alkyl and ArylPhosphates, Alkyl Polysaccharides, Alkylamine Ethoxylates,Alkyl-Naphthalene Sulphonates formaldehyde condensates, Sulfosuccinates,lignosulfonates, Ceto-Oleyl Alcohol Ethoxylates, Condensed NaphthaleneSulphonates, Dialkyl and Alkyl Naphthalene Sulphonates, Di-alkylSulphosuccinates, Ethoxylated nonylphenols, Ethylene Glycol Esters,Fatty Alcohol Alkoxylates, Hydrogenated tallowalkylamines, Mono-alkylSulphosuccinamates, Nonyl Phenol Ethoxylates, Sodium Oleyl N-methylTaurate, Tallowalkylamines, linear and branched dodecylbenzene sulfonicacids

Preferably, the surfactant is selected from the group consisting of:sodium lauryl sulfate, sodium stearyl sulfate, sodium cetyl sulfate,sodium cetostearyl sulfate, sodium docusate, sodium deoxycholate,N-lauroylsarcosine sodium salt, glyceryl monostearate, glyceroldistearate glyceryl palmitostearate, glyceryl behenate, glycerylcaprylate, glyceryl oleate, benzalkonium chloride, CTAB, CTAC,Cetrimide, cetylpyridinium chloride, cetylpyridinium bromide,benzethonium chloride, PEG 40 stearate, PEG 100 stearate, poloxamer 188,poloxamer 407, poloxamer 338, polyoxyl 2 stearyl ether, polyoxyl 100stearyl ether, polyoxyl 20 stearyl ether, polyoxyl 10 stearyl ether,polyoxyl 20 cetyl ether, polysorbate 20, polysorbate 40, polysorbate 60,polysorbate 61, polysorbate 65, polysorbate 80, polyoxyl 35 castor oil,polyoxyl 40 castor oil, polyoxyl 60 castor oil, polyoxyl 100 castor oil,polyoxyl 200 castor oil, polyoxyl 40 hydrogenated castor oil, polyoxyl60 hydrogenated castor oil, polyoxyl 100 hydrogenated castor oil,polyoxyl 200 hydrogenated castor oil, cetostearyl alcohol, macrogel 15hydroxystearate, sorbitan monopalmitate, sorbitan monostearate, sorbitantrioleate, Sucrose Palmitate, Sucrose Stearate, Sucrose Distearate,Sucrose laurate, Glycocholic acid, sodium Glycholate, Cholic Acid,Soidum Cholate, Sodium Deoxycholate, Deoxycholic acid, Sodiumtaurocholate, taurocholic acid, Sodium taurodeoxycholate,taurodeoxycholic acid, soy lecithin, phosphatidylcholine,phosphatidylethanolamine, phosphatidylserine, phosphatidylinositol,PEG4000, PEG6000, PEG8000, PEG10000, PEG20000, alkyl naphthalenesulfonate condensate/Lignosulfonate blend, Calcium DodecylbenzeneSulfonate, Sodium Dodecylbenzene Sulfonate, Diisopropylnaphthaenesulphonate, erythritol distearate, Naphthalene SulfonateFormaldehyde Condensate, nonylphenol ethoxylate (poe-30),Tristyrylphenol Ethoxylate, Polyoxyethylene (15) tallowalkylamines,sodium alkyl naphthalene sulfonate, sodium alkyl naphthalene sulfonatecondensate, sodium alkylbenzene sulfonate, sodium isopropyl naphthalenesulfonate, Sodium Methyl Naphthalene Formaldehyde Sulfonate, sodiumn-butyl naphthalene sulfonate, tridecyl alcohol ethoxylate (poe-18),Triethanolamine isodecanol phosphate ester, Triethanolaminetristyrylphosphate ester, Tristyrylphenol Ethoxylate Sulfate,Bis(2-hydroxyethyl)tallowalkylamines.

Preferably the polymer is selected from the list of:polyvinylpyrrolidones (PVP), polyvinylalcohol, Acrylic acid basedpolymers and copolymers of acrylic acid

Preferably, the milling aid has a concentration selected from the groupconsisting of: 0.1-10 w/w, 0.1-5% w/w, 0.1-2.5% w/w, of 0.1-2% w/w,0.1-1%, 0.5-5% w/w, 0.5-3% w/w, 0.5-2% w/w, 0.5-1.5%, 0.5-1% w/w, of0.75-1.25% w/w, 0.75-1% and 1% w/w.

In another preferred embodiment of the invention, a facilitating agentis used or combination of facilitating agents is used. Preferably, thefacilitating agent is selected from the group consisting of:surfactants, polymers, binding agents, filling agents, lubricatingagents, sweeteners, flavouring agents, preservatives, buffers, wettingagents, disintegrants, effervescent agents, agents that may form part ofa medicament, including a solid dosage form or a dry powder inhalationformulation and other material required for specific drug delivery.Preferably, the facilitating agent is added during dry milling.Preferably, the facilitating agent is added to the dry milling at a timeselected from the group consisting of: with 1-5% of the total millingtime remaining, with 1-10% of the total milling time remaining, with1-20% of the total milling time remaining, with 1-30% of the totalmilling time remaining, with 2-5% of the total milling time remaining,with 2-10% of the total milling time remaining, with 5-20% of the totalmilling time remaining and with 5-20% of the total milling timeremaining. Preferably, the disintegrant is selected from the groupconsisting of: crosslinked PVP, cross linked carmellose and sodiumstarch glycolate. Preferably, the facilitating agent is added to themilled biologically active material and grinding matrix and furtherprocessed in a mechanofusion process. Mechanofusion milling causesmechanical energy to be applied to powders or mixtures of particles inthe micrometre and nanometre range.

The reasons for including facilitating agents include, but are notlimited to providing better dispersibility, control of agglomeration,the release or retention of the active particles from the deliverymatrix. Examples of facilitating agents include, but are not limited tocrosslinked PVP (crospovidone), cross linked carmellose(croscarmellose), sodium starch glycolate, Povidone (PVP), Povidone K12,Povidone K17, Povidone K25, Povidone K29/32 and Povidone K30, stearicacid, magnesium stearate, calcium stearate, sodium stearyl fumarate,sodium stearyl lactylate, zinc stearate, sodium stearate or lithiumstearate, other solid state fatty acids such as oleic acid, lauric acid,palmitic acid, erucic acid, behenic acid, or derivatives (such as estersand salts), Amino acids such as leucine, isoleucine, lysine, valine,methionine, phenylalanine, aspartame or acesulfame K. In a preferredaspect of manufacturing this formulation the facilitating agent is addedto the milled mixture of biologically active material and co-grindingmatrix and further processed in another milling device such asMechnofusion, Cyclomixing, or impact milling such as ball milling, jetmilling, or milling using a high pressure homogeniser, or combinationsthereof. In a highly preferred aspect the facilitating agent is added tothe milling of the mixture of biologically active material andco-grinding matrix as some time before the end of the milling process.

In another preferred embodiment, indomethacin is milled with lactosemonohydrate and alkyl sulfates. Preferably indomethacin is milled withlactose monohydrate and sodium lauryl sulfate. Preferably indomethacinis milled with lactose monohydrate and sodium octadecyl sulfate. Inanother preferred embodiment, Indomethacin is milled with lactosemonohydrate, alkyl sulfates and another surfactant or polymers.Preferably indomethacin is milled with lactose monohydrate, sodiumlauryl sulfate and polyether sulfates. Preferably indomethacin is milledwith lactose monohydrate, sodium lauryl sulfate and polyethylene glycol40 stearate. Preferably indomethacin is milled with lactose monohydrate,sodium lauryl sulfate and polyethylene glycol 100 stearate. Preferablyindomethacin is milled with lactose monohydrate, sodium lauryl sulfateand a poloxamer. Preferably indomethacin is milled with lactosemonohydrate, sodium lauryl sulfate and poloxamer 407. Preferablyindomethacin is milled with lactose monohydrate, sodium lauryl sulfateand poloxamer 338. Preferably indomethacin is milled with lactosemonohydrate, sodium lauryl sulfate and poloxamer 188. Preferablyindomethacin is milled with lactose monohydrate, sodium lauryl sulfateand a solid polyethylene glycol. Preferably indomethacin is milled withlactose monohydrate, sodium lauryl sulfate and polyethylene glycol 6000.Preferably indomethacin is milled with lactose monohydrate, sodiumlauryl sulfate and polyethylene glycol 3000. In another preferredembodiment, Indomethacin is milled with lactose monohydrate andpolyether sulfates. Preferably indomethacin is milled with lactosemonohydrate and polyethylene glycol 40 stearate. Preferably indomethacinis milled with lactose monohydrate and polyethylene glycol 100 stearateIn another preferred embodiment indomethacin is milled with lactosemonohydrate and polyvinyl-pyrrolidine. Preferably indomethacin is milledwith lactose monohydrate and polyvinyl-pyrrolidone with an approximatemolecular weight of 30,000-40,000. In another preferred embodiment,indomethacin is milled with lactose monohydrate and alkyl sulfonates.Preferably indomethacin is milled with lactose monohydrate and docusatesodium. In another preferred embodiment, indomethacin is milled withlactose monohydrate and a surfactant. Preferably indomethacin is milledwith lactose monohydrate and lecithin. Preferably indomethacin is milledwith lactose monohydrate and sodium n-lauroyl sarcosine. Preferablyindomethacin is milled with lactose monohydrate and polyoxyethylenealkyl ether surfactants. Preferably indomethacin is milled with lactosemonohydrate and PEG 6000. In another preferred formulation indomethacinis milled with lactose monohydrate and silica. Preferably indomethacinis milled with lactose monohydrate and Aerosil R972 fumed silica. Inanother preferred embodiment, indomethacin is milled with with lactosemonohydrate, tartaric acid and sodium lauryl sulfate. In anotherpreferred embodiment, indomethacin is milled with with lactosemonohydrate, sodium bicarbonate and sodium lauryl sulfate. In anotherpreferred embodiment, indomethacin is milled with lactose monohydrate,potassium bicarbonate and sodium lauryl sulfate. In another preferredembodiment, indomethacin is milled with mannitol and alkyl sulfates.Preferably indomethacin is milled with mannitol and sodium laurylsulfate. Preferably indomethacin is milled with mannitol and sodiumoctadecyl sulfate. In another preferred embodiment, Indomethacin ismilled with mannitol, alkyl sulfates and another surfactant or polymers.Preferably indomethacin is milled with mannitol, sodium lauryl sulfateand polyether sulfates. Preferably indomethacin is milled with mannitol,sodium lauryl sulfate and polyethylene glycol 40 stearate. Preferablyindomethacin is milled with mannitol, sodium lauryl sulfate andpolyethylene glycol 100 stearate. Preferably indomethacin is milled withmannitol, sodium lauryl sulfate and a poloxamer. Preferably indomethacinis milled with mannitol, sodium lauryl sulfate and poloxamer 407.Preferably indomethacin is milled with mannitol, sodium lauryl sulfateand poloxamer 338. Preferably indomethacin is milled with mannitol,sodium lauryl sulfate and poloxamer 188. Preferably indomethacin ismilled with mannitol, sodium lauryl sulfate and a solid polyethyleneglycol. Preferably indomethacin is milled with mannitol, sodium laurylsulfate and polyethylene glycol 6000. Preferably indomethacin is milledwith mannitol, sodium lauryl sulfate and polyethylene glycol 3000. Inanother preferred embodiment, Indomethacin is milled with mannitol andpolyether sulfates. Preferably indomethacin is milled with mannitol andpolyethylene glycol 40 stearate. Preferably indomethacin is milled withmannitol and polyethylene glycol 100 stearate In another preferredembodiment indomethacin is milled with mannitol andpolyvinyl-pyrrolidine. Preferably indomethacin is milled with mannitoland polyvinyl-pyrrolidone with an approximate molecular weight of30,000-40,000. In another preferred embodiment, indomethacin is milledwith mannitol and alkyl sulfonates. Preferably indomethacin is milledwith mannitol and docusate sodium. In another preferred embodiment,indomethacin is milled with mannitol and a surfactant. Preferablyindomethacin is milled with mannitol and lecithin. Preferablyindomethacin is milled with mannitol and sodium n-lauroyl sarcosine.Preferably indomethacin is milled with mannitol and polyoxyethylenealkyl ether surfactants. Preferably indomethacin is milled with mannitoland PEG 6000. In another preferred formulation indomethacin is milledwith mannitol and silica. Preferably indomethacin is milled withmannitol and Aerosil R972 fumed silica. In another preferred embodiment,indomethacin is milled with with mannitol, tartaric acid and sodiumlauryl sulfate. In another preferred embodiment, indomethacin is milledwith with mannitol, sodium bicarbonate and sodium lauryl sulfate. Inanother preferred embodiment, indomethacin is milled with mannitol,potassium bicarbonate and sodium lauryl sulfate.

In another preferred embodiment, naproxen is milled with lactosemonohydrate and alkyl sulfates. Preferably naproxen is milled withlactose monohydrate and sodium lauryl sulfate. Preferably naproxen ismilled with lactose monohydrate and sodium octadecyl sulfate. In anotherpreferred embodiment, Naproxen is milled with lactose monohydrate, alkylsulfates and another surfactant or polymers. Preferably naproxen ismilled with lactose monohydrate, sodium lauryl sulfate and polyethersulfates. Preferably naproxen is milled with lactose monohydrate, sodiumlauryl sulfate and polyethylene glycol 40 stearate. Preferably naproxenis milled with lactose monohydrate, sodium lauryl sulfate andpolyethylene glycol 100 stearate. Preferably naproxen is milled withlactose monohydrate, sodium lauryl sulfate and a poloxamer. Preferablynaproxen is milled with lactose monohydrate, sodium lauryl sulfate andpoloxamer 407. Preferably naproxen is milled with lactose monohydrate,sodium lauryl sulfate and poloxamer 338. Preferably naproxen is milledwith lactose monohydrate, sodium lauryl sulfate and poloxamer 188.Preferably naproxen is milled with lactose monohydrate, sodium laurylsulfate and a solid polyethylene glycol. Preferably naproxen is milledwith lactose monohydrate, sodium lauryl sulfate and polyethylene glycol6000. Preferably naproxen is milled with lactose monohydrate, sodiumlauryl sulfate and polyethylene glycol 3000. In another preferredembodiment, Naproxen is milled with lactose monohydrate and polyethersulfates. Preferably naproxen is milled with lactose monohydrate andpolyethylene glycol 40 stearate. Preferably naproxen is milled withlactose monohydrate and polyethylene glycol 100 stearate In anotherpreferred embodiment naproxen is milled with lactose monohydrate andpolyvinyl-pyrrolidine. Preferably naproxen is milled with lactosemonohydrate and polyvinyl-pyrrolidone with an approximate molecularweight of 30,000-40,000. In another preferred embodiment, naproxen ismilled with lactose monohydrate and alkyl sulfonates. Preferablynaproxen is milled with lactose monohydrate and docusate sodium. Inanother preferred embodiment, naproxen is milled with lactosemonohydrate and a surfactant. Preferably naproxen is milled with lactosemonohydrate and lecithin. Preferably naproxen is milled with lactosemonohydrate and sodium n-lauroyl sarcosine. Preferably naproxen ismilled with lactose monohydrate and polyoxyethylene alkyl ethersurfactants. Preferably naproxen is milled with lactose monohydrate andPEG 6000. In another preferred formulation naproxen is milled withlactose monohydrate and silica. Preferably naproxen is milled withlactose monohydrate and Aerosil R972 fumed silica. In another preferredembodiment, naproxen is milled with with lactose monohydrate, tartaricacid and sodium lauryl sulfate. In another preferred embodiment,naproxen is milled with with lactose monohydrate, sodium bicarbonate andsodium lauryl sulfate. In another preferred embodiment, naproxen ismilled with lactose monohydrate, potassium bicarbonate and sodium laurylsulfate. In another preferred embodiment, naproxen is milled withmannitol and alkyl sulfates. Preferably naproxen is milled with mannitoland sodium lauryl sulfate. Preferably naproxen is milled with mannitoland sodium octadecyl sulfate. In another preferred embodiment, Naproxenis milled with mannitol, alkyl sulfates and another surfactant orpolymers. Preferably naproxen is milled with mannitol, sodium laurylsulfate and polyether sulfates. Preferably naproxen is milled withmannitol, sodium lauryl sulfate and polyethylene glycol 40 stearate.Preferably naproxen is milled with mannitol, sodium lauryl sulfate andpolyethylene glycol 100 stearate. Preferably naproxen is milled withmannitol, sodium lauryl sulfate and a poloxamer. Preferably naproxen ismilled with mannitol, sodium lauryl sulfate and poloxamer 407.Preferably naproxen is milled with mannitol, sodium lauryl sulfate andpoloxamer 338. Preferably naproxen is milled with mannitol, sodiumlauryl sulfate and poloxamer 188. Preferably naproxen is milled withmannitol, sodium lauryl sulfate and a solid polyethylene glycol.Preferably naproxen is milled with mannitol, sodium lauryl sulfate andpolyethylene glycol 6000. Preferably naproxen is milled with mannitol,sodium lauryl sulfate and polyethylene glycol 3000. In another preferredembodiment, Naproxen is milled with mannitol and polyether sulfates.Preferably naproxen is milled with mannitol and polyethylene glycol 40stearate. Preferably naproxen is milled with mannitol and polyethyleneglycol 100 stearate In another preferred embodiment naproxen is milledwith mannitol and polyvinyl-pyrrolidine. Preferably naproxen is milledwith mannitol and polyvinyl-pyrrolidone with an approximate molecularweight of 30,000-40,000. In another preferred embodiment, naproxen ismilled with mannitol and alkyl sulfonates. Preferably naproxen is milledwith mannitol and docusate sodium. In another preferred embodiment,naproxen is milled with mannitol and a surfactant. Preferably naproxenis milled with mannitol and lecithin. Preferably naproxen is milled withmannitol and sodium n-lauroyl sarcosine. Preferably naproxen is milledwith mannitol and polyoxyethylene alkyl ether surfactants. Preferablynaproxen is milled with mannitol and PEG 6000. In another preferredformulation naproxen is milled with mannitol and silica. Preferablynaproxen is milled with mannitol and Aerosil R972 fumed silica. Inanother preferred embodiment, naproxen is milled with with mannitol,tartaric acid and sodium lauryl sulfate. In another preferredembodiment, naproxen is milled with with mannitol, sodium bicarbonateand sodium lauryl sulfate. In another preferred embodiment, naproxen ismilled with mannitol, potassium bicarbonate and sodium lauryl sulfate.

In another preferred embodiment, diclofenac is milled with lactosemonohydrate and alkyl sulfates. Preferably diclofenac is milled withlactose monohydrate and sodium lauryl sulfate. Preferably diclofenac ismilled with lactose monohydrate and sodium octadecyl sulfate. In anotherpreferred embodiment, Diclofenac is milled with lactose monohydrate,alkyl sulfates and another surfactant or polymers. Preferably diclofenacis milled with lactose monohydrate, sodium lauryl sulfate and polyethersulfates. Preferably diclofenac is milled with lactose monohydrate,sodium lauryl sulfate and polyethylene glycol 40 stearate. Preferablydiclofenac is milled with lactose monohydrate, sodium lauryl sulfate andpolyethylene glycol 100 stearate. Preferably diclofenac is milled withlactose monohydrate, sodium lauryl sulfate and a poloxamer. Preferablydiclofenac is milled with lactose monohydrate, sodium lauryl sulfate andpoloxamer 407. Preferably diclofenac is milled with lactose monohydrate,sodium lauryl sulfate and poloxamer 338. Preferably diclofenac is milledwith lactose monohydrate, sodium lauryl sulfate and poloxamer 188.Preferably diclofenac is milled with lactose monohydrate, sodium laurylsulfate and a solid polyethylene glycol. Preferably diclofenac is milledwith lactose monohydrate, sodium lauryl sulfate and polyethylene glycol6000. Preferably diclofenac is milled with lactose monohydrate, sodiumlauryl sulfate and polyethylene glycol 3000. In another preferredembodiment, Diclofenac is milled with lactose monohydrate and polyethersulfates. Preferably diclofenac is milled with lactose monohydrate andpolyethylene glycol 40 stearate. Preferably diclofenac is milled withlactose monohydrate and polyethylene glycol 100 stearate In anotherpreferred embodiment diclofenac is milled with lactose monohydrate andpolyvinyl-pyrrolidine. Preferably diclofenac is milled with lactosemonohydrate and polyvinyl-pyrrolidone with an approximate molecularweight of 30,000-40,000. In another preferred embodiment, diclofenac ismilled with lactose monohydrate and alkyl sulfonates. Preferablydiclofenac is milled with lactose monohydrate and docusate sodium. Inanother preferred embodiment, diclofenac is milled with lactosemonohydrate and a surfactant. Preferably diclofenac is milled withlactose monohydrate and lecithin. Preferably diclofenac is milled withlactose monohydrate and sodium n-lauroyl sarcosine. Preferablydiclofenac is milled with lactose monohydrate and polyoxyethylene alkylether surfactants. Preferably diclofenac is milled with lactosemonohydrate and PEG 6000. In another preferred formulation diclofenac ismilled with lactose monohydrate and silica. Preferably diclofenac ismilled with lactose monohydrate and Aerosil R972 fumed silica. Inanother preferred embodiment, diclofenac is milled with with lactosemonohydrate, tartaric acid and sodium lauryl sulfate. In anotherpreferred embodiment, diclofenac is milled with with lactosemonohydrate, sodium bicarbonate and sodium lauryl sulfate. In anotherpreferred embodiment, diclofenac is milled with lactose monohydrate,potassium bicarbonate and sodium lauryl sulfate. In another preferredembodiment, diclofenac is milled with mannitol and alkyl sulfates.Preferably diclofenac is milled with mannitol and sodium lauryl sulfate.Preferably diclofenac is milled with mannitol and sodium octadecylsulfate. In another preferred embodiment, Diclofenac is milled withmannitol, alkyl sulfates and another surfactant or polymers. Preferablydiclofenac is milled with mannitol, sodium lauryl sulfate and polyethersulfates. Preferably diclofenac is milled with mannitol, sodium laurylsulfate and polyethylene glycol 40 stearate. Preferably diclofenac ismilled with mannitol, sodium lauryl sulfate and polyethylene glycol 100stearate. Preferably diclofenac is milled with mannitol, sodium laurylsulfate and a poloxamer. Preferably diclofenac is milled with mannitol,sodium lauryl sulfate and poloxamer 407. Preferably diclofenac is milledwith mannitol, sodium lauryl sulfate and poloxamer 338. Preferablydiclofenac is milled with mannitol, sodium lauryl sulfate and poloxamer188. Preferably diclofenac is milled with mannitol, sodium laurylsulfate and a solid polyethylene glycol. Preferably diclofenac is milledwith mannitol, sodium lauryl sulfate and polyethylene glycol 6000.Preferably diclofenac is milled with mannitol, sodium lauryl sulfate andpolyethylene glycol 3000. In another preferred embodiment, Diclofenac ismilled with mannitol and polyether sulfates. Preferably diclofenac ismilled with mannitol and polyethylene glycol 40 stearate Preferablydiclofenac is milled with mannitol and polyethylene glycol 100 stearateIn another preferred embodiment diclofenac is milled with mannitol andpolyvinyl-pyrrolidine. Preferably diclofenac is milled with mannitol andpolyvinyl-pyrrolidone with an approximate molecular weight of30,000-40,000. In another preferred embodiment, diclofenac is milledwith mannitol and alkyl sulfonates. Preferably diclofenac is milled withmannitol and docusate sodium. In another preferred embodiment,diclofenac is milled with mannitol and a surfactant. Preferablydiclofenac is milled with mannitol and lecithin. Preferably diclofenacis milled with mannitol and sodium n-lauroyl sarcosine. Preferablydiclofenac is milled with mannitol and polyoxyethylene alkyl ethersurfactants. Preferably diclofenac is milled with mannitol and PEG 6000.In another preferred formulation diclofenac is milled with mannitol andsilica. Preferably diclofenac is milled with mannitol and Aerosil R972fumed silica. In another preferred embodiment, diclofenac is milled withwith mannitol, tartaric acid and sodium lauryl sulfate. In anotherpreferred embodiment, diclofenac is milled with with mannitol, sodiumbicarbonate and sodium lauryl sulfate. In another preferred embodiment,diclofenac is milled with mannitol, potassium bicarbonate and sodiumlauryl sulfate.

In another preferred embodiment, meloxicam is milled with lactosemonohydrate and alkyl sulfates. Preferably meloxicam is milled withlactose monohydrate and sodium lauryl sulfate. Preferably meloxicam ismilled with lactose monohydrate and sodium octadecyl sulfate. In anotherpreferred embodiment, Meloxicam is milled with lactose monohydrate,alkyl sulfates and another surfactant or polymers. Preferably meloxicamis milled with lactose monohydrate, sodium lauryl sulfate and polyethersulfates. Preferably meloxicam is milled with lactose monohydrate,sodium lauryl sulfate and polyethylene glycol 40 stearate. Preferablymeloxicam is milled with lactose monohydrate, sodium lauryl sulfate andpolyethylene glycol 100 stearate. Preferably meloxicam is milled withlactose monohydrate, sodium lauryl sulfate and a poloxamer. Preferablymeloxicam is milled with lactose monohydrate, sodium lauryl sulfate andpoloxamer 407. Preferably meloxicam is milled with lactose monohydrate,sodium lauryl sulfate and poloxamer 338. Preferably meloxicam is milledwith lactose monohydrate, sodium lauryl sulfate and poloxamer 188.Preferably meloxicam is milled with lactose monohydrate, sodium laurylsulfate and a solid polyethylene glycol. Preferably meloxicam is milledwith lactose monohydrate, sodium lauryl sulfate and polyethylene glycol6000. Preferably meloxicam is milled with lactose monohydrate, sodiumlauryl sulfate and polyethylene glycol 3000. In another preferredembodiment, Meloxicam is milled with lactose monohydrate and polyethersulfates. Preferably meloxicam is milled with lactose monohydrate andpolyethylene glycol 40 stearate. Preferably meloxicam is milled withlactose monohydrate and polyethylene glycol 100 stearate In anotherpreferred embodiment meloxicam is milled with lactose monohydrate andpolyvinyl-pyrrolidine. Preferably meloxicam is milled with lactosemonohydrate and polyvinyl-pyrrolidone with an approximate molecularweight of 30,000-40,000. In another preferred embodiment, meloxicam ismilled with lactose monohydrate and alkyl sulfonates. Preferablymeloxicam is milled with lactose monohydrate and docusate sodium. Inanother preferred embodiment, meloxicam is milled with lactosemonohydrate and a surfactant. Preferably meloxicam is milled withlactose monohydrate and lecithin. Preferably meloxicam is milled withlactose monohydrate and sodium n-lauroyl sarcosine. Preferably meloxicamis milled with lactose monohydrate and polyoxyethylene alkyl ethersurfactants. Preferably meloxicam is milled with lactose monohydrate andPEG 6000. In another preferred formulation meloxicam is milled withlactose monohydrate and silica. Preferably meloxicam is milled withlactose monohydrate and Aerosil R972 fumed silica. In another preferredembodiment, meloxicam is milled with with lactose monohydrate, tartaricacid and sodium lauryl sulfate. In another preferred embodiment,meloxicam is milled with with lactose monohydrate, sodium bicarbonateand sodium lauryl sulfate. In another preferred embodiment, meloxicam ismilled with lactose monohydrate, potassium bicarbonate and sodium laurylsulfate. In another preferred embodiment, meloxicam is milled withmannitol and alkyl sulfates. Preferably meloxicam is milled withmannitol and sodium lauryl sulfate. Preferably meloxicam is milled withmannitol and sodium octadecyl sulfate. In another preferred embodiment,Meloxicam is milled with mannitol, alkyl sulfates and another surfactantor polymers. Preferably meloxicam is milled with mannitol, sodium laurylsulfate and polyether sulfates. Preferably meloxicam is milled withmannitol, sodium lauryl sulfate and polyethylene glycol 40 stearate.Preferably meloxicam is milled with mannitol, sodium lauryl sulfate andpolyethylene glycol 100 stearate. Preferably meloxicam is milled withmannitol, sodium lauryl sulfate and a poloxamer. Preferably meloxicam ismilled with mannitol, sodium lauryl sulfate and poloxamer 407.Preferably meloxicam is milled with mannitol, sodium lauryl sulfate andpoloxamer 338. Preferably meloxicam is milled with mannitol, sodiumlauryl sulfate and poloxamer 188. Preferably meloxicam is milled withmannitol, sodium lauryl sulfate and a solid polyethylene glycol.Preferably meloxicam is milled with mannitol, sodium lauryl sulfate andpolyethylene glycol 6000. Preferably meloxicam is milled with mannitol,sodium lauryl sulfate and polyethylene glycol 3000. In another preferredembodiment, Meloxicam is milled with mannitol and polyether sulfates.Preferably meloxicam is milled with mannitol and polyethylene glycol 40stearate. Preferably meloxicam is milled with mannitol and polyethyleneglycol 100 stearate In another preferred embodiment meloxicam is milledwith mannitol and polyvinyl-pyrrolidine. Preferably meloxicam is milledwith mannitol and polyvinyl-pyrrolidone with an approximate molecularweight of 30,000-40,000. In another preferred embodiment, meloxicam ismilled with mannitol and alkyl sulfonates. Preferably meloxicam ismilled with mannitol and docusate sodium. In another preferredembodiment, meloxicam is milled with mannitol and a surfactant.Preferably meloxicam is milled with mannitol and lecithin. Preferablymeloxicam is milled with mannitol and sodium n-lauroyl sarcosine.Preferably meloxicam is milled with mannitol and polyoxyethylene alkylether surfactants. Preferably meloxicam is milled with mannitol and PEG6000. In another preferred formulation meloxicam is milled with mannitoland silica. Preferably meloxicam is milled with mannitol and AerosilR972 fumed silica. In another preferred embodiment, meloxicam is milledwith with mannitol, tartaric acid and sodium lauryl sulfate. In anotherpreferred embodiment, meloxicam is milled with with mannitol, sodiumbicarbonate and sodium lauryl sulfate. In another preferred embodiment,meloxicam is milled with mannitol, potassium bicarbonate and sodiumlauryl sulfate.

In another preferred embodiment, metaxalone is milled with lactosemonohydrate and alkyl sulfates. Preferably metaxalone is milled withlactose monohydrate and sodium lauryl sulfate. Preferably metaxalone ismilled with lactose monohydrate and sodium octadecyl sulfate. In anotherpreferred embodiment, Metaxalone is milled with lactose monohydrate,alkyl sulfates and another surfactant or polymers. Preferably metaxaloneis milled with lactose monohydrate, sodium lauryl sulfate and polyethersulfates. Preferably metaxalone is milled with lactose monohydrate,sodium lauryl sulfate and polyethylene glycol 40 stearate. Preferablymetaxalone is milled with lactose monohydrate, sodium lauryl sulfate andpolyethylene glycol 100 stearate. Preferably metaxalone is milled withlactose monohydrate, sodium lauryl sulfate and a poloxamer. Preferablymetaxalone is milled with lactose monohydrate, sodium lauryl sulfate andpoloxamer 407. Preferably metaxalone is milled with lactose monohydrate,sodium lauryl sulfate and poloxamer 338. Preferably metaxalone is milledwith lactose monohydrate, sodium lauryl sulfate and poloxamer 188.Preferably metaxalone is milled with lactose monohydrate, sodium laurylsulfate and a solid polyethylene glycol. Preferably metaxalone is milledwith lactose monohydrate, sodium lauryl sulfate and polyethylene glycol6000. Preferably metaxalone is milled with lactose monohydrate, sodiumlauryl sulfate and polyethylene glycol 3000. In another preferredembodiment, Metaxalone is milled with lactose monohydrate and polyethersulfates. Preferably metaxalone is milled with lactose monohydrate andpolyethylene glycol 40 stearate. Preferably metaxalone is milled withlactose monohydrate and polyethylene glycol 100 stearate. In anotherpreferred embodiment metaxalone is milled with lactose monohydrate andpolyvinyl-pyrrolidine. Preferably metaxalone is milled with lactosemonohydrate and polyvinyl-pyrrolidone with an approximate molecularweight of 30,000-40,000. In another preferred embodiment, metaxalone ismilled with lactose monohydrate and alkyl sulfonates. Preferablymetaxalone is milled with lactose monohydrate and docusate sodium. Inanother preferred embodiment, metaxalone is milled with lactosemonohydrate and a surfactant. Preferably metaxalone is milled withlactose monohydrate and lecithin. Preferably metaxalone is milled withlactose monohydrate and sodium n-lauroyl sarcosine. Preferablymetaxalone is milled with lactose monohydrate and polyoxyethylene alkylether surfactants. Preferably metaxalone is milled with lactosemonohydrate and PEG 6000. In another preferred formulation metaxalone ismilled with lactose monohydrate and silica. Preferably metaxalone ismilled with lactose monohydrate and Aerosil R972 fumed silica. Inanother preferred embodiment, metaxalone is milled with with lactosemonohydrate, tartaric acid and sodium lauryl sulfate. In anotherpreferred embodiment, metaxalone is milled with with lactosemonohydrate, sodium bicarbonate and sodium lauryl sulfate. In anotherpreferred embodiment, metaxalone is milled with with lactosemonohydrate, sodium bicarbonate, poloxamer 407 and sodium laurylsulfate. In another preferred embodiment, metaxalone is milled withlactose monohydrate, potassium bicarbonate and sodium lauryl sulfate. Inanother preferred embodiment, metaxalone is milled with with lactosemonohydrate, potassium bicarbonate, poloxamer 407 and sodium laurylsulfate.

In another preferred embodiment, metaxalone is milled with mannitol andalkyl sulfates. Preferably metaxalone is milled with mannitol and sodiumlauryl sulfate. Preferably metaxalone is milled with mannitol and sodiumoctadecyl sulfate. In another preferred embodiment, Metaxalone is milledwith mannitol, alkyl sulfates and another surfactant or polymers.Preferably metaxalone is milled with mannitol, sodium lauryl sulfate andpolyether sulfates. Preferably metaxalone is milled with mannitol,sodium lauryl sulfate and polyethylene glycol 40 stearate. Preferablymetaxalone is milled with mannitol, sodium lauryl sulfate andpolyethylene glycol 100 stearate. Preferably metaxalone is milled withmannitol, sodium lauryl sulfate and a poloxamer. Preferably metaxaloneis milled with mannitol, sodium lauryl sulfate and poloxamer 407.Preferably metaxalone is milled with mannitol, sodium lauryl sulfate andpoloxamer 338. Preferably metaxalone is milled with mannitol, sodiumlauryl sulfate and poloxamer 188. Preferably metaxalone is milled withmannitol, sodium lauryl sulfate and a solid polyethylene glycol.Preferably metaxalone is milled with mannitol, sodium lauryl sulfate andpolyethylene glycol 6000. Preferably metaxalone is milled with mannitol,sodium lauryl sulfate and polyethylene glycol 3000. In another preferredembodiment, Metaxalone is milled with mannitol and polyether sulfates.Preferably metaxalone is milled with mannitol and polyethylene glycolstearate Preferably metaxalone is milled with mannitol and polyethyleneglycol 100 stearate In another preferred embodiment metaxalone is milledwith mannitol and polyvinyl-pyrrolidine. Preferably metaxalone is milledwith mannitol and polyvinyl-pyrrolidone with an approximate molecularweight of 30,000-40,000. In another preferred embodiment, metaxalone ismilled with mannitol and alkyl sulfonates. Preferably metaxalone ismilled with mannitol and docusate sodium. In another preferredembodiment, metaxalone is milled with mannitol and a surfactant.Preferably metaxalone is milled with mannitol and lecithin. Preferablymetaxalone is milled with mannitol and sodium n-lauroyl sarcosine.Preferably metaxalone is milled with mannitol and polyoxyethylene alkylether surfactants. Preferably metaxalone is milled with mannitol and PEG6000. In another preferred formulation metaxalone is milled withmannitol and silica. Preferably metaxalone is milled with mannitol andAerosil R972 fumed silica. In another preferred embodiment, metaxaloneis milled with with mannitol, tartaric acid and sodium lauryl sulfate.In another preferred embodiment, metaxalone is milled with withmannitol, sodium bicarbonate and sodium lauryl sulfate. In anotherpreferred embodiment, metaxalone is milled with mannitol, potassiumbicarbonate and sodium lauryl sulfate. In another preferred embodiment,metaxalone is milled with mannitol, sodium bicarbonate and sodium laurylsulphate and Polxamer 407. In another preferred embodiment, metaxaloneis milled with mannitol, potassium bicarbonate and sodium laurylsulphate and Polxamer 407.

In another preferred embodiment, the particles have a volume weightedmean (D4,3), determined on a particle volume basis, equal or greaterthan a size selected from the group consisting of: 5000 nm, 10,000 nm,15,000 nm, 20,000 nm, 25,000 nm, 35,000 nm, 40,000 nm and 50,000 nm.

In another preferred embodiment, the powder handling characteristic is acharacteristic selected from the group consisting of: flow property,static charge, aggregation property, content uniformity, contentuniformity after segregation, adherence property, cohesivity, dustlevel, powder rheology, segregation property, bulk density, tapped bulkdensity, powder flow, angle of repose, compressibility, permeability andminimum ignition property. In another preferred embodiment, the contentuniformity and/or content uniformity after segregation of thebiologically active material throughout the blend varies from theaverage content by a percentage less than or equal to a percentageselected from the group consisting of: 0.1%, 0.2%, 0.3%, 0.4%, 0.5%0.75%, 1.0%, 1.5%, 2.0%, 3.0%, 4.0% and 5.0%. In another preferredembodiment the static property is selected from the group consisting of:less than 10 nC/g, less than 5 nC/g, less than 3 nC/g, less than 2 nC/g,less than 1.5 nC/g, less than 1.25 nC/g, less than 1 nC/g less than 0.75nC/g, less than 0.5 nC/g, less than 0.25 nC/g and less than 0.1 nC/g. Inanother preferred embodiment, the biologically active material and/orblend containing biologically active material has a lower propensity foradherence to other materials such as but not limited to stainless steel,glass, plastic, polyethylene and polypropylene compared to thepropensity for adherence of a biologically active material and/or blendwith the same, similar or larger biologically active material particlesize manufactured using a conventional process.

In a third aspect the invention comprises a biologically active materialproduced by the method described herein and composition comprising thebiologically active material as described herein. Preferably, theaverage particle size of the biologically active material, determined ona particle number basis, is equal to or less than a size selected fromthe group 10,000 nm, 8000 nm, 6000 nm, 5000 nm, 4000 nm, 3000 nm, 2000nm, 1900 nm, 1800 nm, 1700 nm, 1600 nm, 1500 nm, 1400 nm, 1300 nm, 1200nm, 1100 nm, 1000 nm, 900 nm, 800 nm, 700 nm, 600 nm, 500 nm, 400 nm,300 nm, 200 nm and 100 nm. Preferably, the average particle size of thebiologically active material is equal to or greater than 25 nm.Preferably, the particles of the biologically active material have amedian particle size, determined on a particle volume basis, equal orless than a size selected from the group consisting of: 20,000 nm,15,000 nm, 10,000 nm, 8000 nm, 6000 nm, 5000 nm, 4000 nm, 3000 nm, 2000nm, 1900 nm, 1800 nm, 1700 nm, 1600 nm, 1500 nm, 1400 nm, 1300 nm, 1200nm, 1100 nm, 1000 nm, 900 nm, 800 nm, 700 nm, 600 nm, 500 nm, 400 nm,300 nm, 200 nm and 100 nm. Preferably, the median particle size of thebiologically active material is equal to or greater than 25 nm.Preferably, the percentage of particles, on a particle volume basis, isselected from the group consisting of: 50%, 60%, 70%, 80%, 90%, 95% and100% less than 20,000 nm (%<20,000 nm). Preferably, the percentage ofparticles, on a particle volume basis, is selected from the groupconsisting of: 50%, 60%, 70%, 80%, 90%, 95% and 100% less than 10,000 nm(%<10,000 nm). Preferably, the percentage of particles, on a particlevolume basis, is selected from the group consisting of: 50%, 60%, 70%,80%, 90%, 95% and 100% less than 5000 nm (%<5000 nm). Preferably, thepercentage of particles, on a particle volume basis, is selected fromthe group consisting of: 50%, 60%, 70%, 80%, 90%, 95% and 100% less than2000 nm (%<2000 nm). Preferably, the percentage of particles, on aparticle volume basis, is selected from the group consisting of: 50%,60%, 70%, 80%, 90%, 95% and 100% less than 1000 nm (%<1000 nm).Preferably, the percentage of particles, on a particle volume basis, isselected from the group consisting of: 0%, 10%, 20%, 30%, 40%, 50%, 60%,70%, 80%, 90%, 95% and 100% less than 500 nm (%<500 nm). Preferably, thepercentage of particles, on a particle volume basis, is selected fromthe group consisting of: 0%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%,90%, 95% and 100 less than 300 nm (%<300 nm). Preferably, the percentageof particles, on a particle volume basis, is selected from the groupconsisting of: 0%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95% and100% less than 200 nm (%<200 nm). Preferably, the Dx of the particlesize distribution, as measured on a particle volume basis, is selectedfrom the group consisting of less than or equal to 10,000 nm, 5000 nm,3000 nm, 2000 nm, 1900 nm, 1800 nm, 1700 nm, 1600 nm, 1500 nm, 1400 nm,1300 nm, 1200 nm, 1100 nm, 1000 nm, 900 nm, 800 nm, 700 nm, 600 nm, 500nm, 400 nm, 300 nm, 200 nm, and 100 nm; wherein x is greater than orequal to 90 Preferably, the crystallinity profile of the biologicallyactive material is selected from the group consisting of: at least 50%of the biologically active material is crystalline, at least 60% of thebiologically active material is crystalline, at least 70% of thebiologically active material is crystalline, at least 75% of thebiologically active material is crystalline, at least 85% of thebiologically active material is crystalline, at least 90% of thebiologically active material is crystalline, at least 95% of thebiologically active material is crystalline and at least 98% of thebiologically active material is crystalline. Preferably, thecrystallinity profile of the biologically active material issubstantially equal to the crystallinity profile of the biologicallyactive material before the material was subject to the method describedherein. Preferably, the amorphous content of the biologically activematerial is selected from the group consisting of: less than 50% of thebiologically active material is amorphous, less than 40% of thebiologically active material is amorphous, less than 30% of thebiologically active material is amorphous, less than 25% of thebiologically active material is amorphous, less than 15% of thebiologically active material is amorphous, less than 10% of thebiologically active material is amorphous, less than 5% of thebiologically active material is amorphous and less than 2% of thebiologically active material is amorphous. Preferably, the biologicallyactive material has had no significant increase in amorphous contentfollowing subjecting the material to the method as described herein.Preferably, the biologically active material comprised in thecomposition is selected from the group consisting of: fungicides,pesticides, herbicides, seed treatments, cosmeceuticals, cosmetics,complementary medicines, natural products, vitamins, nutrients,nutraceuticals, pharmaceutical actives, biologics, amino acids,proteins, peptides, nucleotides, nucleic acids, additives, foods andfood ingredients and analogs, homologs and first order derivativesthereof. Preferably, where the biologically active material is anaturally occurring material or a derivate of a naturally occurringmaterial, such as but not limited to, seeds, cocoa and cocoa solids,coffee, herbs, spices, other plant materials, minerals, animal products,shells and other skeletal material, the particles of the biologicallyactive material have a median particle size, determined on a particlevolume basis, equal or less than a size selected from the group 20,000,15,000 nm, 10,000 nm, 8000 nm, 6000 nm, 5000 nm, 4000 nm and 3000 nm.Preferably, the biologically active material is selected from the groupconsisting of: anti-obesity drugs, central nervous system stimulants,carotenoids, corticosteroids, elastase inhibitors, anti-fungals,oncology therapies, anti-emetics, analgesics, cardiovascular agents,anti-inflammatory agents, such as NSAIDs and COX-2 inhibitors,anthelmintics, anti-arrhythmic agents, antibiotics (includingpenicillins), anticoagulants, antidepressants, antidiabetic agents,antiepileptics, antihistamines, antihypertensive agents, antimuscarinicagents, antimycobacterial agents, antineoplastic agents,immunosuppressants, antithyroid agents, antiviral agents, anxiolytics,sedatives (hypnotics and neuroleptics), astringents, alpha-adrenergicreceptor blocking agents, beta-adrenoceptor blocking agents, bloodproducts and substitutes, cardiac inotropic agents, contrast media,cough suppressants (expectorants and mucolytics), diagnostic agents,diagnostic imaging agents, diuretics, dopaminergics (anti-parkinsonianagents), haemostatics, immunological agents, lipid regulating agents,muscle relaxants, parasympathomimetics, parathyroid calcitonin andbiphosphonates, prostaglandins, radio-pharmaceuticals, sex hormones(including steroids), anti-allergic agents, stimulants and anoretics,sympathomimetics, thyroid agents, vasodilators, and xanthenes.Preferably, the biologically active material is selected from the groupconsisting of: indomethacin, diclofenac, naproxen, meloxicam,metaxalone, cyclosporin A, progesterone celecoxib, cilostazol,ciprofloxacin, 2,4-dichlorophenoxyacetic acid, anthraquinone, creatinemonohydrate, glyphosate, halusulfuron, mancozeb, metsulfuron,salbutamol, sulphur, tribenuran and estradiol or any salt or derivativethereof.

Preferably, the biologically active material is selected from the groupconsisting of: anti-obesity drugs, central nervous system stimulants,carotenoids, corticosteroids, elastase inhibitors, anti-fungals,oncology therapies, anti-emetics, analgesics, cardiovascular agents,anti-inflammatory agents, such as NSAIDs and COX-2 inhibitors,anthelmintics, anti-arrhythmic agents, antibiotics (includingpenicillins), anticoagulants, antidepressants, antidiabetic agents,antiepileptics.

Preferably cosmeceuticals, cosmetics, complementary medicines, naturalproducts, vitamins, nutrients and nutraceuticals are selected from thegroup consisting of: Glycolic acids, Lactic acids, Carrageenan, Almonds,Mahogany wood, Andrographis Paniculata, Aniseed, Anthemis nobilis(chamomile), Apricot kernel, leaves of bearberry, leaves of cranberry,leaves of blueberry, leaves of pear trees, beta-carotene, blackelderberry, black raspberry, black walnut shell, blackberry,bladderwrack, bletilla striata, borage seed, boysenberry, brazil nut,burdock root, butcher's broom extract, calamine, calcium gluconate,calendula, carnosic acid, Cantella asiatica, charcoal, chaste treefruit, Chicory root extract, chitosan, choline, Cichorium intybus,Clematis vitalba, Coffea Arabica, coumarin, crithmum maritimum,curcumin, coffee, cocoa, cocoa powder, cocoa nibs, cocoa mass, cocoaliquor, cocoa products, dogwood, Echinacea, echium lycopsis, anise,atragalus, bilberry, bitter orange, black cohosh, cat's claw, chamomile,chasteberry, cranberry, dandelion, Echinacea, ephedra, European elderEpilobium angustifolium, horse chestnut, cloves, evening primrose,fennel seed, fenugreek, feverfew, flaxseed, fumaria officinalis, garlic,geranium, ginger, ginkgo, ginseng, goldenseal, grape seed, green tea,guava, hawthorn, hayflower, hazelnut, helichrysum, hoodia, horseradish,mulbe italicum, hibiscus, hierochloe odorata, hops, horse chestnut, ilexparaguariensis, indian gooseberry, irish moss, juniper berry, kudzuroot, lady's thistle, lavender, lemongrass, lentius edodes, licorice,longifolene, loquat, lotus seed, luffa cylindrica, lupine, maroinberry,marjoram, meadowsweet, milk vetch root, mimosa tenuiflora, mistletoe,mulberry, noni, kelp, oatmeal, oregano, papaya, parsley, peony root,pomegranate, pongamia glabra seed, pongamia pinnata, quinoa seed, redraspberry, rose hip, rosemary, sage, saw palmetto, soy bean, szechuanpeppercorn, tephrosia purpurea, terminalia catappa, terminalia sericea,thunder god vine, thyme, turmeric, valeriana officinalis, walnuts, whitetea leaf, yam, witch hazel, wormwood, yarrow, valerian, yohimbe,mangosteen, sour sob, goji berry, spirulina and durian skin. In onepreferred embodiment, the invention comprises compositions comprisingthe biologically active ingredient together with a grinding matrix, amixture of grinding matrix materials, milling aids, mixtures of millingaids, facilitating agents and/or mixtures of facilitating agents asdescribed herein, in concentrations and ratios as described herein underthe methods of the invention.

In a fourth aspect the invention comprises a pharmaceutical compositioncomprising a biologically active material produced by the methoddescribed herein and compositions described herein. Preferably, theinvention comprises pharmaceutical compositions comprising thebiologically active ingredient together with a grinding matrix, amixture of grinding matrix materials, milling aids, mixtures of millingaids, facilitating agents and/or mixtures of facilitating agents asdescribed herein, in concentrations and ratios as described herein underthe methods of the invention. Preferably, the average particle size ofthe biologically active material, determined on a particle number basis,is equal to or less than a size selected from the group 10,000 nm, 8000nm, 6000 nm, 5000 nm, 4000 nm, 3000 nm, 2000 nm, 1900 nm, 1800 nm, 1700nm, 1600 nm, 1500 nm, 1400 nm, 1300 nm, 1200 nm, 1100 nm, 1000 nm, 900nm, 800 nm, 700 nm, 600 nm, 500 nm, 400 nm, 300 nm, 200 nm and 100 nm.Preferably, the average particle size of the biologically activematerial is equal to or greater than 25 nm. Preferably, the particles ofthe biologically active material have a median particle size, determinedon a particle volume basis, equal or less than a size selected from thegroup 20,000 nm, 15,000 nm, 10,000 nm, 8000 nm, 6000 nm, 5000 nm, 4000nm, 3000 nm, 2000 nm, 1900 nm, 1800 nm, 1700 nm, 1600 nm, 1500 nm, 1400nm, 1300 nm, 1200 nm, 1100 nm, 1000 nm, 900 nm, 800 nm, 700 nm, 600 nm,500 nm, 400 nm, 300 nm, 200 nm and 100 nm. Preferably, the medianparticle size of the biologically active material is equal to or greaterthan 25 nm. Preferably, the percentage of particles, on a particlevolume basis, is selected from the group consisting of: 50%, 60%, 70%,80%, 90%, 95% and 100% less than 20,000 nm (%<20,000 nm). Preferably,the percentage of particles, on a particle volume basis, is selectedfrom the group consisting of: 50%, 60%, 70%, 80%, 90%, 95% and 100% lessthan 10,000 nm (%<10,000 nm). Preferably, the percentage of particles,on a particle volume basis, is selected from the group consisting of:50%, 60%, 70%, 80%, 90%, 95% and 100% less than 5000 nm (%<5000 nm).Preferably, the percentage of particles, on a particle volume basis, isselected from the group consisting of: 50%, 60%, 70%, 80%, 90%, 95% and100% less than 2000 nm (%<2000 nm). Preferably, the percentage ofparticles, on a particle volume basis, is selected from the groupconsisting of: 50%, 60%, 70%, 80%, 90%, 95% and 100% less than 1000 nm(%<1000 nm). Preferably, the percentage of particles, on a particlevolume basis, is selected from the group consisting of: 0%, 10%, 20%,30%, 40%, 50%, 60%, 70%, 80%, 90%, 95% and 100% less than 500 nm (%<500nm). Preferably, the percentage of particles, on a particle volumebasis, is selected from the group consisting of: 0%, 10%, 20%, 30%, 40%,50%, 60%, 70%, 80%, 90%, 95% and 100% less than 300 nm (%<300 nm).Preferably, the percentage of particles, on a particle volume basis, isselected from the group consisting of: 0%, 10%, 20%, 30%, 40%, 50%, 60%,70%, 80%, 90%, 95% and 100% less than 200 nm (%<200 nm). Preferably, theDx of the particle size distribution, as measured on a particle volumebasis, is selected from the group consisting of less than or equal to10,000 nm, 5000 nm, 3000 nm, 2000 nm, 1900 nm, 1800 nm, 1700 nm, 1600nm, 1500 nm, 1400 nm, 1300 nm, 1200 nm, 1100 nm, 1000 nm, 900 nm, 800nm, 700 nm, 600 nm, 500 nm, 400 nm, 300 nm, 200 nm, and 100 nm; whereinx is greater than or equal to 90. Preferably, the biologically activematerial is selected from the group consisting of: fungicides,pesticides, herbicides, seed treatments, cosmeceuticals, cosmetics,complementary medicines, natural products, vitamins, nutrients,nutraceuticals, pharmaceutical actives, biologics, amino acids,proteins, peptides, nucleotides, nucleic acids, additives, foods andfood ingredients and analogs, homologs and first order derivativesthereof. Preferably, the biologically active material is selected fromthe group consisting of: anti-obesity drugs, central nervous systemstimulants, carotenoids, corticosteroids, elastase inhibitors,anti-fungals, oncology therapies, anti-emetics, analgesics,cardiovascular agents, anti-inflammatory agents, such as NSAIDs andCOX-2 inhibitors, anthelmintics, anti-arrhythmic agents, antibiotics(including penicillins), anticoagulants, antidepressants, antidiabeticagents, antiepileptics, antihistamines, antihypertensive agents,antimuscarinic agents, antimycobacterial agents, antineoplastic agents,immunosuppressants, antithyroid agents, antiviral agents, anxiolytics,sedatives (hypnotics and neuroleptics), astringents, alpha-adrenergicreceptor blocking agents, beta-adrenoceptor blocking agents, bloodproducts and substitutes, cardiac inotropic agents, contrast media,cough suppressants (expectorants and mucolytics), diagnostic agents,diagnostic imaging agents, diuretics, dopaminergics (anti-parkinsonianagents), haemostatics, immunological agents, lipid regulating agents,muscle relaxants, parasympathomimetics, parathyroid calcitonin andbiphosphonates, prostaglandins, radio-pharmaceuticals, sex hormones(including steroids), anti-allergic agents, stimulants and anoretics,sympathomimetics, thyroid agents, vasodilators, and xanthenes.Preferably, the biologically active material is selected from the groupconsisting of: indomethacin, diclofenac, naproxen, meloxicam,metaxalone, cyclosporin A, progesterone celecoxib, cilostazol,ciprofloxacin, 2,4-dichlorophenoxyacetic acid, anthraquinone, creatinemonohydrate, glyphosate, halusulfuron, mancozeb, metsulfuron,salbutamol, sulphur, tribenuran and estradiol or any salt or derivativethereof. In a preferred embodiment, the composition is adapted fordelivery by inhalation, intranasal delivery and/or pulmonary delivery.

In a fifth aspect the invention comprises a method of treating a humanin need of such treatment comprising the step of administering to thehuman an effective amount of a pharmaceutical composition as describedherein. In a preferred embodiment, the composition is administered byinhalation, intranasal delivery and/or pulmonary delivery.

In a sixth aspect, the invention comprises the use of a pharmaceuticalcomposition as described herein in the manufacture of a medicament forthe treatment of a human in need of such treatment. In a preferredembodiment, the medicament is adapted to be administered by inhalation,intranasal delivery and/or pulmonary delivery.

In a seventh aspect the invention comprises a method for manufacturing apharmaceutical composition as described herein comprising the step ofcombining a therapeutically effective amount of a biologically activematerial prepared by a method described herein or a composition asdescribed herein, together with a pharmaceutically acceptable carrier toproduce a pharmaceutically acceptable dosage form.

In a eighth aspect the invention comprises a method for manufacturing aveterinary product comprising the step of combining a therapeuticallyeffective amount of the biologically active material prepared by amethod as described herein or a composition as described herein,together with an acceptable excipient to produce a dosage formacceptable for veterinary use.

In an ninth aspect the invention comprises a method for manufacturing anagricultural product comprising the step of combining an effectiveamount of the biologically active material prepared by a methoddescribed herein or a composition as described herein. Preferably theagricultural product is combined with an acceptable excipient to producea formulation such as, but not limited to a water dispersible granule,wettable granule, dry flowable granule or soluble granule that is usedto prepare a solution for use in agricultural applications. Preferably,the product is selected from the group consisting of: herbicides,pesticides, seed treatments, herbicide safeners, plant growth regulatorsand fungicides. The methods of the invention can be used to increase thedissolution of the biologically active material particles in water orother solvents, resulting in better, faster or more complete preparationand mixing. This will result in a more consistent product performancesuch as better weed, disease and pest control and other practicalbenefits such as faster machinery, tank and sprayer cleanout, lessrinsate, and a reduced impact on the environment.

In another aspect of the method of invention, the invention providesmethods to produce powders that have active particles with a highsurface area. Such powders would provide better performance in areassuch as seed treatment where dry powders are applied to seeds asfungicides, herbicide safeners, plant growth regulators and othertreatments. The higher surface area would provide more activity per massof active used.

In another preferred aspect, actives such as pesticides, fungicides andseed treatments subject to the method of invention are formulated toproduce suspensions of the actives when added to water or othersolvents. As these suspensions will have particles of very small sizeand high surface area they will possess at least three highly desirabletraits. The first is that small particles with high surface area willadhere better to surfaces such as leafs and other foliage that thesuspension is applied to. This will result in better rain fastness and alonger period of activity. The second aspect is that smaller particleswith a higher surface area deliver superior coverage per unit mass ofactive applied. For example, if 100 particles are needed on a leaf andif the particle diameter is reduced to one third of the former diameterby the methods of this invention, then the dosage can be reduced toabout 11% of the former dosage, resulting in lower cost, less residue onharvested crops, and mitigation of environmental impact. In the thirdaspect the smaller particles will deliver better bioavailability. Withmany low solubility actives, such as fungicides and pesticides theparticles that adhere to plant material slowly dissolve over days andweeks providing continued protection from disease and pests. With thismethod of invention able to deliver better bioavailability in manycircumstances it will be possible to reduce the amount of active thatneeds to be applied. As with the second aspect such an outcome wouldlower costs, minimize residues and mitigate environmental impact. In ahighly preferred aspect of the invention the powder produced in themilling process would be subject to a process such as wet or drygranulation that makes the powder free flowing and low in dust contentyet easily dispersible once in water or other solvent.

Preferably the biologically active material is a herbicide, pesticide,seed treatment, herbicide safener, plant growth regulator or fungicideselected from the group consisting of: 2-phenylphenol,8-hydroxyquinoline sulfate, acibenzolar, allyl alcohol, azoxystrobin,basic benomyl, benzalkonium chloride, biphenyl, blasticidin-S, Bordeauxmixture, Boscalid, Burgundy mixture, butylamine, Cadendazim, calciumpolysulfide, Captan, carbamate fungicides, carbendazim, carvone,chloropicrin, chlorothalonil, ciclopirox, clotrimazole, conazolefungicides, Copper hydroxide, copper oxychloride, copper sulfate,copper(II) carbonate, copper(II) sulfate, cresol, cryprodinil, cuprousoxide, cycloheximide, Cymoxanil, DBCP, dehydroacetic acid, dicarboximidefungicides, difenoconazole, dimethomorph, diphenylamine, disulfiram,ethoxyquin, famoxadone, fenamidone, Fludioxonil, formaldehyde, fosetyl,Fosetyl-aluminium, furfural, griseofulvin, hexachlorobenzene,hexachlorobutadiene, hexachlorophene, hexaconazole, imazalil,Imidacloprid, iodomethane, Iprodione, Lime sulfur, mancozeb, mercuricchloride, mercuric oxide, mercurous chloride, Metalaxyl, metam, methylbromide, methyl isothiocyanate, metiram, natamycin, nystatin, organotinfungicides, oxythioquinox, pencycuron, pentachlorophenol, phenylmercuryacetate, potassium thiocyanate, procymidone, propiconazole, propineb,pyraclostrobin, pyrazole fungicides, pyridine fungicides, pyrimethanil,pyrimidine fungicides, pyrrole fungicides, quinoline fungicides, quinonefungicides, sodium azide, streptomycin, sulfur, Tebucanazole,thiabendazole, thiomersal, tolnaftate, Tolylfluanid, triadimersol,tributyltin oxide, Trifloxystrobin, triflumuron, Undecylenic acid, ureafungicides, vinclozolin, Ziram,3-dihydro-3-methyl-1,3-thiazol-2-ylidene-xylidene, 4-D esters, 4-DBesters, 4-parathion methyl, Acetamiprid, aclonifen, acrinathrin,alachlor, allethrin, alpha-cypermethrin, Aluminium phosphide, amitraz,anilophos, azaconazole, azinphos-ethyl, azinphos-methyl, benalaxyl,benfluralin, benfuracarb, benfuresate, bensulide, benzoximate,benzoylprop-ethyl, betacyfluthrin, beta-cypermethrin, bifenox,bifenthrin, binapacryl, bioallethrin, bioallethrin S, bioresmethrin,biteranol, Brodifacoum, bromophos, bromopropylate, bromoxynil,bromoxynil esters, bupirimate, buprofezin, butacarboxim, butachlor,butamifos, butoxycarboxin, butralin, butylate, calcium sulfate,cambda-cyhalothrin, carbetamide, carboxin, chlordimeform,chlorfenvinphos, chlorflurazuron, chlormephos, chlornitrofen,chlorobenzilate, chlorophoxim, chloropropylate, chlorpropham,Chlorpyrifos, chlorpyrifos-methyl, cinmethylin, clethodim, clomazone,clopyralid esters, CMPP esters, cyanophos, cycloate, cycloprothrin,cycloxydim, cyfluthrin, cyhalothrin, cypermethrin, cyphenothrin,cyproconazole, deltamethrin, demeton-S-methyl, desmedipham, dichlorpropesters, dichlorvos, diclofop-methyldiethatyl, dicofol, difenoconazole,dimethachlor, dimethomoph, diniconazole, dinitramine, dinobuton,dioxabenzafos, dioxacarb, disulfoton, ditalimfos, dodemorph, dodine,edifenphos, emamectin, empenthrin, endosulfan, EPNethiofencarb,epoxyconazole, esfenvalerate, ethalfluralin, ethofumesate, ethoprophos,ethoxyethyl, etofenprox, etridiazole, etrimphos, Famoxadone, fenamiphos,fenarimol, fenazaquin, fenitrothion, fenobucarb, fenoxapropethyl,fenoxycarb, fenpropathrin, fenpropidin, fenpropimorph, fenthiocarb,fenthion, fenvalerate, fluazifop, fluazifop-P, fluchloralin,flucythrinate, flufenoxim, flufenoxuron, flumetralin, fluorodifen,fluoroglycofen ethyl, fluoroxypyr esters, flurecol butyl,flurochloralin, flusilazole, formothion, gamma-HCH, haloxyfop,haloxyfop-methyl, hexaflumuron, hydroprene, imibenconazole, indoxacarb,ioxynil esters, isofenphos, isoprocarb, isopropalin, isoxathion,malathion, maneb, MCPA esters, mecoprop-P esters, mephospholan,Metaldehyde, methidathion, Methomyl, methoprene, methoxychlor,metolachlor, mevinphos, monalide, myclobutanil, N-2, napropamide,nitrofen, nuarimol, oxadiazon, oxycarboxin, oxyfluorfen, penconazole,pendimethalin, permethrin, phenisopham, phenmedipham, phenothrin,phenthoate, phosalone, phosfolan, phosmet, picloram esters, pirimicarb,pirimiphos-ethyl, pirimiphos-methyl, pretilachlor, prochloraz,profenofos, profluralin, promecarb, propachlor, propanil, propaphos,propaquizafop, propargite, propetamphos, pymetrozine, pyrachlofos,pyridate, pyrifenox, quinalphos, quizalofop-P, resmethrin, Spinetoram J,Spinetoram L, Spinosad A, Spinosad B, tau-fluvalinate, tebuconazole,Tebufenozide, tefluthrin, temephos, terbufos, tetrachlorinphos,tetraconazole, tetradifon, tetramethrin, Thiamethoxam, tolclofos-methyl,tralomethrin, triadimefon, triadimenol, triazophos, triclopyr esters,tridemorph, tridiphane, triflumizole, trifluralin, xylylcarb,3-dihydro-3-methyl-1,3-thiazol-2-ylidene-xylidene, 4-D esters, 4-DBesters, 4-parathion methyl, Acetamiprid, acetochlor, aclonifen,acrinathrin, alachlor, allethrin, alpha-cypermethrin, Aluminiumphosphide, amitraz, anilophos, azaconazole, azinphos-ethyl,azinphos-methyl, benalaxyl, benfluralin, benfuracarb, benfuresate,bensulide, benzoximate, benzoylprop-ethyl, betacyfluthrin,beta-cypermethrin, bifenox, bifenthrin, binapacryl, bioallethrin,bioallethrin S, bioresmethrin, biteranol, Brodifacoum, bromophos,bromopropylate, bromoxynil, bromoxynil esters, bupirimate, buprofezin,Butacarboxim, butachlor, butamifos, butoxycarboxin, butralin, butylate,calcium sulfate, cambda-cyhalothrin, carbetamide, carboxin,chlordimeform, chlorfenvinphos, chlorflurazuron, chlormephos,chlornitrofen, chlorobenzilate, chlorophoxim, chloropropylate,chlorpropham, Chlorpyrifos, chlorpyrifos-methyl, cinmethylin, clethodim,clomazone, clopyralid esters, CMPP esters, cyanophos, cycloate,cycloprothrin, cycloxydim, cyfluthrin, cyhalothrin, cypermethrin,cyphenothrin, cyproconazole, deltamethrin, demeton-S-methyl,desmedipham, dichlorprop esters, dichlorvos, diclofop-methyldiethatyl,dicofol, dimethachlor, dimethomoph, diniconazole, dinitramine,dinobuton, dioxabenzafos, dioxacarb, disulfoton, ditalimfos, dodemorph,dodine, edifenphos, emamectin, empenthrin, endosulfan, EPNethiofencarb,epoxyconazole, esfenvalerate, ethalfluralin, ethofumesate, ethoprophos,ethoxyethyl, ethoxyquin, etofenprox, etridiazole, etrimphos, fenamiphos,fenarimol, fenazaquin, fenitrothion, fenobucarb, fenoxapropethyl,fenoxycarb, fenpropathrin, fenpropidin, fenpropimorph, fenthiocarb,fenthion, fenvalerate, fluazifop, fluazifop-P, fluchloralin,flucythrinate, flufenoxim, flufenoxuron, flumetralin, fluorodifen,fluoroglycofen ethyl, fluoroxypyr esters, flurecol butyl,flurochloralin, flusilazole, formothion, gamma-HCH, haloxyfop,haloxyfop-methyl, hexaflumuron, hydroprene, imibenconazole, indoxacarb,ioxynil esters, isofenphos, isoprocarb, isopropalin, isoxathion,malathion, maneb, MCPA esters, mecoprop-P esters, mephospholan,Metaldehyde, methidathion, Methomyl, methoprene, methoxychlor,mevinphos, monalide, myclobutanil, myclobutanil, N-2, napropamide,nitrofen, nuarimol, oxadiazon, oxycarboxin, oxyfluorfen, penconazole,permethrin, phenisopham, phenmedipham, phenothrin, phenthoate,phosalone, phosfolan, phosmet, picloram esters, pirimicarb,pirimiphos-ethyl, pirimiphos-methyl, pretilachlor, prochloraz,profenofos, profluralin, promecarb, propachlor, propanil, propaphos,propaquizafop, propargite, propetamphos, pymetrozine, pyridate,pyrifenox, quinalphos, quizalofop-P, resmethrin, Spinetoram J,Spinetoram L, Spinosad A, Spinosad B, tau-fluvalinate, Tebufenozide,tefluthrin, temephos, terbufos, tetrachlorinphos, tetraconazole,tetradifon, tetramethrin, Thiamethoxam, tolclofos-methyl, tralomethrin,triadimenol, triazophos, triclopyr esters, tridemorph, tridiphane,triflumizole, trifluralin, xylylcarb and any combination thereof.

In an ninth aspect the invention comprises a method for manufacturing ofa pharmaceutical formulation comprising the step of combining aneffective amount of the biologically active material prepared by amethod described herein together with acceptable excipients to produce aformulation that can deliver a therapeutically effective amount ofactive to the pulmonary or nasal area. Such a formulation could be, butis not limited to a dry powder formulation for oral inhalation to thelungs or a formulation for nasal inhalation. Preferably the method formanufacturing such a formulation uses lactose, mannitol, sucrose,sorbitol, xylitol or other sugars or polyols as the co-grinding matrixtogether with surfactant such as, but not limited to lecithin, DPPC(dipalmitoyl phosphatidylcholine), PG (phosphatidylglycerol),dipalmitoyl phosphatidyl ethanolamine (DPPE), dipalmitoylphosphatidylinositol (DPPI) or other phospholipid. The particle size ofthe material produced by the invention disclosed herein results in thematerials being readily aerosolized and suitable for methods of deliveryto a subject in need thereof, including pulmonary and nasal deliverymethods. In a tenth aspect, the invention comprises a method for themanufacture of a composition for industrical application, such as, butnot limited to paints, polymers or other functional coatings, comprisingthe step of combining an effective amount of the active materialprepared by a method described herein together with an acceptableexcipient to produce a composition that can deliver an active particlesuch as, but not limited to, a fungicide in solid form to a coatingresistant to attack by biologically agents such as, but not limited to,a fungus or algae. Because small particles provide a greater surfacecoverage of active agent per unit mass than conventionally sizedparticles less active is required in the composition. The particlesgenerated by the invention would also provide ascetic advantages as theycan be incorporated into a coating formulation without the appearance ofhaving particulate matter in the coating. Preferably the method formanufacturing such a composition uses titanium dioxide, silica, sodiumchloride or other inorganic salts with a suitable surfactant or polymer.Preferably the active is a fungicide selected from the list ofherbicides, pesticides, seed treatments, herbicide safeners, plantgrowth regulators and fungicides described above.

In an eleventh aspect, the invention comprises a method for themanufacture of a radio-contrast agent for use in radiologicalexaminations. A common example of such an agent would be barium sulfatewhich is commonly used in examinations of the gastrointestinal tract.Agents such as barium sulfate are essentially insoluble in water andfunction as discrete particles dispersed throughout the area ofexamination. Formulations of active material used as radio-contrastagents as prepared by a method described herein with other acceptableexcipients could be used to provide enhanced sensitivity and lowertoxicity due to the increased surface area provided by the particle sizereduction. The increased surface area will provide greater coverage ofthe tissue to be measured providing better contrast. If the agent hastoxic side effects greater contrast per unit mass would allow for lesscontrast agent to be used compared with conventional formulations.Another advantage of preparing such a formulation using the methoddescribed herein is the ability to administer that contrast agent as adry formulation thus eliminating undesirable aspects of drinking aliquid formulation.

In a twelfth aspect, the invention comprises a method for themanufacture of a composition for use as a food product where theproduction of small particles has other functional advantages inaddition to a faster dissolution of the active. One example would bewhere the active agent is cocoa or cocoa derived solids. When cocoa isprocessed in the manufacture of chocolate the particle size must bereduced below a size threshold such that the chocolate has a smooth feelwhen eaten. In the same way better flavour is thought to come from smallcocoa particles. Premium chocolate is known to have a small particlesize distribution. By combining an appropriate amount of the activematerial, such as cocoa, cocoa powder, cocoa nibs, cocoa mass or cocoaliquor prepared by a method described herein together with other foodingredients a food product such as chocolate can be prepared. This canbe done to both enhance existing food products such as chocolate orprovide a more efficient and less costly process for some aspects of thefood product manufacture. Another aspect of this invention is thepreparation of a food product for drinking by combining an appropriateamount of the active material, such as cocoa, cocoa powder, cocoa nibs,cocoa mass, cocoa liquor or coffee, prepared by the method describedherein together with other food ingredients. Materials produced usingthis invention, having very small particles, could be directly used indrink products without leaving residue in the products due to largeparticle size. An example of this would be a drinking cocoa or drinkingchocolate were a cocoa material could be milled with a matrix such asbut not limited to sugar, glucose or lactose. Apart from greater releaseof flavours, such a product could directly use the natural product whereconventional food products only use water soluble extracts. A clearexample of this is coffee products. Instant coffee provides a convenientform of the product but is made by extracting flavor from coffee beansand then processing it into a soluble powder. In doing so some of thecomplex flavor of coffee is lost. In comparison, coffee made from groundcoffee beans provides an enhanced flavor rich drink but requires greaterpreparation and often uses expensive apparatuses. Some coffee stylesused ground coffee beans directly in a cup but this method leaves athick sludge in the bottom of the cup. Material produced by the methoddescribed herein would overcome these limitations of the prior art. Bypreparing the composition from coffee beans the full flavor can beaccessed and the small particle size produced by this invention producesa drink where the particles are suspended in the liquid which do notform a thick sludge. A further advantage of this invention is that thematerial produced is a dry powder which can then be easily packaged orprocessed further to provide a saleable product. A further advantage ofof this invention is that natural products such as coffee areencapsulated into the carrier matrix and thus have superior powderhandling properties compared to natural products milled on there own.Materials such as coffee can be milled in high energy mills to produceparticles with small size but the material is sticky and hard to handle.Other technologies, such as wet milling would be more costly as furtherprocessing, like spray drying, would be required to produce a powder.Preferred matrices used for milling in this aspect include, but are notlimited to, lactose, sucrose, fructose, mannitol, glucose, xylitol, milkpowders, other milk solids and lethicin. In one embodiment, theparticles of biologically active material of the invention are a sizeequal to or less than 20,000 nm. In one embodiment, the particles ofbiologically active material of the invention are a size equal to orless than 10,000 nm. In one embodiment, the particles of biologicallyactive material of the invention are a size equal to or less than 5,000nm.

While the method of the present invention has particular application inthe preparation of poorly water-soluble biologically active materials,the scope of the invention is not limited thereto. For example, themethod of the present invention enables production of highlywater-soluble biologically active materials. Such materials may exhibitadvantages over conventional materials by way of, for example, morerapid therapeutic action or lower dose. In contrast, wet grindingtechniques utilizing water (or other comparably polar solvents) areincapable of being applied to such materials, as the particles dissolveappreciably in the solvent.

Other aspects and advantages of the invention will become apparent tothose skilled in the art from a review of the ensuing description.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1A. Powder charge composition and particle size distribution ofmaterial milled in SPEX mill, examples A to S.

FIG. 1B. Powder charge composition and particle size distribution ofmaterial milled in SPEX mill, examples T to AL.

FIG. 1C. Powder charge composition and particle size distribution ofmaterial milled in SPEX mill, examples AM to BE.

FIG. 1D. Powder charge composition and particle size distribution ofmaterial milled in SPEX mill, examples BF to BX.

FIG. 1E. Powder charge composition and particle size distribution ofmaterial milled in SPEX mill, examples BY to CQ.

FIG. 1F. Powder charge composition and particle size distribution ofmaterial milled in SPEX mill, examples CR to DJ.

FIG. 1G. Powder charge composition and particle size distribution ofmaterial milled in SPEX mill, examples DK to EC.

FIG. 1H. The figure shows the X-Ray diffraction patterns: (A) aftermilling of Naproxen sodium in tartaric acid; (B) unmilled Naproxensodium and (C) unmilled Naproxen acid.

FIG. 2A. Powder charge composition and particle size distribution ofmaterial milled in 110 mL HD01 Attritor mill, examples A to F.

FIG. 3A. Powder charge composition and particle size distribution ofmaterial containing a mixture of 2 matrices, milled in SPEX mill,examples A to E.

FIG. 4A. Powder charge composition and particle size distribution ofmaterial milled in 1 L HD01 Attritor mill, examples A to G.

FIG. 5A. Powder charge composition and particle size distribution ofmaterial milled in 750 mL 1S Attritor mill, examples A to F.

FIG. 6A. Powder charge composition and particle size distribution ofmaterial milled in ½ Gallon 15 Attritor mill, examples A to R.

FIG. 6B. Powder charge composition and particle size distribution ofmaterial milled in ½ Gallon 15 Attritor mill, examples S to AK.

FIG. 6C. Powder charge composition and particle size distribution ofmaterial milled in ½ Gallon 15 Attritor mill, examples AL to AU.

FIG. 7A. Powder charge composition and particle size distribution ofMetaxalone milled in a variety of mills, examples A to O.

FIG. 8A. Powder charge composition and particle size distribution ofmaterial milled in HICOM mill, examples A to P.

FIG. 9A. Powder charge composition and particle size distribution ofmaterial milled in 1½ Gallon 1S Attritor mill, examples A to S.

FIG. 9B. Powder charge composition and particle size distribution ofmaterial milled in 1½ Gallon 1S Attritor mill, examples T to AL.

FIG. 10A. Powder charge composition and particle size distribution ofmaterial milled in a variety of large scale mills, examples A to F.

FIG. 11A. Powder charge composition and particle size distribution offood grade material milled in SPEX mill, examples A to S.

FIG. 11B. Powder charge composition and particle size distribution offood grade material milled in SPEX mill, examples T to AC.

FIG. 11C. Powder charge composition and particle size distribution offood grade material milled in SPEX mill, examples AD to AV.

FIG. 12A. Powder charge composition and particle size distribution offood grade material milled in ½ Gallon 1S Attritor mill, examples A toF.

FIG. 12B: Photos at the end of the milling in example 12 sample B.

FIG. 13A. Powder charge composition and particle size distribution ofNaproxen Acid milled in Mannitol in a ½ Gallon 1S Attritor mill,examples A to M.

FIG. 14A. Powder charge composition and particle size distribution ofNaproxen Acid milled in SPEX mill and particle size distribution afterfiltration, examples A to L.

FIG. 15: Table describing the milling of various actives and somematrices without active and the particle size of these actives as wellas the particle size of actives in a variety of other blends made forpowder handling characteristic testing.

FIG. 16: Powder adherence, angle of repose and particle size as measuredby dry powder laser diffraction of various actives/blends from example16

FIG. 17: Powder adherence measurements for stainless steel; A: Example16, M; B: Example 16, E; C Example 16, L; D: Example 16, K.

FIG. 18: Powder adherence measurements for Polypropylene; A: Example 16,B; B: Example 16, G; C Example 16, F; D: Example 16, L.

FIG. 19: Powder adherence measurements for Glass; A: Example 16, G; B:Example 16, M; C Example 16, F; D: Example 16, B.

FIG. 20: Bulk and Tap bulk density data and data from powder rheologymeasurements of various actives/blends from example 16

FIG. 21: SEM of Example 16 Sample S after 20 minutes milling 1,000×

FIG. 22 SEM of Example 16 Sample S after 20 minutes milling 6,000×

FIG. 23: SEM of Example 16 Sample S after 20 minutes milling 60,000×

FIG. 24 SEM of Example 16 Sample S after 30 minutes milling 1,000×

FIG. 25: SEM of Example 16 Sample S after 30 minutes milling 100,000×

FIG. 26: SEM of Example 16 Sample R after 20 minutes milling 1,000×

FIG. 27: SEM of Example 16 Sample R after 20 minutes milling 100,000×

FIG. 28: SEM of Example 16 Sample R after 20 minutes milling 100,000×

DETAILED DESCRIPTION OF THE INVENTION

General

Those skilled in the art will appreciate that the invention describedherein is susceptible to variations and modifications other than thosespecifically described. It is to be understood that the inventionincludes all such variations and modifications. The invention alsoincludes all of the steps, features, compositions and materials referredto or indicated in the specification, individually or collectively andany and all combinations or any two or more of the steps or features.

The present invention is not to be limited in scope by the specificembodiments described herein, which are intended for the purpose ofexemplification only. Functionally equivalent products, compositions andmethods are clearly within the scope of the invention as describedherein.

The invention described herein may include one or more ranges of values(e.g. size, concentration etc). A range of values will be understood toinclude all values within the range, including the values defining therange, and values adjacent to the range that lead to the same orsubstantially the same outcome as the values immediately adjacent tothat value which defines the boundary to the range.

The entire disclosures of all publications (including patents, patentapplications, journal articles, laboratory manuals, books, or otherdocuments) cited herein are hereby incorporated by reference. Inclusiondoes not constitute an admission is made that any of the referencesconstitute prior art or are part of the common general knowledge ofthose working in the field to which this invention relates.

Throughout this specification, unless the context requires otherwise,the word “comprise” or variations, such as “comprises” or “comprising”will be understood to imply the inclusion of a stated integer, or groupof integers, but not the exclusion of any other integers or group ofintegers. It is also noted that in this disclosure, and particularly inthe claims and/or paragraphs, terms such as “comprises”, “comprised”,“comprising” and the like can have the meaning attributed to it in USPatent law; e.g., they can mean “includes”, “included”, “including”, andthe like.

“Therapeutically effective amount” as used herein with respect tomethods of treatment and in particular drug dosage, shall mean thatdosage that provides the specific pharmacological response for which thedrug is administered in a significant number of subjects in need of suchtreatment. It is emphasized that “therapeutically effective amount,”administered to a particular subject in a particular instance will notalways be effective in treating the diseases described herein, eventhough such dosage is deemed a “therapeutically effective amount” bythose skilled in the art. It is to be further understood that drugdosages are, in particular instances, measured as oral dosages, or withreference to drug levels as measured in blood.

The term “inhibit” is defined to include its generally accepted meaningwhich includes prohibiting, preventing, restraining, and lowering,stopping, or reversing progression or severity, and such action on aresultant symptom. As such the present invention includes both medicaltherapeutic and prophylactic administration, as appropriate.

The term “biologically active material” is defined to mean abiologically active compound or a substance which comprises abiologically active compound. In this definition, a compound isgenerally taken to mean a distinct chemical entity where a chemicalformula or formulas can be used to describe the substance. Suchcompounds would generally, but not necessarily be identified in theliterature by a unique classification system such as a CAS number. Somecompounds may be more complex and have a mixed chemical structure. Forsuch compounds they may only have an empirical formula or bequalitatively identified. A compound would generally be a pure material,although it would be expected that up to 10%, 20%, 30%, 40%, 50%, 60%,70%, 80%, 90% of the substance could be other impurities and the like.Examples of biologically active compounds are, but not limited to,fungicides, pesticides, herbicides, seed treatments, cosmeceuticals,cosmetics, complementary medicines, natural products, vitamins,nutrients, nutraceuticals, pharmaceutical actives, biologics, aminoacids, proteins, peptides, nucleotides, nucleic acids, additives, foodsand food ingredients and analogs, homologs and first order derivativesthereof. A substance that contains a biologically active compound is anysubstance which has as one of its components a biologically activecompound. Examples of substances containing biologically activecompounds are, but not limited to, pharmaceutical formulations andproducts, cosmetic formulations and products, industrial formulationsand products, agricultural formulations and products, foods, seeds,cocoa and cocoa solids, coffee, herbs, spices, other plant materials,minerals, animal products, shells and other skeletal material.

Any of the terms, “biological(ly) active”, “active”, “active material”shall have the same meaning as biologically active material.

The term “grinding matrix” is defined as any inert substance that abiologically active material can or is combined with and milled. Theterms “co-grinding matrix” and “matrix” are interchangeable with“grinding matrix”.

The term “of the same, similar or larger particle size” is defined aswhere the median (by volume) particle size of an active materialproduced by a conventional manufacturing process is the same, with amedian size+/−20%; similar, with a median size+/−5 micron; or larger,where the median size is greater than the particle size of an activematerial produced by the process described herein but is less than orequal to 20 micron.

The term “conventional process” is defined as another (different to theone described herein) dry manufacturing process where a biologicallyactive material is subject to particle size reduction. Examples of suchprocesses are, but are not limited to, conventional ball milling (whereno matrix is present or the active material is greater than 80% w/w),pin mills, air jet mills or other fluid energy mills

The term “nanoparticle” is defined as having a median diameter (byvolume) of 1000 nm or less. The term “microparticle” is defined ashaving a median diameter (by volume) of 1000 nm to 20,000 nm inclusive

The term “composite particle” is defined as the combination ofnanopaticle and/or microparticles of a biologically active materialtogether with the particles of the grinding matrix (milled or partiallymilled) into a larger particle.

The term “blend” is defined as the resultant mixture of a biologicallyactive material and excipient particles combined together in a processthat has the effect or intended effect of distributing the active andexcipient particles in a uniform distribution throughout the finalpowder blend. In this definition the term excipient and matrix areinterchangeable. An ensemble of composite particles as produced by theinvention described herein is one example of a blend. Preferably a blendis made using simple blending processes that do not involve granulationbut may involve a milling step.

The term “content uniformity” is defined as the measure of how evenly anactive material is distributed throughout a blend. A blend with superiorcontent uniformity will have the same concentration of active in manysamples taken from different places (eg: top middle and bottom) in ablend. Typically content uniformity is measured by assaying the sampleby HPLC or similar technique to determine the concentration of active ina sample. Typically content uniformity is expressed as the % deviationof the many samples from the known concentration of the whole blend.

The term “segregation” is stratification of the particle sizedistribution of a powder or blend. It can be caused by any physicalprocess, but typically it occurs when a powder or blend undergoes flowor other movement. Examples of processes that can introduce segregationare, but not limited to, transport, blending and flow in a hopper orother processing equipment. A powder or blend in an unsegregated statewill have an even distribution of particle sizes throughout the wholepowder or blend such that any sample taken from any part of the bag orcontainer holding the powder (such as top, middle, bottom) will give thesame particle size distribution. In a powder that has undergonesegregation some parts of the powder will have more large particles thatother parts and some parts will have more small particles than otherparts of the powder. In a powder with segregation samples taken from avariety of positions in the bag or container holding the powder (such astop, middle, bottom) will typically show some difference in the particlesize distribution.

Blends and Composite Particles

A conventional approach to reducing the size (in a dry process) ofactive particles is fluid energy milling. An example of this is airjetmilling (also known as micronisation). This technique and other similarmilling techniques typically reduced the particle size to between 2 and10 micron. The powder that results from air milling typically has poorpowder handling characteristics. This powder is often cohesive, has poorflow properties, has high static charge and low bulk density. In orderto process this micronized active material into a product such as, butnot limited to, a solid oral dose or inhaled powder, it must first beprocessed into a suitable blend with other excipients. The creation of ablend is not a trivial process with the poor handling properties of amicronized material making any process difficult. The creation of theblend has many benefits such as diluting the active to lower doses,bulking the active up to make dosage forms of a practical size and thecreation of a powder with superior flow properties making it easier tohandle in subsequent manufacturing processes, such as granulation ortabletting.

To create a blend with improved powder handling properties, excipientswith a particle size significantly larger than the micronized activecould be used. However, this approach has the disadvantage of potentialsegregation during the blending or subsequent process. If thesegregation of such a blend occurs, the content uniformity will be poorwhich is highly undesirable in pharmaceutical manufacturing. Ifexcipients with a particle size similar to the micronized active areused, then segregation is less likely but the powder handling propertiesof the material would be poor. In practice a compromise is usuallyundertaken whereby an intermediate sized excipient is used. In thiscase, careful blending and processing can maintain acceptable contentuniformity and the powder handling properties are improved enough tofacilitate further processing such as wet or dry granulation.

If a high level of content uniformity is required an alternativeapproach would be to process the excipient and active in an airjet milltogether. This process would create a blend where the excipient andactive have almost identical particle size thus preventing segregation.However this material would have poor powder handling properties andwould require careful handling in subsequent processes. This materialwould likely need to be wet or dry granulated.

In a surprising and unexpected discovery, the invention described hereinovercomes both of these problems. Even more surprising is that theinvention overcomes these problems even when the active particlesproduced in the milling process are significantly smaller than activeparticles produced in conventional milling process such as air jetmilling. One skilled in the art would expect that if 2 μm particles havepoor powder handling properties then 200 nm particles would havesignificantly poorer powder handling properties.

It is thought that the process described herein overcomes both the issueof poor powder handling and poor content uniformity by the simultaneousproduction of active nanoparticles and/or microparticle, the blending ofthese with the grinding matrix (excipients) and the formation ofcomposite particles of the active particles and matrix particles. Inthis way, powder with three clear benefits is produced in a “one pot”process. Firstly, active nanoparticles and/or microparticle are made,secondly, the particle size of the blend produced is large enough togive superior powder handling properties compared to conventionalmethods and, thirdly, the formation of the composite particlesdeliveries robust content uniformity.

It is thought that during the process described herein the activeparticles are uniformly distributed throughout the composite particlesso that each composite particle contains the same proportion of activeand excipient. This means that even if segregation were to occur, theblend would retain superior content uniformity. In contrast, aconventional blend made with active particles smaller than the excipientparticles would have poor content uniformity if the blend were tosegregate.

Those skilled in the art recognise that it is beneficial to measure theparticle size distribution of a powder or blend of powders because thisinformation can be used to predict the powder handling properties.Methods use to determine the particle size of powders are well known inthe art. Some common methods include laser diffraction measurements of astream of the powder dispersed in air. Laser diffraction measurementscan also be made in solvents where the solvent does not dissolve any ofthe powder or particles in the powder. The same methods can be used todetermine the size distribution of a powder blend or, in the case of theinvention herein, the composite particles. In the case of thisinvention, the particle size distribution of the composite and the blendare the same thing. In the case where a solvent based measurement isused to characterise the composite particles, care must be taken toensure that the solvent does not break up the composite as this will notgive a true indication of the composite behaviour as a dry powder. Forthis reason it is preferable to measure the particle size distributionof the composites using a dry powder method such as air dispersioncoupled with laser diffraction.

Preferably, the blend particles have a median particle size, determinedon a particle volume basis, equal or greater than a size selected fromthe group consisting of: 2000 nm, 3000 nm, 4000 nm, 5000 nm, 6000 nm,8000 nm, 10,000 nm, 15,000 nm, 20,000 nm. Preferably, the medianparticle size is equal to or less than 50 micron.

Preferably, the blend particles have a volume weighted mean (D4,3) equalor greater than a size selected from the group consisting of: 5000 nm,10,000 nm, 15,000 nm, 20,000 nm, 25,000 nm, 35,000 nm, 40,000 nmPreferably, the median particle size is equal to or less than 70 micron.

Preferably, the percentage of particles in the blend, on a particlevolume basis, is selected from the group consisting of: greater than 2micron (%>2 micron) is selected from the group 50%, 60%, 70%, 80%, 85%,90% and 95%; greater than 10 micron (%>10 micron) is selected from thegroup 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 85%, 90% and 95%; equal toor less than 20 micron (%<20 micron) is selected from the group 10%,20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95% and 100%

Powder Handling Characteristics

The expression “powder handling characteristics” refers to, but is notlimited to, at least one of the product's flow properties; staticcharge, aggregation properties, cohesive properties, uniformityproperties, content uniformity, content uniformity after segregation,dust levels, powder rheology, segregation properties, bulk density,powder flow, compressibility, permeability and/or ignition properties.The process described herein to mill biologically active material andgenerate reduced particle size wherein the powders and/or blends made bythe process of the present invention have powder handling propertiesthat are superior to those of powders made by a conventional processdelivering the same, similar or larger particle size of the biologicallyactive material when the product: is stored in vials, bags, containersor other closures; is dispensed; is blended; is granulated (wet or dry);is packaged or filled and processed and/or transported during othermanufacturing steps.

In one preferred embodiment, the powder handling characteristics of thebiologically active material subject to this invention is an improvementover the powder handling characteristics of a biologically activematerial of the same, similar or larger particle size manufactured usinga conventional process. Preferably, the biologically active materialsubject to this invention has superior powder flow properties comparedto the powder flow properties of a biologically active material with thesame, similar or larger particle size manufactured using a conventionalprocess. This is a particular advantage during processing of thematerial. Preferably, the biologically active material subject to thisinvention has a lower static charge compared to the static charge of abiologically active material with the same, similar or larger particlesize manufactured using a conventional process. Preferably the staticcharge of the product is selected from the group consisting of: lessthan 10 nC/g, less than 5 nC/g, less than 3 nC/g, less than 2 nC/g, lessthan 1.5 nC/g, less than 1.25 nC/g, less than 1 nC/g less than 0.75nC/g, less than 0.5 nC/g, less than 0.25 nC/g or less than 0.1 nC/g.Preferably, the biologically active material subject to this inventionhas a lower cohesiveness profile compared to the cohesiveness profile ofa biologically active material with the same, similar or larger particlesize manufactured using a conventional process. Preferably the specificenergy (were a lower value indicates less cohesiveness), as measured bypowder rheology, of the product is selected from the group consistingof: less than 12 mJ/g, less than 10 mJ/g, less than 9 mJ/g, less than 8mJ/g, less than 7 mJ/g, less than 6 mJ/g, less than 5 mJ/g less than 4mJ/g or less than 3 mJ/g. Preferably, the biologically active materialsubject to this invention has a lower propensity for aggregationcompared to the propensity for aggregation of a biologically activematerial with the same, similar or larger particle size manufacturedusing a conventional process. Preferably, the biologically activematerial subject to this invention has a lower propensity for adherenceto other materials such as but not limited to stainless steel, glass,plastic, polyethylene and polypropylene compared to the propensity foradherence of a biologically active material with the same, similar orlarger particle size manufactured using a conventional process.

Preferably, the biologically active material subject to this inventionhas increased uniformity compared to a biologically active material withthe same, similar or larger particle size manufactured using aconventional process. Preferably the biological active materialmaintains its superior uniformity despite numerous process steps andmodifications to the material. Preferably, the biological activematerial maintains its superior uniformity despite some level ofsegregation. For example, even if the biological material particles ofvarying size segregate, a uniform amount of active is maintained in theparticles. Preferably the content uniformity of the biologically activematerial throughout the blend (even after segregation) varies from theaverage content by a percentage less than or equal to a percentageselected from the group consisting of: 0.1%, 0.2%, 0.3%, 0.4%, 0.5%0.75%, 1.0%, 1.5%, 2.0%, 3.0%, 4.0% and 5.0%.

Preferably, the composite particles made by the methods of the inventioncomprises both biologically active material and matrix material andthese composite particles have increased uniformity compared to mattermade by conventional processes. This has advantages in the preparationof pharmaceuticals whereby the composite particles made by the methodsof the invention is ready to use and does not require the addition offurther excipients to bulk up the matter so that it can be formulated.In addition, the composite particles made by the methods of theinvention comprises both biologically active material and matrixmaterial and these composite particles have superior flow propertiescompared to those made by conventional processes.

This translates into significant advantages in the preparation ofnanoparticle and/or microparticles. For example, during the formulationof micronized actives by a conventional process, the actives must beblended with bulking excipients and then further processed (dry or wetgranulation to improve product flow) carefully so as to avoidsegregation of poor content uniformity. However, actives made by thisinvention (which can be made at sizes less than 1 μm, which the skilledaddressee would expect to have significantly worse segregation problems)are in the same process made into composite particles with the matrixmaterial thus having superior uniformity properties compared to activesmade by conventional processes, and do not need further processingsteps.

Preferably, the biologically active material subject to this inventionhas reduced levels of dust compared to a biologically active materialwith the same, similar or larger particle size manufactured using aconventional process. Preferably, the biologically active materialsubject to this invention has improved rheology compared to abiologically active material with the same, similar or larger particlesize manufactured using a conventional process.

Preferably the sheer Stress of the product is selected from the group:less than 3 kPa, less than 2.75 kPa, less than 2.5 kPa, less than 2.35kPa, less than 2.25 kPa, less than 2.1 kPa, less than 2.0 kPa, less than1.85 kPa, less than 1.75 kPa, less than 1.50 kPa, less than 1.25 kPa orless than 1.0 kPa. Preferably the basic flow energy of the product isselected from the group: less than 500 mJ, less than 450 mJ, less than400 mJ, less than 375 mJ, less than 350 mJ, less than 325 mJ, less than300 mJ, or less than 250. Preferably, the biologically active materialsubject to this invention has reduced segregation compared to abiologically active material with the same, similar or larger particlesize manufactured using a conventional process. Preferably, thebiologically active material subject to this invention has increasedbulk density or tapped bulk density compared to a biologically activematerial with the same, similar or larger particle size manufacturedusing a conventional process. Preferably the bulk density of the productis selected from the group consisting of: greater than 0.3 g/ml, greaterthan 0.4 g/ml, greater than 0.45 g/ml, greater than 0.5 g/ml, greaterthan 0.55 g/ml, greater than 0.60 g/ml, greater than 0.65 g/ml, greaterthan 0.7 g/ml, greater than 0.75 g/ml, greater than 0.80 g/ml, greaterthan 0.85 g/ml. greater than 0.90 g/ml or greater than 1.0 g/ml.Preferably the tapped bulk density of the product is selected from thegroup consisting of: greater than 0.3 g/ml, greater than 0.4 g/ml,greater than 0.45 g/ml, greater than 0.5 g/ml, greater than 0.55 g/ml,greater than 0.60 g/ml, greater than 0.65 g/ml, greater than 0.7 g/ml,greater than 0.75 g/ml, greater than 0.80 g/ml, greater than 0.85 g/ml.greater than 0.90 g/ml or greater than 1.0 g/ml. Preferably, thebiologically active material subject to this invention has superiorpowder flow as defined by the Hausner ratio or Carr's index compared toa biologically active material with the same, similar or larger particlesize manufactured using a conventional process. Preferably, thebiologically active material subject to this invention has lowercompressibility compared to a biologically active material with thesame, similar or larger particle size manufactured using a conventionalprocess. Preferably the % compressibility, as measured using a powderrheometer is less than the % selected for the group: 30, 25, 20, 17, 15,13 and 10. Preferably, the biologically active material subject to thisinvention has increased permeability compared to a biologically activematerial with the same, similar or larger particle size manufacturedusing a conventional process. Preferably the the pressure drop (where alow pressure drop indicates superior permeability), as measured as thepressure drop across a bed of powder in a powder rheometer, is selectedfor the group consisting of: less than 20 mBar, less than 15 mBar, lessthan 10 mBar, less than 7 mBar, less than 5 mBar, less than 4 mBar orless than 3 mBar. Preferably, the biologically active material subjectto this invention has a higher minimum ignition energy compared to abiologically active material with the same, similar or larger particlesize manufactured using a conventional process. Preferably, thebiologically active material subject to this invention has higher hopperflow rates compared to a biologically active material with the same,similar or larger particle size manufactured using a conventionalprocess. Preferably, the biologically active material subject to thisinvention has smaller critical orifice diameter compared to abiologically active material with the same, similar or larger particlesize manufactured using a conventional process. Preferably, thebiologically active material subject to this invention has smaller angleof repose compared to a biologically active material with the same,similar or larger particle size manufactured using a conventionalprocess. Preferably, the biologically active material subject to thisinvention has smaller dynamic angle of repose compared to a biologicallyactive material with the same, similar or larger particle sizemanufactured using a conventional process.

In one preferred embodiment, the powder handling characteristics of ablend made using this invention is an improvement over the powderhandling characteristics of a blend (containing biologically activematerial of the same, similar or larger particle size) manufacturedusing a conventional process. Preferably, the blend made using thisinvention has superior powder flow properties compared to the powderflow properties of a blend (containing biologically active material ofthe same, similar or larger particle size) manufactured using aconventional process. This is a particular advantage during processingof the material. Preferably, the blend made using this invention has alower static charge compared to the static charge of a blend (containingbiologically active material of the same, similar or larger particlesize) manufactured using a conventional process. Preferably the staticcharge of the product is selected from the group consisting of: lessthan 10 nC/g, less than 5 nC/g, less than 3 nC/g, less than 2 nC/g, lessthan 1.5 nC/g, less than 1.25 nC/g, less than 1 nC/g less than 0.75nC/g, less than 0.5 nC/g, less than 0.25 nC/g or less than 0.1 nC/g.Preferably, the blend made using this invention has a lower cohesivenessprofile compared to the cohesiveness profile of a blend (containingbiologically active material of the same, similar or larger particlesize) manufactured using a conventional process. Preferably the specificenergy (were a lower value indicates less cohesiveness), as measured bypowder rheology, of the product is selected from the group consistingof: less than 12 mJ/g, less than 10 mJ/g, less than 9 mJ/g, less than 8mJ/g, less than 7 mJ/g, less than 6 mJ/g, less than 5 mJ/g less than 4mJ/g or less than 3 mJ/g. Preferably, the blend made using thisinvention has a lower propensity for aggregation compared to thepropensity for aggregation of a blend (containing biologically activematerial of the same, similar or larger particle size) manufacturedusing a conventional process. Preferably, the blend made using thisinvention has a lower propensity for adherence to other materials suchas but not limited to stainless steel, glass, plastic, polyethylene andpolypropylene compared to the propensity for adherence of a blend(containing biologically active material of the same, similar or largerparticle size) manufactured using a conventional process.

Preferably, the blend made using this invention has increased uniformitycompared to a blend (containing biologically active material of thesame, similar or larger particle size) manufactured using a conventionalprocess. Preferably the biological active material maintains itssuperior uniformity despite numerous process steps and modifications tothe material. Preferably, the biological active material maintains itssuperior uniformity despite some level of segregation. For example, evenif the biological material particles of varying size segregate, auniform amount of active is maintained in the particles. Preferably thecontent uniformity of the biologically active material throughout theblend (even after segregation) varies from the average content by apercentage less than or equal to a percentage selected from the groupconsisting of: 0.1%, 0.2%, 0.3%, 0.4%, 0.5% 0.75%, 1.0%, 1.5%, 2.0%,3.0%, 4.0% and 5.0%.

Preferably, the blend made using this invention has reduced levels ofdust compared to a blend (containing biologically active material of thesame, similar or larger particle size) manufactured using a conventionalprocess. Preferably, the blend made using this invention has improvedrheology compared to a blend (containing biologically active material ofthe same, similar or larger particle size) manufactured using aconventional process.

Preferably the sheer Stress of the product is selected from the group:less than 3 kPa, less than 2.75 kPa, less than 2.5 kPa, less than 2.35kPa, less than 2.25 kPa, less than 2.1 kPa, less than 2.0 kPa, less than1.85 kPa, less than 1.75 kPa, less than 1.50 kPa, less than 1.25 kPa orless than 1.0 kPa. Preferably the basic flow energy of the product isselected from the group: less than 500 mJ, less than 450 mJ, less than400 mJ, less than 375 mJ, less than 350 mJ, less than 325 mJ, less than300 mJ, or less than 250. Preferably, the blend made using thisinvention has reduced segregation compared to a blend (containingbiologically active material of the same, similar or larger particlesize) manufactured using a conventional process. Preferably, the blendmade using this invention has increased bulk density or tapped bulkdensity compared to a blend (containing biologically active material ofthe same, similar or larger particle size) manufactured using aconventional process. Preferably the bulk density of the blend isselected from the group: greater than 0.3 g/ml, greater than 0.4 g/ml,greater than 0.45 g/ml, greater than 0.5 g/ml, greater than 0.55 g/ml,greater than 0.60 g/ml, greater than 0.65 g/ml, greater than 0.7 g/ml,greater than 0.75 g/ml, greater than 0.80 g/ml, greater than 0.85 g/ml.greater than 0.90 g/ml or greater than 1.0 g/ml. Preferably the tappedbulk density of the blend is selected from the group: greater than 0.3g/ml, greater than 0.4 g/ml, greater than 0.45 g/ml, greater than 0.5g/ml, greater than 0.55 g/ml, greater than 0.60 g/ml, greater than 0.65g/ml, greater than 0.7 g/ml, greater than 0.75 g/ml, greater than 0.80g/ml, greater than 0.85 g/ml. greater than 0.90 g/ml or greater than 1.0g/ml. Preferably, the blend made using this invention has superiorpowder flow as defined by the Hausner ratio or Carr's index compared toa blend (containing biologically active material of the same, similar orlarger particle size) manufactured using a conventional process.Preferably, the blend made using this invention has lowercompressibility compared to a blend (containing biologically activematerial of the same, similar or larger particle size) manufacturedusing a conventional process. Preferably the % compressibility, asmeasured using a powder rheometer is less than the selected for thegroup: 30, 25, 20, 17, 15, 13 and 10. Preferably, the blend made usingthis invention has increased permeability compared to a blend(containing biologically active material of the same, similar or largerparticle size) manufactured using a conventional process. Preferably thethe pressure drop (where a low pressure drop indicates superiorpermeability), as measured as the pressure drop across a bed of powderin a powder rheometer is selected for the group: less than 20 mBar, lessthan 15 mBar, less than 10 mBar, less than 7 mBar, less than 5 mBar,less than 4 mBar or less than 3 mBar. Preferably, the blend made usingthis invention has a higher minimum ignition energy compared to a blend(containing biologically active material of the same, similar or largerparticle size) manufactured using a conventional process. Preferably,the blend made using this invention has higher hopper flow ratescompared to a blend (containing biologically active material of thesame, similar or larger particle size) manufactured using a conventionalprocess. Preferably, the blend made using this invention has smallercritical orifice diameter compared to a blend (containing biologicallyactive material of the same, similar or larger particle size)manufactured using a conventional process.

Preferably, the blend made using this invention has smaller angle ofrepose compared to a blend (containing biologically active material ofthe same, similar or larger particle size) manufactured using aconventional process. Preferably, the blend made using this inventionhas smaller dynamic angle of repose compared to a blend (containingbiologically active material of the same, similar or larger particlesize) manufactured using a conventional process. For example, theprocess improves powder handling characteristics relative toconventional powders of the same, similar or larger particle size whenthe biologically active material is manufactured, processed andformulated and finally stored in a capsule. The material is more easilypoured into a capsule from a dispensing device. The material hasimproved flow properties so that it flows smoothly into the capsule anddoes not aggregate significantly when it pores, nor does it adheresignificantly to any handling apparatuses or containers, and thus doesnot result in a significant loss of product. It's static parameters haveimproved such that the material does not adhere to the dispensing deviceor containers. The powder handling characteristics have improved suchthat it can be efficiently manufactured, processed and stored withoutsignificant loss of material from poor product flow, high aggregation,high adherence and high static properties. The powder handlingcharacteristics have improved such that it can be manufactured to meetassay and content uniformity requirements as set out in the USP. Thematerial has improved powder handling characteristics when dry. Thematerial has improved powder handling characteristics when combined withextra functional excipients. For example the material has improvedpowder handling characteristics when combined with disintegrants,binders, wetting agents, fillers, disintegrants, binders, wetting agentsand the like such that there are no issues with segregation oruniformity of the active through the blended material. The powderhandling characteristics have improved such that it can be easilyprocessed through standard processing equipment such as a rollercompactor (dry granulator) or a wet granulator.

Particle Size

There are a wide range of techniques that can be utilized tocharacterize the particle size of a material. Those skilled in the artalso understand that almost all these techniques do not physicallymeasure the actually particle size, as one might measure something witha ruler, but measure a physical phenomena which is interpreted toindicate a particle size. As part of the interpretation process someassumptions need to be made to enable mathematical calculations to bemade. These assumptions deliver results such as an equivalent sphericalparticle size, or a hydrodynamic radius.

Amongst these various methods, two types of measurements are mostcommonly used. Photon correlation spectroscopy (PCS), also known as‘dynamic light scattering’ (DLS) is commonly used to measure particleswith a size less than 10 micron. Typically this measurement yields anequivalent hydrodynamic radius often expressed as the average size of anumber distribution. The other common particle size measurement is laserdiffraction which is commonly used to measure particle size from 100 nmto 2000 micron. This technique calculates a volume distribution ofequivalent spherical particles that can be expressed using descriptorssuch as the median particle size or the % of particles under a givensize.

Those skilled in the art recognize that different characterizationtechniques such as photon correlation spectroscopy and laser diffractionmeasure different properties of a particle ensemble. As a resultmultiple techniques will give multiple answers to the question, “what isthe particle size.” In theory one could convert and compare the variousparameters each technique measures, however, for real world particlesystems this is not practical. As a result the particle size used todescribe this invention will be given as two different sets of valuesthat each relate to these two common measurement techniques, such thatmeasurements could be made with either technique and then evaluatedagainst the description of this invention.

For measurements made using a photo correlation spectroscopy instrument,or an equivalent method known in the art, the term “number averageparticle size” is defined as the average particle diameter as determinedon a number basis.

For measurements made using a laser diffraction instrument, or anequivalent method known in the art, the term “median particle size” isdefined as the median particle diameter as determined on an equivalentspherical particle volume basis. Where the term median is used, it isunderstood to describe the particle size that divides the population inhalf such that 50% of the population is greater than or less than thissize. The median particle size is often written as D50, D(0.50) orD[0.5] or similar. As used herein D50, D(0.50) or D[0.5] or similarshall be taken to mean ‘median particle size’.

The term “Dx of the particle size distribution” refers to the xthpercentile of the distribution; thus, D90 refers to the 90^(th)percentile, D95 refers to the 95^(th) percentile, and so forth. TakingD90 as an example this can often be written as, D(0.90) or D[0.9] orsimilar. With respect to the median particle size and Dx an upper case Dor lowercase d are interchangeable and have the same meaning. Anotherway to quantitate a particle size distribution is the volume weightedmean (D4,3). D4,3 is defined as sum of the diameters to the power 4divided by the sum of the diameters cubed.

Another commonly used way of describing a particle size distributionmeasured by laser diffraction, or an equivalent method known in the art,is to describe what % of a distribution is under or over a nominatedsize. The term “percentage less than” also written as “%<” is defined asthe percentage, by volume, of a particle size distribution under anominated size—for example the %<1000 nm. The term “percentage greaterthan” also written as “%>” is defined as the percentage, by volume, of aparticle size distribution over a nominated size—for example the %>1000nm.

The particle size used to describe this invention should be taken tomean the particle size as measured at or shortly before the time of use.For example, the particle size is measured 2 months after the materialis subject to the milling method of this invention. In a preferred form,the particle size is measured at a time selected from the groupconsisting of: 1 day after milling, 2 days after milling, 5 days aftermilling, 1 month after milling, 2 months after milling, 3 months aftermilling, 4 months after milling, 5 months after milling, 6 months aftermilling, 1 year after milling, 2 years after milling, 5 years aftermilling.

For many of the materials subject to the methods of this invention theparticle size can be easily measured. Where the active material has poorwater solubility and the matrix it is milled in has good watersolubility the powder can simply be dispersed in an aqueous solvent. Inthis scenario the matrix dissolves leaving the active material dispersedin the solvent. This suspension can then be measured by techniques suchas PCS or laser diffraction.

Suitable methods to measure an accurate particle size where the activematerial has substantive aqueous solubility or the matrix has lowsolubility in a water based dispersant are outlined below.

-   -   1. In the circumstance where insoluble matrix such as        microcrystalline cellulose prevents the measurement of the        active material separation techniques such as filtration or        centrifugation could be used to separate the insoluble matrix        from the active material particles. Other ancillary techniques        would also be required to determine if any active material was        removed by the separation technique so that this could be taken        into account.    -   2. In the case where the active material is too soluble in water        other solvents could be evaluated for the measurement of        particle size. Where a solvent could be found that active        material is poorly soluble in but is a good solvent for the        matrix a measurement would be relatively straight forward. If        such a solvent is difficult to find another approach would be to        measure the ensemble of matrix and active material in a solvent        (such as iso-octane) which both are insoluble in. Then the        powder would be measured in another solvent where the active        material is soluble but the matrix is not. Thus with a        measurement of the matrix particle size and a measurement of the        size of the matrix and active material together an understanding        of the active material particle size can be obtained.    -   3. In some circumstances image analysis could be used to obtain        information about the particle size distribution of the active        material. Suitable image measurement techniques might include        transmission electron microscopy (TEM), scanning electron        microscopy (SEM), optical microscopy and confocal microscopy. In        addition to these standard techniques some additional technique        would be required to be used in parallel to differentiate the        active material and matrix particles. Depending on the chemical        makeup of the materials involved possible techniques could be        elemental analysis, raman spectroscopy, FTIR spectroscopy or        fluorescence spectroscopy.

Other Definitions

Throughout this specification, unless the context requires otherwise,the phrase “dry mill” or variations, such as “dry milling”, should beunderstood to refer to milling in at least the substantial absence ofliquids. If liquids are present, they are present in such amounts thatthe contents of the mill retain the characteristics of a dry powder.

“Flowable” means a powder having physical characteristics rendering itsuitable for further processing using typical equipment used for themanufacture of pharmaceutical compositions and formulations.

Other definitions for selected terms used herein may be found within thedetailed description of the invention and apply throughout. Unlessotherwise defined, all other scientific and technical terms used hereinhave the same meaning as commonly understood to one of ordinary skill inthe art to which the invention belongs.

The term “millable” means that the grinding matrix is capable of beingphysically degraded under the dry milling conditions of the method ofthe invention. In one embodiment of the invention, the milled grindingmatrix is of a comparable particle size to the biologically activematerial. In another embodiment of the invention the particle size ofthe matrix is substantially reduced but not as small as the biologicallyactive material

Other definitions for selected terms used herein may be found within thedetailed description of the invention and apply throughout. Unlessotherwise defined, all other scientific and technical terms used hereinhave the same meaning as commonly understood to one of ordinary skill inthe art to which the invention belongs.

Specific

In one embodiment, the present invention is directed to a method forproducing a composition, comprising the steps of: dry milling a solidbiologically active material and a millable grinding matrix in a millcomprising a plurality of milling bodies, for a time period sufficientto produce particles of the biologically active material dispersed in anat least partially milled grinding material.

The mixture of active material and matrix may then be separated from themilling bodies and removed from the mill.

In one aspect the mixture of active material and matrix is then furtherprocessed. In another aspect, the grinding matrix is separated from theparticles of biologically active material. In a further aspect, at leasta portion of the milled grinding matrix is separated from theparticulate biologically active material.

The milling bodies are essentially resistant to fracture and erosion inthe dry milling process. The quantity of the grinding matrix relative tothe quantity of biologically active material in particulate form, andthe extent of milling of the grinding matrix, is sufficient to inhibitre-agglomeration of the particles of the active material.

The present invention also relates to biologically active materialsproduced by said methods, to medicaments produced using saidbiologically active materials and to methods of treatment of an animal,including man, using a therapeutically effective amount of saidbiologically active materials administered by way of said medicaments.

Commercial Scale

The present invention is directed to the unexpected finding thatparticles of a biologically active material can be produced by drymilling processes as described herein at commercial scale. In onesurprising aspect the particle size of the biologically active materialproduced by the process is equal to or less than 20,000 nm. In anothersurprising aspect the particle size of the biologically active materialproduced by the process is equal to or less than 10,000 nm. In anothersurprising aspect the particle size of the biologically active materialproduced by the process is equal to or less than 5,000 nm. In anothersurprising aspect the particle size of the biologically active materialproduced by the process is equal to or less than 2000 nm. In anothersurprising aspect the particle size of the biologically active materialproduced by the process is equal to or less than 1000 nm. This canresult in a more efficient and cost effective process. One of the keygoals of reducing manufacturing costs is the encapsulation of thenanoparticles into materials that do not have to be removed. Thisenables a simple manufacturing process where conventional formulationtechnologies can be used to progress the matrix encapsulatednanoparticles directly to a final product. In order to do this thematerials used within the matrix must be acceptable to industryregulators. In some cases materials may be acceptable for use but onlyin limited quantities. Another aspect of matrix choice is functionality.Some matrices that produce superior encapsulated nanoparticles may beacceptable from a safety perspective but these materials may makemanufacture of a dosage form such as tablet limited.

Improving the Dissolution Profile

The process results in the biologically active material having animproved dissolution profile. An improved dissolution profile hassignificant advantages including the improvement of bioavailability ofthe biologically active material in vivo. Preferably, the improveddissolution profile is observed in vitro. Alternatively, the improveddissolution profile is observed in vivo by the observation of animproved bioavailability profile. Standard methods for determining thedissolution profile of a material in vitro are available in the art. Asuitable method to determine an improved dissolution profile in vitromay include determining the concentration of the sample material in asolution over a period of time and comparing the results from the samplematerial to a control sample. An observation that peak solutionconcentration for the sample material was achieved in less time than thecontrol sample would indicate (assuming it is statisticallysignificant), that the sample material has an improved dissolutionprofile. The measurement sample is herein defined as the mixture ofbiologically active material with grinding matrix and/or other additivesthat has been subject to the processes of the invention described here.Herein a control sample is defined as a physical mixture (not subject tothe processes described in this invention) of the components in themeasurement sample with the same relative proportions of active, matrixand/or additive as the measurement sample. For the purposes of thedissolution testing a prototype formulation of the measurement samplecould also be used. In this case the control sample would be formulatedin the same way. Standard methods for determining the improveddissolution profile of a material in vivo are available in the art. Asuitable method to determine an improved dissolution profile in a humanmay be after delivering the dose to measure the rate of active materialabsorption by measuring the plasma concentration of the sample compoundover a period of time and comparing the results from the sample compoundto a control. An observation that peak plasma concentration for thesample compound was achieved in less time than the control wouldindicate (assuming it is statistically significant) that the samplecompound has improved bioavailability and an improved dissolutionprofile. Preferably, the improved dissolution profile is observed at arelevant gastrointestinal pH, when it is observed in vitro. Preferably,the improved dissolution profile is observed at a pH which is favourableat indicating improvements in dissolution when comparing the measurementsample to the control compound. Suitable methods for quantifying theconcentration of a compound in an in vitro sample or an in vivo sampleare widely available in the art. Suitable methods could include the useof spectroscopy or radioisotope labeling. In one preferred embodimentthe method of quantification of dissolution is determined in a solutionwith a pH selected from the group consisting of: pH 1, pH 2, pH 3, pH 4,pH 5, pH 6, pH 7, pH 7.3, pH 7.4, pH 8, pH 9, pH 10, pH 11, pH 12, pH13, pH 14 or a pH with 0.5 of a pH unit of any of this group.

Crystallization Profile

Methods for determining the crystallinity profile of the biologicallyactive material are widely available in the art. Suitable methods mayinclude X-ray diffraction, differential scanning calorimetry, raman orIR spectrocopy.

Amorphicity Profile

Methods for determining the amorphous content of the biologically activematerial are widely available in the art. Suitable methods may includeX-ray diffraction, differential scanning calorimetry, raman or IRspectroscopy.

Grinding Matrix

As will be described subsequently, selection of an appropriate grindingmatrix affords particular advantageous applications of the method of thepresent invention.

A highly advantageous application of the method of the invention is theuse of a water-soluble grinding matrix in conjunction with a poorlywater-soluble biologically active material. This affords at least twoadvantages. The first being when the powder containing the biologicallyactive material is placed into water—such as the ingestion of the powderas part of an oral medication—the matrix dissolves, releasing theparticulate active material such that there is maximum surface areaexposed to solution, thereby allowing a rapid dissolution of the activecompound. The second key advantage is the ability, if required, toremove or partially remove the matrix prior to further processing orformulation.

Another advantageous application of the method of the invention is theuse of a water-insoluble grinding matrix, particularly in the area ofagricultural use, when a biologically active material such as afungicide is commonly delivered as part of a dry powder or a suspension.The presence of a water insoluble matrix will afford benefits such asincreased rain fastness.

Without wishing to be bound by theory, it is believed that the physicaldegradation (including but not limited to particle size reduction) ofthe millable grinding matrix affords the advantage of the invention, byacting as a more effective diluent than grinding matrix of a largerparticle size. Again, as will be described subsequently, a highlyadvantageous aspect of the present invention is that certain grindingmatrixes appropriate for use in the method of the invention are alsoappropriate for use in a medicament. The present invention encompassesmethods for the production of a medicament incorporating both thebiologically active material and the grinding matrix or in some casesthe biologically active material and a portion of the grinding matrix,medicaments so produced, and methods of treatment of an animal,including man, using a therapeutically effective amount of saidbiologically active materials by way of said medicaments.

Analogously, as will be described subsequently, a highly advantageousaspect of the present invention is that certain grinding matrixesappropriate for use in the method of the invention are also appropriatefor use in a carrier for an agricultural chemical, such as a pesticide,fungicide, or herbicide. The present invention encompasses methods forthe production of an agricultural chemical composition incorporatingboth the biologically active material in particulate form and thegrinding matrix, or in some cases the biologically active material, anda portion of the grinding matrix, and agricultural chemical compositionsso produced. The medicament may include only the biologically activematerial together with the milled grinding matrix or, more preferably,the biologically active material and milled grinding matrix may becombined with one or more pharmaceutically acceptable carriers, as wellas any desired excipients or other like agents commonly used in thepreparation of medicaments.

Analogously, the agricultural chemical composition may include only thebiologically active material together with the milled grinding matrixor, more preferably, the biologically active materials and milledgrinding matrix may be combined with one or more carriers, as well asany desired excipients or other like agents commonly used in thepreparation of agricultural chemical compositions.

In one particular form of the invention, the grinding matrix is bothappropriate for use in a medicament and readily separable from thebiologically active material by methods not dependent on particle size.Such grinding matrixes are described in the following detaileddescription of the invention. Such grinding matrixes are highlyadvantageous in that they afford significant flexibility in the extentto which the grinding matrix may be incorporated with the biologicallyactive material into a medicament.

In a highly preferred form, the grinding matrix is harder than thebiologically active material, and is thus capable of reducing theparticle size of the active material under the dry milling conditions ofthe invention. Again without wishing to be bound by theory, under thesecircumstances it is believed that the millable grinding matrix affordsthe advantage of the present invention through a second route, with thesmaller particles of grinding matrix produced under the dry millingconditions enabling greater interaction with the biologically activematerial. The quantity of the grinding matrix relative to the quantityof biologically active material, and the extent of physical degradationof the grinding matrix, is sufficient to inhibit re-agglomeration of theparticles of the active material Preferably, the quantity of thegrinding matrix relative to the quantity of biologically activematerial, and the extent of physical degradation of the grinding matrix,is sufficient to inhibit re-agglomeration of the particles of the activematerial in nanoparticulate form. The grinding matrix is not generallyselected to be chemically reactive with the biologically active materialunder the milling conditions of the invention, excepting for example,where the matrix is deliberately chosen to undergo a mechanico-chemicalreaction. Such a reaction might be the conversion of a free base or acidto a salt or vice versa.

As stated above, the method of the present invention requires thegrinding matrix to be milled with the biologically active material; thatis, the grinding matrix will physically degrade under the dry millingconditions of the invention to facilitate the formation and retention ofparticulates of the biologically active material with reduced particlesize. The precise extent of degradation required will depend on certainproperties of the grinding matrix and the biologically active material,the ratio of biologically active material to grinding matrix, and theparticle size distribution of the particles comprising the biologicallyactive material.

The physical properties of the grinding matrix necessary to achieve therequisite degradation are dependent on the precise milling conditions.For example, a harder grinding matrix may degrade to a sufficient extentprovided it is subjected to more vigorous dry milling conditions.Physical properties of the grinding matrix relevant to the extent thatthe agent will degrade under dry milling conditions include hardness,friability, as measured by indicia such as hardness, fracture toughnessand brittleness index.

A low hardness (typically a Mohs Hardness less than 7) of thebiologically active material is desirable to ensure fracture of theparticles during processing, so that composite microstructures developduring milling. Preferably, the hardness is less than 3 as determinedusing the Mohs Hardness scale.

Preferably, the grinding matrix is of low abrasivity. Low abrasivity isdesirable to minimise contamination of the mixture of the biologicallyactive material in the grinding matrix by the milling bodies and/or themilling chamber of the media mill. An indirect indication of theabrasivity can be obtained by measuring the level of milling-basedcontaminants.

Preferably, the grinding matrix has a low tendency to agglomerate duringdry milling. While it is difficult to objectively quantify the tendencyto agglomerate during milling, it is possible to obtain a subjectivemeasure by observing the level of “caking” of the grinding matrix on themilling bodies and the milling chamber of the media mill as dry millingprogresses.

The grinding matrix may be an inorganic or organic substance.

In one embodiment, the grinding matrix is selected from the following,either as a single substance or a combination of two or more substances:Polyols (sugar alcohols) for example (but not limited to) mannitol,sorbitol, isomalt, xylitol, maltitol, lactitol, erythritol, arabitol,ribitol, monosaccharides for example (but not limited to) glucose,fructose, mannose, galactose, disaccharides and trisaccharides forexample (but not limited to) anhydrous lactose, lactose monohydrate,sucrose, maltose, trehalose, polysaccharides for example (but notlimited to) maltodextrins, dextrin, Inulin, dextrates, polydextrose,other carbohydrates for example (but not limited to) starch, wheatflour, corn flour, rice flour, rice starch, tapioca flour, tapiocastarch, potato flour, potato starch, other flours and starches, soyflour, soy meal or other soy products, cellulose, microcrystallinecellulose, microcrystalline cellulose based co blended excipients,chemically modified excipients such as pregelatinized (or partially)starch, modified celluloses such as HPMC, CMC, HPC, enteric polymercoatings such as hypromellose phthalate, cellulose acetate phthalate(Aquacoat®), polyvinyl acetate phthalate (Sureteric®), hypromelloseacetate succinate (AQOAT®), and polmethacrylates (Eudragit® andAcryl-EZE®), Milk products for example (but not limited to) milk powder,skim milk powders, other milk solids and derivatives, other functionalExcipients, organic acids for example (but not limited to) citric acid,tartaric acid, malic acid, maleic acid fumaric acid, ascorbic acid,succinic acid, the conjugate salt of organic acids for example (but notlimited to) sodium citrate, sodium tartrate, sodium malate, sodiumascorbate, potassium citrate, potassium tartrate, potassium malate,potassium ascorbate, inorganics such as sodium carbonate, potassiumcarbonate, magnesium carbonate, sodium bicarbonate, potassiumbicarbonate and calcium carbonate. dibasic calcium phosphate, tribasiccalcium phosphate, sodium sulfate, sodium chloride, sodiummetabisulphite, sodium thiosulfate, ammonium chloride, Glauber's salt,ammonium carbonate, sodium bisulfate, magnesium sulfate, potash alum,potassium chloride, sodium hydrogen sulfate, sodium hydroxide,crystalline hydroxides, hydrogen carbonates, hydrogen carbonates ofpharmaceutical acceptable alkali metals, such as but not limited by,sodium, potassium, lithium, calcium, and barium, ammonium salts (orsalts of volatile amines), for example (but not limited to) ammoniumchloride, methylamine hydrochloride, ammonium bromide, other inorganicsfor example (but not limited to), thermal silica, chalk, mica, silica,alumina, titanium dioxide, talc, kaolin, bentonite, hectorite, magnesiumtrisilicate, other clay or clay derivatives or aluminium silicates, asurfactant for example (but not limited to) sodium lauryl sulfate,sodium stearyl sulfate, sodium cetyl sulfate, sodium cetostearylsulfate, sodium docusate, sodium deoxycholate, N-lauroylsarcosine sodiumsalt, glyceryl monostearate, glycerol distearate glycerylpalmitostearate, glyceryl behenate, glyceryl caprylate, glyceryl oleate,benzalkonium chloride, CTAB, CTAC, Cetrimide, cetylpyridinium chloride,cetylpyridinium bromide, benzethonium chloride, PEG 40 stearate, PEG 100stearate, poloxamer 188, poloxamer 407, poloxamer 338, polyoxyl 2stearyl ether, polyoxyl 100 stearyl ether, polyoxyl 20 stearyl ether,polyoxyl 10 stearyl ether, polyoxyl 20 cetyl ether, polysorbate 20,polysorbate 40, polysorbate 60, polysorbate 61, polysorbate 65,polysorbate 80, polyoxyl 35 castor oil, polyoxyl 40 castor oil, polyoxyl60 castor oil, polyoxyl 100 castor oil, polyoxyl 200 castor oil,polyoxyl 40 hydrogenated castor oil, polyoxyl 60 hydrogenated castoroil, polyoxyl 100 hydrogenated castor oil, polyoxyl 200 hydrogenatedcastor oil, cetostearyl alcohol, macrogel 15 hydroxystearate, sorbitanmonopalmitate, sorbitan monostearate, sorbitan trioleate, SucrosePalmitate, Sucrose Stearate, Sucrose Distearate, Sucrose laurate,Glycocholic acid, sodium Glycholate, Cholic Acid, Soidum Cholate, SodiumDeoxycholate, Deoxycholic acid, Sodium taurocholate, taurocholic acid,Sodium taurodeoxycholate, taurodeoxycholic acid, soy lecithin,phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine,phosphatidylinositol, PEG4000, PEG6000, PEG8000, PEG10000, PEG20000,alkyl naphthalene sulfonate condensate/Lignosulfonate blend, CalciumDodecylbenzene Sulfonate, Sodium Dodecylbenzene Sulfonate, Diisopropylnaphthaenesulphonate, erythritol distearate, Naphthalene SulfonateFormaldehyde Condensate, nonylphenol ethoxylate (poe-30),Tristyrylphenol Ethoxylate, Polyoxyethylene (15) tallowalkylamines,sodium alkyl naphthalene sulfonate, sodium alkyl naphthalene sulfonatecondensate, sodium alkylbenzene sulfonate, sodium isopropyl naphthalenesulfonate, Sodium Methyl Naphthalene Formaldehyde Sulfonate, sodiumn-butyl naphthalene sulfonate, tridecyl alcohol ethoxylate (poe-18),Triethanolamine isodecanol phosphate ester, Triethanolaminetristyrylphosphate ester, Tristyrylphenol Ethoxylate Sulfate,Bis(2-hydroxyethyl)tallowalkylamines.

In a preferred embodiment, the grinding matrix is a matrix that isconsidered GRAS (generally regarded as safe) by persons skilled in thepharmaceutical arts.

In another preferred aspect a combination of two or more suitablematrices, such as those listed above, can be used as the grinding matrixto provide improved properties such as the reduction of caking, andgreater improvement of the dissolution profile. Combination matrices mayalso be advantageous when the matrices have different solubility'sallowing the removal or partial removal of one matrix, while leaving theother or part of the other to provide encapsulation or partialencapsulation of the biologically active material.

Another highly preferred aspect of the method is the inclusion of asuitable milling aid in the matrix to improve milling performance.Improvements to milling performance would be things such as, but notlimited to, a reduction in caking or higher recovery of powder from themill. Examples of suitable milling aids include surfactants, polymersand inorganics such as silica (including colloidal silica), aluminiumsilicates and clays.

There are a wide range of surfactants that will make suitable millingaids. The highly preferred form is where the surfactant is a solid, orcan be manufactured into a solid. Preferably, the surfactant is selectedfrom the group consisting of: polyoxyethylene alkyl ethers,polyoxyethylene stearates, polyethylene glycols (PEG), poloxamers,poloxamines, sarcosine based surfactants, polysorbates, aliphaticalcohols, alkyl and aryl sulfates, alkyl and aryl polyether sulfonatesand other sulfate surfactants, trimethyl ammonium based surfactants,lecithin and other phospholipids, bile salts, polyoxyethylene castor oilderivatives, polyoxyethylene sorbitan fatty acid esters, Sorbitan fattyacid esters, Sucrose fatty acid esters, alkyl glucopyranosides, alkylmaltopyranosides, glycerol fatty acid esters, Alkyl Benzene SulphonicAcids, Alkyl Ether Carboxylic Acids, Alkyl and aryl Phosphate esters,Alkyl and aryl Sulphate esters, Alkyl and aryl Sulphonic acids, AlkylPhenol Phosphates esters, Alkyl Phenol Sulphates esters, Alkyl and ArylPhosphates, Alkyl Polysaccharides, Alkylamine Ethoxylates,Alkyl-Naphthalene Sulphonates formaldehyde condensates, Sulfosuccinates,lignosulfonates, Ceto-Oleyl Alcohol Ethoxylates, Condensed NaphthaleneSulphonates, Dialkyl and Alkyl Naphthalene Sulphonates, Di-alkylSulphosuccinates, Ethoxylated nonylphenols, Ethylene Glycol Esters,Fatty Alcohol Alkoxylates, Hydrogenated tallowalkylamines, Mono-alkylSulphosuccinamates, Nonyl Phenol Ethoxylates, Sodium Oleyl N-methylTaurate, Tallowalkylamines, linear and branched dodecylbenzene sulfonicacids Preferably, the surfactant is selected from the group consistingof: sodium lauryl sulfate, sodium stearyl sulfate, sodium cetyl sulfate,sodium cetostearyl sulfate, sodium docusate, sodium deoxycholate,N-lauroylsarcosine sodium salt, glyceryl monostearate, glyceroldistearate glyceryl palmitostearate, glyceryl behenate, glycerylcaprylate, glyceryl oleate, benzalkonium chloride, CTAB, CTAC,Cetrimide, cetylpyridinium chloride, cetylpyridinium bromide,benzethonium chloride, PEG 40 stearate, PEG 100 stearate, poloxamer 188,poloxamer 338, poloxamer 407 polyoxyl 2 stearyl ether, polyoxyl 100stearyl ether, polyoxyl 20 stearyl ether, polyoxyl 10 stearyl ether,polyoxyl 20 cetyl ether, polysorbate 20, polysorbate 40, polysorbate 60,polysorbate 61, polysorbate 65, polysorbate 80, polyoxyl 35 castor oil,polyoxyl 40 castor oil, polyoxyl 60 castor oil, polyoxyl 100 castor oil,polyoxyl 200 castor oil, polyoxyl 40 hydrogenated castor oil, polyoxyl60 hydrogenated castor oil, polyoxyl 100 hydrogenated castor oil,polyoxyl 200 hydrogenated castor oil, cetostearyl alcohol, macrogel 15hydroxystearate, sorbitan monopalmitate, sorbitan monostearate, sorbitantrioleate, Sucrose Palmitate, Sucrose Stearate, Sucrose Distearate,Sucrose laurate, Glycocholic acid, sodium Glycholate, Cholic Acid,Soidum Cholate, Sodium Deoxycholate, Deoxycholic acid, Sodiumtaurocholate, taurocholic acid, Sodium taurodeoxycholate,taurodeoxycholic acid, soy lecithin, phosphatidylcholine,phosphatidylethanolamine, phosphatidylserine, phosphatidylinositol,PEG4000, PEG6000, PEG8000, PEG10000, PEG20000, alkyl naphthalenesulfonate condensate/Lignosulfonate blend, Calcium DodecylbenzeneSulfonate, Sodium Dodecylbenzene Sulfonate, Diisopropylnaphthaenesulphonate, erythritol distearate, Naphthalene SulfonateFormaldehyde Condensate, nonylphenol ethoxylate (poe-30),Tristyrylphenol Ethoxylate, Polyoxyethylene (15) tallowalkylamines,sodium alkyl naphthalene sulfonate, sodium alkyl naphthalene sulfonatecondensate, sodium alkylbenzene sulfonate, sodium isopropyl naphthalenesulfonate, Sodium Methyl Naphthalene Formaldehyde Sulfonate, sodiumn-butyl naphthalene sulfonate, tridecyl alcohol ethoxylate (poe-18),Triethanolamine isodecanol phosphate ester, Triethanolaminetristyrylphosphate ester, Tristyrylphenol Ethoxylate Sulfate,Bis(2-hydroxyethyl)tallowalkylamines.

Preferably the polymer is selected from the list of:polyvinylpyrrolidones (PVP), polyvinylalcohol,

Acrylic acid based polymers and copolymers of acrylic acid Preferably,the milling aid has a concentration selected from the group consistingof: 0.1-10 w/w, 0.1-5% w/w, 0.1-2.5% w/w, of 0.1-2% w/w, 0.1-1%, 0.5-5%w/w, 0.5-3% w/w, 0.5-2% w/w, 0.5-1.5%, 0.5-1% w/w, of 0.75-1.25% w/w,0.75-1% and 1% w/w.

Milling Bodies

In the method of the present invention, the milling bodies arepreferably chemically inert and rigid. The term “chemically-inert”, asused herein, means that the milling bodies do not react chemically withthe biologically active material or the grinding matrix.

As described above, the milling bodies are essentially resistant tofracture and erosion in the milling process.

The milling bodies are desirably provided in the form of bodies whichmay have any of a variety of smooth, regular shapes, flat or curvedsurfaces, and lacking sharp or raised edges. For example, suitablemilling bodies can be in the form of bodies having ellipsoidal, ovoid,spherical or right cylindrical shapes. Preferably, the milling bodiesare provided in the form of one or more of beads, balls, spheres, rods,right cylinders, drums or radius-end right cylinders (i.e., rightcylinders having hemispherical bases with the same radius as thecylinder).

Depending on the nature of the biologically active material and thegrinding matrix, the milling media bodies desirably have an effectivemean particle diameter (i.e. “particle size”) between about 0.1 and 30mm, more preferably between about 1 and about 15 mm, still morepreferably between about 3 and 10 mm.

The milling bodies may comprise various substances such as ceramic,glass, metal or polymeric compositions, in a particulate form. Suitablemetal milling bodies are typically spherical and generally have goodhardness (i.e. RHC 60-70), roundness, high wear resistance, and narrowsize distribution and can include, for example, balls fabricated fromtype 52100 chrome steel, type 316 or 440C stainless steel or type 1065high carbon steel.

Preferred ceramics, for example, can be selected from a wide array ofceramics desirably having sufficient hardness and resistance to fractureto enable them to avoid being chipped or crushed during milling and alsohaving sufficiently high density. Suitable densities for milling mediacan range from about 1 to 15 g/cm³′, preferably from about 1 to 8 g/cm³.Preferred ceramics can be selected from steatite, aluminum oxide,zirconium oxide, zirconia-silica, yttria-stabilized zirconium oxide,magnesia-stabilized zirconium oxide, silicon nitride, silicon carbide,cobalt-stabilized tungsten carbide, and the like, as well as mixturesthereof.

Preferred glass milling media are spherical (e.g. beads), have a narrowsize distribution, are durable, and include, for example, lead-free sodalime glass and borosilicate glass. Polymeric milling media arepreferably substantially spherical and can be selected from a wide arrayof polymeric resins having sufficient hardness and friability to enablethem to avoid being chipped or crushed during milling,abrasion-resistance to minimize attrition resulting in contamination ofthe product, and freedom from impurities such as metals, solvents, andresidual monomers. Preferred polymeric resins, for example, can beselected from crosslinked polystyrenes, such as polystyrene crosslinkedwith divinylbenzene, styrene copolymers, polyacrylates such aspolymethylmethacrylate, polycarbonates, polyacetals, vinyl chloridepolymers and copolymers, polyurethanes, polyamides, high densitypolyethylenes, polypropylenes, and the like. The use of polymericmilling media to grind materials down to a very small particle size (asopposed to mechanochemical synthesis) is disclosed, for example, in U.S.Pat. Nos. 5,478,705 and 5,500,331. Polymeric resins typically can havedensities ranging from about 0.8 to 3.0 g/cm³. Higher density polymericresins are preferred. Alternatively, the milling media can be compositeparticles comprising dense core particles having a polymeric resinadhered thereon. Core particles can be selected from substances known tobe useful as milling media, for example, glass, alumina, zirconiasilica, zirconium oxide, stainless steel, and the like. Preferred coresubstances have densities greater than about 2.5 g/cm³.

In one embodiment of the invention, the milling media are formed from aferromagnetic substance, thereby facilitating removal of contaminantsarising from wear of the milling media by the use of magnetic separationtechniques.

Each type of milling body has its own advantages. For example, metalshave the highest specific gravities, which increase grinding efficiencydue to increased impact energy. Metal costs range from low to high, butmetal contamination of final product can be an issue. Glasses areadvantageous from the standpoint of low cost and the availability ofsmall bead sizes as low as 0.004 mm. However, the specific gravity ofglasses is lower than other media and significantly more milling time isrequired. Finally, ceramics are advantageous from the standpoint of lowwear and contamination, ease of cleaning, and high hardness.

Dry Milling

In the dry milling process of the present invention, the biologicallyactive material and grinding matrix, in the form of crystals, powders,or the like, are combined in suitable proportions with the plurality ofmilling bodies in a milling chamber that is mechanically agitated (i.e.with or without stirring) for a predetermined period of time at apredetermined intensity of agitation. Typically, a milling apparatus isused to impart motion to the milling bodies by the external applicationof agitation, whereby various translational, rotational or inversionmotions or combinations thereof are applied to the milling chamber andits contents, or by the internal application of agitation through arotating shaft terminating in a blade, propeller, impeller or paddle orby a combination of both actions.

During milling, motion imparted to the milling bodies can result inapplication of shearing forces as well as multiple impacts or collisionshaving significant intensity between milling bodies and particles of thebiologically active material and grinding matrix. The nature andintensity of the forces applied by the milling bodies to thebiologically active material and the grinding matrix is influenced by awide variety of processing parameters including: the type of millingapparatus; the intensity of the forces generated, the kinematic aspectsof the process; the size, density, shape, and composition of the millingbodies; the weight ratio of the biologically active material andgrinding matrix mixture to the milling bodies; the duration of milling;the physical properties of both the biologically active material and thegrinding matrix; the atmosphere present during activation; and others.

Advantageously, the media mill is capable of repeatedly or continuouslyapplying mechanical compressive forces and shear stress to thebiologically active material and the grinding matrix. Suitable mediamills include but are not limited to the following: high-energy ball,sand, bead or pearl mills, basket mill, planetary mill, vibratory actionball mill, multi-axial shaker/mixer, stirred ball mill, horizontal smallmedia mill, multi-ring pulverizing mill, and the like, including smallmilling media. The milling apparatus also can contain one or morerotating shafts.

In a preferred form of the invention, the dry milling is performed in aball mill. Throughout the remainder of the specification reference willbe made to dry milling being carried out by way of a ball mill. Examplesof this type of mill are attritor mills, nutating mills, tower mills,planetary mills, vibratory mills and gravity-dependent-type ball mills.It will be appreciated that dry milling in accordance with the method ofthe invention may also be achieved by any suitable means other than ballmilling. For example, dry milling may also be achieved using jet mills,rod mills, roller mills or crusher mills.

Biologically Active Material

The biologically active material includes active compounds, includingcompounds for veterinary and human use such as but not limited to,pharmaceutical actives, nutraceuticals, cosmeceuticals, cosmetics,complementary medicines, natural products, vitamins, nutrients,biologics, amino acids, proteins, peptides, nucleotides, nucleic acids.and agricultural compounds such as pesticides, herbicides andfungicides, germinating agents and the like. Other biologically activematerials include, but are not limited to, foods, seeds, cocoa, cocoapowder, cocoa nibs, cocoa mass, cocoa liquor, cocoa solids, coffee,herbs, spices, other plant materials, minerals, animal products, shellsand other skeletal material.

In a preferred form of the invention, the biologically active materialis an organic compound. In a highly preferred form of the invention, thebiologically active material is an organic, therapeutically activecompound for veterinary or human use.

In a preferred form of the invention, the biologically active materialis an inorganic compound. In a highly preferred form of the invention,the biologically active material is sulphur, copper hydroxide, anorganometallic complex or copper oxychloride.

The biologically active material is ordinarily a material for which oneof skill in the art desires improved dissolution properties. Thebiologically active material may be a conventional active agent or drug,although the process of the invention may be employed on formulations oragents that already have reduced particle size compared to theirconventional form. Biologically active materials suitable for use in theinvention include actives, biologics, amino acids, proteins, peptides,nucleotides, nucleic acids, and analogs, homologs and first orderderivatives thereof. The biologically active material can be selectedfrom a variety of known classes of drugs, including, but not limited to:anti-obesity drugs, central nervous system stimulants, carotenoids,corticosteroids, elastase inhibitors, anti-fungals, oncology therapies,anti-emetics, analgesics, cardiovascular agents, anti-inflammatoryagents, such as NSAIDs and COX-2 inhibitors, anthelmintics,anti-arrhythmic agents, antibiotics (including penicillins),anticoagulants, antidepressants, antidiabetic agents, antiepileptics,antihistamines, antihypertensive agents, antimuscarinic agents,antimycobacterial agents, antineoplastic agents, immunosuppressants,antithyroid agents, antiviral agents, anxiolytics, sedatives (hypnoticsand neuroleptics), astringents, alpha-adrenergic receptor blockingagents, beta-adrenoceptor blocking agents, blood products andsubstitutes, cardiac inotropic agents, contrast media, coughsuppressants (expectorants and mucolytics), diagnostic agents,diagnostic imaging agents, diuretics, dopaminergics (anti-Parkinsonianagents), haemostatics, immunological agents, lipid regulating agents,muscle relaxants, parasympathomimetics, parathyroid calcitonin andbiphosphonates, prostaglandins, radio-pharmaceuticals, sex hormones(including steroids), anti-allergic agents, stimulants and anoretics,sympathomimetics, thyroid agents, vasodilators, and xanthines.

A description of these classes of active agents and a listing of specieswithin each class can be found in Martindale's The Extra Pharmacopoeia,31st Edition (The Pharmaceutical Press, London, 1996), specificallyincorporated by reference. Another source of active agents is thePhysicians Desk Reference (60^(th) Ed., pub. 2005), familiar to those ofskill in the art. The active agents are commercially available and/orcan be prepared by techniques known in the art.

An exhaustive list of drugs for which the methods of the invention aresuitable would be burdensomely long for this specification; however,reference to the general pharmacopoeia listed above would allow one ofskill in the art to select virtually any drug to which the method of theinvention may be applied.

In addition it is also expected that new chemical entities (NCE) andother actives for which the methods of the invention are suitable willbe created or become commercially available in the future.

Notwithstanding the general applicability of the method of theinvention, more specific examples of biologically active materialsinclude, but are not limited to: haloperidol (dopamine antagonist), DLisoproterenol hydrochloride (β-adrenergic agonist), terfenadine(H1-antagonist), propranolol hydrochloride (β-adrenergic antagonist),desipramine hydrochloride (antidepressant), sildenafil citrate,tadalafil and vardenafil. Minor analgesics (cyclooxygenase inhibitors),fenamic acids, Piroxicam, Cox-2 inhibitors, and Naproxen, and others,may all benefit from being prepared.

As discussed in the context of the background to the invention,biologically active materials that are poorly water soluble atgastrointestinal pH will particularly benefit from being prepared, andthe method of the present invention is particularly advantageouslyapplied to materials that are poorly water soluble at gastrointestinalpH.

Such materials include, but are not limited to: albendazole, albendazolesulfoxide, alfaxalone, acetyl digoxin, acyclovir analogs, alprostadil,aminofostin, anipamil, antithrombin III, atenolol, azidothymidine,beclobrate, beclomethasone, belomycin, benzocaine and derivatives, betacarotene, beta endorphin, beta interferon, bezafibrate, binovum,biperiden, bromazepam, bromocryptine, bucindolol, buflomedil,bupivacaine, busulfan, cadralazine, camptothesin, canthaxanthin,captopril, carbamazepine, carboprost, cefalexin, cefalotin, cefamandole,cefazedone, cefluoroxime, cefinenoxime, cefoperazone, cefotaxime,cefoxitin, cefsulodin, ceftizoxime, chlorambucil, chromoglycinic acid,ciclonicate, ciglitazone, clonidine, cortexolone, corticosterone,cortisol, cortisone, cyclophosphamide, cyclosporin A and othercyclosporins, cytarabine, desocryptin, desogestrel, dexamethasone esterssuch as the acetate, dezocine, diazepam, diclofenac, dideoxyadenosine,dideoxyinosine, digitoxin, digoxin, dihydroergotamine, dihydroergotoxin,diltiazem, dopamine antagonists, doxorubicin, econazole, endralazine,enkephalin, enalapril, epoprostenol, estradiol, estramustine,etofibrate, etoposide, factor ix, factor viii, felbamate, fenbendazole,fenofibrate, fexofenedine, flunarizin, flurbiprofen, 5-fluorouracil,flurazepam, fosfomycin, fosmidomycin, furosemide, gallopamil, gammainterferon, gentamicin, gepefrine, gliclazide, glipizide, griseofulvin,haptoglobulin, hepatitis B vaccine, hydralazine, hydrochlorothiazide,hydrocortisone, ibuprofen, ibuproxam, indinavir, indomethacin, iodinatedaromatic x-ray contrast agents such as iodamide, ipratropium bromide,ketoconazole, ketoprofen, ketotifen, ketotifen fumarate, K-strophanthin,labetalol, lactobacillus vaccine, lidocaine, lidoflazin, lisuride,lisuride hydrogen maleate, lorazepam, lovastatin, mefenamic acid,melphalan, memantin, mesulergin, metergoline, methotrexate, methyldigoxin, methylprednisolone, metronidazole, metisoprenol, metipranolol,metkephamide, metolazone, metoprolol, metoprolol tartrate, miconazole,miconazole nitrate, minoxidil, misonidazol, molsidomin, nadolol,nafiverine, nafazatrom, naproxen, natural insulins, nesapidil,nicardipine, nicorandil, nifedipine, niludipin, nimodipine, nitrazepam,nitrendipine, nitrocamptothesin, 9-nitrocamptothesin, olanzapine,oxazepam, oxprenolol, oxytetracycline, penicillins such as penicillin Gbenethamine, penecillin O, phenylbutazone, picotamide, pindolol,piposulfan, piretanide, piribedil, piroxicam, pirprofen, plasminogeniciactivator, prednisolone, prednisone, pregnenolone, procarbacin,procaterol, progesterone, proinsulin, propafenone, propanolol,propentofyllin, propofol, propranolol, raloxifene, rifapentin,simvastatin, semi-synthetic insulins, sobrerol, somastotine and itsderivatives, somatropin, stilamine, sulfinalol hydrochloride,sulfinpyrazone, suloctidil, suprofen, sulproston, synthetic insulins,talinolol, taxol, taxotere, testosterone, testosterone propionate,testosterone undecanoate, tetracane HI, tiaramide HCl, tolmetin,tranilast, triquilar, tromantadine HCl, urokinase, valium, verapamil,vidarabine, vidarabine phosphate sodium salt, vinblastine, vinburin,vincamine, vincristine, vindesine, vinpocetine, vitamin A, vitamin Esuccinate, and x-ray contrast agents. Drugs can be neutral species orbasic or acidic as well as salts of an acid or base. Specifically thechemical makeup and the functional groups, including an acid or basegroup, are generally not the determinant factor, excepting a possiblechemical reaction with a specific matrix, for the successful creation ofa biologically active substance with a reduced particle size. Thisinvention is not limited to any drug specific class, application type,chemical type or function grouping. Rather the suitability of abiologically active material for use in this invention is primarilydetermined by the mechanical properties of the material. In addition,some biologically active materials may have the benefit of absorptionthrough the skin if presented in a particle formulation. Suchbiologically active materials include, but are not limited to, Voltaren(diclofenac), rofecoxib, and ibuprofen.

Conveniently, the biologically active material is capable ofwithstanding temperatures that are typical in uncooled dry milling,which may exceed 80° C. Therefore, materials with a melting point about80° C. or greater are highly suitable. For biologically active materialswith lower melting points, the media mill may be cooled, therebyallowing materials with significantly lower melting temperatures to beprocessed according to the method of the invention. For instance, asimple water-cooled mill will keep temperatures below 50° C., or chilledwater could be used to further lower the milling temperature. Thoseskilled in the art will understand that a high energy ball mill could bedesigned to run at any temperature between say −30 to 200° C. For somebiologically active materials it may be advantageous to control themilling temperature to temperatures significantly below the meltingpoints of the biologically active materials. The biologically activematerial is obtained in a conventional form commercially and/or preparedby techniques known in the art.

It is preferred, but not essential, that the particle size of thebiologically active material be less than about 1000 μm, as determinedby sieve analysis. If the coarse particle size of the biologicallyactive material is greater than about 1000 μm, then it is preferred thatthe particles of the biologically active material substrate be reducedin size to less than 1000 μm using another standard milling method.

Processed Biologically Active Material

Preferably, the biologically active materials, which have been subjectto the methods of the invention, comprises particles of biologicallyactive material of an average particle size, determined on a particlenumber basis, is equal to or less than a size selected from the group10,000 nm, 5000 nm, 2000 nm, 1900 nm, 1800 nm, 1700 nm, 1600 nm, 1500nm, 1400 nm, 1300 nm, 1200 nm, 1100 nm, 1000 nm, 900 nm, 800 nm, 700 nm,600 nm, 500 nm, 400 nm, 300 nm, 200 nm and 100 nm.

Preferably, the biologically active materials, which have been subjectto the methods of the invention, comprises particles of biologicallyactive material of a median particle size, determined on a particlevolume basis, equal or less than a size selected from the group 20,000nm, 15,000 nm, 10,000 nm, 5000 nm, 2000 nm, 1900 nm, 1800 nm, 1700 nm,1600 nm, 1500 nm, 1400 nm, 1300 nm, 1200 nm, 1100 nm, 1000 nm, 900 nm,800 nm, 700 nm, 600 nm, 500 nm, 400 nm, 300 nm, 200 nm and 100 nm.

These sizes refer to particles either fully dispersed or partiallyagglomerated.

Agglomerates of Biologically Active Material after Processing

Agglomerates comprising particles of biologically active material, saidparticles having a particle size within the ranges specified above,should be understood to fall within the scope of the present invention,regardless of whether the agglomerates exceed the ranges specifiedabove. Agglomerates comprising particles of biologically activematerial, said agglomerates having a total agglomerate size within theranges specified above, should be understood to fall within the scope ofthe present invention.

Agglomerates comprising particles of biologically active material shouldbe understood to fall within the scope of the present invention if atthe time of use, or further processing, the particle size of theagglomerate is within the ranges specified above.

Agglomerates comprising particles of biologically active material, saidparticles having a particle size within the ranges specified above, atthe time of use, or further processing, should be understood to fallwithin the scope of the present invention, regardless of whether theagglomerates exceed the ranges specified above.

Processing Time

Preferably, the biologically active material and the grinding matrix aredry milled for the shortest time necessary to form the mixture of thebiologically active material in the grinding matrix such that the activematerial has improved dissolution to minimise any possible contaminationfrom the media mill and/or the plurality of milling bodies. This timevaries greatly, depending on the biologically active material and thegrinding matrix, and may range from as short as 1 minute to severalhours. Dry milling times in excess of 2 hours may lead to degradation ofthe biologically active material and an increased level of undesirablecontaminants.

Suitable rates of agitation and total milling times are adjusted for thetype and size of milling apparatus as well as the milling media, theweight ratio of the biologically active material and grinding matrixmixture to the plurality of milling bodies, the chemical and physicalproperties of the biologically active material and grinding matrix, andother parameters that may be optimized empirically.

Inclusion of the Grinding Matrix with the Biologically Active Materialand Separation of the Grinding Matrix from the Biologically ActiveMaterial

In a preferred aspect, the grinding matrix is not separated from thebiologically active material but is maintained with the biologicallyactive material in the final product. Preferably the grinding matrix isconsidered to be Generally Regarded as Safe (GRAS) for pharmaceuticalproducts.

In an alternative aspect, the grinding matrix is separated from thebiologically active material. In one aspect, where the grinding matrixis not fully milled, the unmilled grinding matrix is separated from thebiologically active material. In a further aspect, at least a portion ofthe milled grinding matrix is separated from the biologically activematerial.

Any portion of the grinding matrix may be removed, including but notlimited to 10%, 25%, 50%, 75%, or substantially all of the grindingmatrix.

In some embodiments of the invention, a significant portion of themilled grinding matrix may comprise particles of a size similar toand/or smaller than the particles comprising the biologically activematerial. Where the portion of the milled grinding matrix to beseparated from the particles comprising the biologically active materialcomprises particles of a size similar to and/or smaller than theparticles comprising the biologically active material, separationtechniques based on size distribution are inapplicable.

In these circumstances, the method of the present invention may involveseparation of at least a portion of the milled grinding matrix from thebiologically active material by techniques including but not limited toelectrostatic separation, magnetic separation, centrifugation (densityseparation), hydrodynamic separation, froth flotation.

Advantageously, the step of removing at least a portion of the milledgrinding matrix from the biologically active material may be performedthrough means such as selective dissolution, washing, or sublimation.

An advantageous aspect of the invention would be the use of grindingmatrix that has two or more components where at least one component iswater soluble and at least one component has low solubility in water. Inthis case washing can be used to remove the matrix component soluble inwater leaving the biologically active material encapsulated in theremaining matrix components. In a highly advantageous aspect of theinvention the matrix with low solubility is a functional excipient.

A highly advantageous aspect of the present invention is that certaingrinding matrixes appropriate for use in the method of the invention (inthat they physically degrade to the desired extent under dry millingconditions) are also pharmaceutically acceptable and thus appropriatefor use in a medicament. Where the method of the present invention doesnot involve complete separation of the grinding matrix from thebiologically active material, the present invention encompasses methodsfor the production of a medicament incorporating both the biologicallyactive material and at least a portion of the milled grinding matrix,medicaments so produced and methods of treatment of an animal, includingman, using a therapeutically effective amount of said biologicallyactive materials by way of said medicaments.

The medicament may include only the biologically active material and thegrinding matrix or, more preferably, the biologically active materialsand grinding matrix may be combined with one or more pharmaceuticallyacceptable carriers, as well as any desired excipients or other likeagents commonly used in the preparation of medicaments.

Analogously, a highly advantageous aspect of the present invention isthat certain grinding matrixes appropriate for use in the method of theinvention (in that they physically degrade to a desirable extent underdry milling conditions) are also appropriate for use in an agriculturalchemical composition. Where the method of the present invention does notinvolve complete separation of the grinding matrix from the biologicallyactive material, the present invention encompasses methods for theproduction of a agricultural chemical composition incorporating both thebiologically active material and at least a portion of the milledgrinding matrix, agricultural chemical composition so produced andmethods of use of such compositions.

The agricultural chemical composition may include only the biologicallyactive material and the grinding matrix or, more preferably, thebiologically active materials and grinding matrix may be combined withone or more acceptable carriers, as well as any desired excipients orother like agents commonly used in the preparation of agriculturalchemical compositions.

In one particular form of the invention, the grinding matrix is bothappropriate for use in a medicament and readily separable from thebiologically active material by methods not dependent on particle size.Such grinding matrixes are described in the following detaileddescription of the invention. Such grinding matrixes are highlyadvantageous in that they afford significant flexibility in the extentto which the grinding matrix may be incorporated with the biologicallyactive material into a medicament.

The mixture of biologically active material and grinding matrix may thenbe separated from the milling bodies and removed from the mill.

In one embodiment, the grinding matrix is separated from the mixture ofbiologically active material and grinding matrix. Where the grindingmatrix is not fully milled, the unmilled grinding matrix is separatedfrom the biologically active material. In a further aspect, at least aportion of the milled grinding matrix is separated from the biologicallyactive material.

The milling bodies are essentially resistant to fracture and erosion inthe dry milling process.

The quantity of the grinding matrix relative to the quantity ofbiologically active material, and the extent of milling of the grindingmatrix, is sufficient to provide reduced particle size of thebiologically active material.

The grinding matrix is neither chemically nor mechanically reactive withthe pharmaceutical material under the dry milling conditions of themethod of the invention except, for example, where the matrix isdeliberately chosen to undergo a mechanico-chemical reaction. Such areaction might be the conversion of a free base or acid to a salt orvice versa.

Preferably, the medicament is a solid dosage form, however, other dosageforms may be prepared by those of ordinary skill in the art.

In one form, after the step of separating said mixture of biologicallyactive material and grinding matrix from the plurality of millingbodies, and before the step of using said mixture of biologically activematerial and grinding matrix in the manufacture of a medicament, themethod may comprise the step of:

removing a portion of the grinding matrix from said mixture ofbiologically active material and grinding matrix to provide a mixtureenriched in the biologically active material;

and the step of using said mixture of biologically active material andgrinding matrix in the manufacture of a medicament, more particularlycomprises the step of using the mixture of biologically active materialand grinding matrix enriched in the biologically active material form inthe manufacture of a medicament.

The present invention includes medicaments manufactured by said methods,and methods for the treatment of an animal, including man, by theadministration of a therapeutically effective amount of the biologicallyactive materials by way of said medicaments.

In another embodiment of the invention, a facilitating agent or acombination of facilitating agents is also comprised in the mixture tobe milled. Such facilitating agents appropriate for use in the inventioninclude diluents, surfactants, polymers, binding agents, filling agents,lubricating agents, sweeteners, flavouring agents, preservatives,buffers, wetting agents, disintegrants, effervescent agents and agentsthat may form part of a medicament, including a solid dosage form, orother excipients required for other specific drug delivery, such as theagents and media listed below under the heading Medicinal andPharmaceutical Compositions, or any combination thereof.

Biologically Active Materials and Compositions

The present invention encompasses pharmaceutically acceptable materialsproduced according to the methods of the present invention, compositionsincluding such materials, including compositions comprising suchmaterials together with the grinding matrix with or without millingaids, facilitating agents, with at least a portion of the grindingmatrix or separated from the grinding matrix.

The pharmaceutically acceptable materials within the compositions of theinvention are present at a concentration of between about 0.1% and about99.0% by weight. Preferably, the concentration of pharmaceuticallyacceptable materials within the compositions will be about 5% to about80% by weight, while concentrations of 10% to about 50% by weight arehighly preferred. Desirably, the concentration will be in the range ofabout 10 to 15% by weight, 15 to 20% by weight, 20 to 25% by weight, 25to 30% by weight, 30 to 35% by weight, 35 to 40% by weight, 40 to 45% byweight, 45 to 50% by weight, 50 to 55% by weight, 55 to 60% by weight,60 to 65% by weight, 65 to 70% by weight, 70 to 75% by weight or 75 to80% by weight for the composition prior to any later removal (ifdesired) of any portion of the grinding matrix. Where part or all of thegrinding matrix has been removed, the relative concentration ofpharmaceutically acceptable materials in the composition may beconsiderably higher depending on the amount of the grinding matrix thatis removed. For example, if all of the grinding matrix is removed theconcentration of particles in the preparation may approach 100% byweight (subject to the presence of facilitating agents).

Compositions produced according to the present invention are not limitedto the inclusion of a single species of pharmaceutically acceptablematerials. More than one species of pharmaceutically acceptablematerials may therefore be present in the composition. Where more thanone species of pharmaceutically acceptable materials is present, thecomposition so formed may either be prepared in a dry milling step, orthe pharmaceutically acceptable materials may be prepared separately andthen combined to form a single composition.

Medicaments

The medicaments of the present invention may include thepharmaceutically acceptable material, optionally together with thegrinding matrix or at least a portion of the grinding matrix, with orwithout milling aids, facilitating agents, combined with one or morepharmaceutically acceptable carriers, as well as other agents commonlyused in the preparation of pharmaceutically acceptable compositions.

As used herein “pharmaceutically acceptable carrier” includes any andall solvents, dispersion media, coatings, antibacterial and antifungalagents, isotonic and absorption delaying agents, and the like that arephysiologically compatible. Preferably, the carrier is suitable forparenteral administration, intravenous, intraperitoneal, intramuscular,sublingual, pulmonary, transdermal or oral administration.Pharmaceutically acceptable carriers include sterile aqueous solutionsor dispersions and sterile powders for the extemporaneous preparation ofsterile injectable solutions or dispersion. The use of such media andagents for the manufacture of medicaments is well known in the art.Except insofar as any conventional media or agent is incompatible withthe pharmaceutically acceptable material, use thereof in the manufactureof a pharmaceutical composition according to the invention iscontemplated.

Pharmaceutical acceptable carriers according to the invention mayinclude one or more of the following examples:

-   -   (1) surfactants and polymers including, but not limited to        polyethylene glycol (PEG), polyvinylpyrrolidone (PVP),        polyvinylalcohol, crospovidone,        polyvinylpyrrolidone-polyvinylacrylate copolymer, cellulose        derivatives, hydroxypropylmethyl cellulose, hydroxypropyl        cellulose, carboxymethylethyl cellulose, hydroxypropylmethyl        cellulose phthalate, polyacrylates and polymethacrylates, urea,        sugars, polyols, and their polymers, emulsifiers, sugar gum,        starch, organic acids and their salts, vinyl pyrrolidone and        vinyl acetate    -   (2) binding agents such as various celluloses and cross-linked        polyvinylpyrrolidone, microcrystalline cellulose; and or    -   (3) filling agents such as lactose monohydrate, lactose        anhydrous, microcrystalline cellulose and various starches; and        or    -   (4) lubricating agents such as agents that act on the        flowability of the powder to be compressed, including colloidal        silicon dioxide, talc, stearic acid, magnesium stearate, calcium        stearate, silica gel; and or    -   (5) sweeteners such as any natural or artificial sweetener        including sucrose, xylitol, sodium saccharin, cyclamate,        aspartame, and acesulfame K; and or    -   (6) flavouring agents; and or    -   (7) preservatives such as potassium sorbate, methylparaben,        propylparaben, benzoic acid and its salts, other esters of        parahydroxybenzoic acid such as butylparaben, alcohols such as        ethyl or benzyl alcohol, phenolic chemicals such as phenol, or        quaternary compounds such as benzalkonium chloride; and or    -   (8) buffers; and or    -   (9) Diluents such as pharmaceutically acceptable inert fillers,        such as microcrystalline cellulose, lactose, dibasic calcium        phosphate, saccharides, and/or mixtures of any of the foregoing;        and or    -   (10) wetting agents such as corn starch, potato starch, maize        starch, and modified starches, croscarmellose sodium,        crospovidone, sodium starch glycolate, and mixtures thereof; and        or    -   (11) disintegrants; and or    -   (12) effervescent agents such as effervescent couples such as an        organic acid (e.g., citric, tartaric, malic, fumaric, adipic,        succinic, and alginic acids and anhydrides and acid salts), or a        carbonate (e.g. sodium carbonate, potassium carbonate, magnesium        carbonate, sodium glycine carbonate, L-lysine carbonate, and        arginine carbonate) or bicarbonate (e.g. sodium bicarbonate or        potassium bicarbonate); and or    -   (13) other pharmaceutically acceptable excipients.

Medicaments of the invention suitable for use in animals and inparticular in man typically must be stable under the conditions ofmanufacture and storage. The medicaments of the invention comprising thebiologically active material can be formulated as a solid, a solution, amicroemulsion, a liposome, or other ordered structures suitable to highdrug concentration. Actual dosage levels of the biologically activematerial in the medicament of the invention may be varied in accordancewith the nature of the biologically active material, as well as thepotential increased efficacy due to the advantages of providing andadministering the biologically active material (e.g., increasedsolubility, more rapid dissolution, increased surface area of thebiologically active material, etc.). Thus as used herein“therapeutically effective amount” will refer to an amount ofbiologically active material required to effect a therapeutic responsein an animal. Amounts effective for such a use will depend on: thedesired therapeutic effect; the route of administration; the potency ofthe biologically active material; the desired duration of treatment; thestage and severity of the disease being treated; the weight and generalstate of health of the patient; and the judgment of the prescribingphysician.

In another embodiment, the biologically active material, optionallytogether with the grinding matrix or at least a portion of the grindingmatrix, of the invention may be combined into a medicament with anotherbiologically active material, or even the same biologically activematerial. In the latter embodiment, a medicament may be achieved whichprovides for different release characteristics—early release from thebiologically active material, and later release from a larger averagesize biologically active material.

Modes of Administration of Medicaments Comprising Biologically ActiveMaterials

Medicaments of the invention can be administered to animals, includingman, in any pharmaceutically acceptable manner, such as orally,rectally, pulmonary, intravaginally, locally (powders, ointments ordrops), transdermal, parenteral administration, intravenous,intraperitoneal, intramuscular, sublingual or as a buccal or nasal spray

Solid dosage forms for oral administration include capsules, tablets,pills, powders, pellets, and granules. Further, incorporating any of thenormally employed excipients, such as those previously listed, andgenerally 5-95% of the biologically active agent, and more preferably ata concentration of 10%-75% will form a pharmaceutically acceptablenon-toxic oral composition. Medicaments of the invention may beparenterally administered as a solution of the biologically active agentsuspended in an acceptable carrier, preferably an aqueous carrier. Avariety of aqueous carriers may be used, e.g. water, buffered water,0.4% saline, 0.3% glycine, hyaluronic acid and the like. Thesecompositions may be sterilized by conventional, well known sterilizationtechniques, or may be sterile filtered. The resulting aqueous solutionsmay be packaged for use as is, or lyophilized, the lyophilizedpreparation being combined with a sterile solution prior toadministration.

For aerosol administration, medicaments of the invention are preferablysupplied along with a surfactant or polymer and propellant. Thesurfactant or polymer must, of course, be non-toxic, and preferablysoluble in the propellant. Representative of such agents are the estersor partial esters of fatty acids containing from 6 to 22 carbon atoms,such as caproic, octanoic, lauric, palmitic, stearic, linoleic,linolenic, olesteric and oleic acids with an aliphatic polyhydricalcohol or its cyclic anhydride. Mixed esters, such as mixed or naturalglycerides may be employed. The surfactant or polymer may constitute0.1%-20% by weight of the composition, preferably 0.25-5%. The balanceof the composition is ordinarily propellant. A carrier can also beincluded, as desired, as with, e.g., lecithin for intranasal delivery.

Medicaments of the invention may also be administered via liposomes,which serve to target the active agent to a particular tissue, such aslymphoid tissue, or targeted selectively to cells. Liposomes includeemulsions, foams, micelles, insoluble monolayers, liquid crystals,phospholipid dispersions, lamellar layers and the like. In thesepreparations the composite microstructure composition is incorporated aspart of a liposome, alone or in conjunction with a molecule that bindsto or with other therapeutic or immunogenic compositions.

As described above, the biologically active material can be formulatedinto a solid dosage form (e.g., for oral or suppository administration),together with the grinding matrix or at least a portion of it. In thiscase there may be little or no need to add stabilizing agents since thegrinding matrix may effectively act as a solid-state stabilizer.

However, if the biologically active material is to be utilized in aliquid suspension, the particles comprising the biologically activematerial may require further stabilization once the solid carrier hasbeen substantially removed to ensure the elimination, or at leastminimisation of particle agglomeration.

Inhaled and Intranasal Delivery

Dry powder formulations of active pharmaceutical ingredients (includingblends of active and excipients) for inhalation or nasal delivery areimportant tools for the delivery of medications. Common uses have beenin the delivery of pharmaceutical agents that act locally. Examples ofthis are asthma medications delivered to the lungs or decongestantsdelivered by an intranasal route. These delivery routes are alsobecoming more important for systemic delivery. Thus the pharmaceuticalformulator will require more and improved techniques to manufactureformulations for these purposes.

Two of the critical parameters for inhaled or intranasal dry powderformulations are particle size and the flowability of the powder. Thepowder in the device used by the patient needs to flow well so that afull and consistent dose of the powder formulation leaves the device. Ifthe powder flow is poor, powder may remain behind in the device or stickto the device as it is dispensed. The particle size of the powder isthen critical to ensure that the powder (and active material) is (are)delivered to the required absorption zone.

One common measure of particle size used to characterize dry powderformulations is the Mass Median Aerodynamic Diameter (MMAD). This isdefined as the aerodynamic diameter at which 50% of the particles bymass are larger and 50% are smaller. Aerodynamic particle sizemeasurements are typically made using devices such as the AndersonCascade Impactor or the New Generation Impactor which use a series ofstages that have descending cut off diameters. Other particle sizemeasures such as the median particle size measured by a laserdiffraction dry powder analysis are also useful. However, MMAD is thepreferred measurement for an inhaled formulation as it betterapproximates the aerodynamic properties of the lungs. For an inhaledformulation the MMAD is preferably less than 10 microns, more preferablyless than 5 microns. Where dry powder sizing by laser diffraction isused, the median particle size is preferably less than 10 microns.

Powders suitable for intranasal delivery would preferably have anaerodynamic particle size equal to or greater than 10 micron. Thus wheredry powder sizing by laser diffraction is used the median particle sizeis preferably equal to or greater than 10 microns. The area ofdeposition within the nasal cavity is also governed by the particle sizeof the powder. Generally powder that has an aerodynamic particle sizegreater than 20 micron will be deposited in the anterior portion of thenose where longer residence times occur. Generally powder that has anaerodynamic particle size equal to or greater than 10 micron but lessthan 20 microns will be deposited in the posterior portion of the nosewhere permeability is generally higher providing good systemicabsorption.

In the aspect of this invention relating to intranasal formulationswhere dry powder sizing by laser diffraction is used, the medianparticle size is preferably equal to or greater than 10 microns.Preferably, the median particle size is equal to or greater than 10microns and less than 20 micron for posterior delivery. Preferably, themedian particle size is equal to or greater than 20 micron for anteriordelivery.

Suitable methods for preparing formulations for intranasal delivery arewidely known in the art. For example, WO2009/027337 (Applicant: NovartisAG, and hereby incorporated by reference), provides methods for makingformulations for intranasal delivery using wet processes followed byspray drying steps. The methods described in the WO2009/027337publication use complex recipes, equipment and multiple steps. Incontrast, the invention which is the subject of this application is asimple one step dry milling process.

Therapeutic Uses

Therapeutic uses of the medicaments of the invention include painrelief, anti-inflammatory, migraine, asthma, and other disorders thatrequire the active agent to be administered with a high bioavailability.

One of the main areas when rapid bioavailability of a biologicallyactive material is required is in the relief of pain. The minoranalgesics, such as cyclooxgenase inhibitors (aspirin related drugs) maybe prepared as medicaments according to the present invention.

Medicaments of the invention may also be used for treatment of eyedisorders. That is, the biologically active material may be formulatedfor administration on the eye as an aqueous suspension in physiologicalsaline, or a gel. In addition, the biologically active material may beprepared in a powder form for administration via the nose for rapidcentral nervous system penetration.

Treatment of cardiovascular disease may also benefit from biologicallyactive materials according to the invention, such as treatment of anginapectoris and, in particular, molsidomine may benefit from betterbioavailability. Other therapeutic uses of the medicaments of thepresent invention include treatment of hair loss, sexual dysfunction, ordermal treatment of psoriasis.

The present invention will now be described with reference to thefollowing non-limiting Examples. The description of the Examples is inno way limiting on the preceding paragraphs of this specification, butis provided for exemplification of the methods and compositions of theinvention.

EXAMPLES

It will be apparent to persons skilled in the milling and pharmaceuticalarts that numerous enhancements and modifications can be made to theabove described processes without departing from the basic inventiveconcepts. For example, in some applications the biologically activematerial may be pretreated and supplied to the process in the pretreatedform. All such modifications and enhancements are considered to bewithin the scope of the present invention, the nature of which is to bedetermined from the foregoing description and the appended claims.Furthermore, the following Examples are provided for illustrativepurposes only, and are not intended to limit the scope of the processesor compositions of the invention.

The following materials were used in the examples

Active pharmaceutical ingredients were sourced from commercialsuppliers, excipients from either commercial suppliers such asSigma-Aldrich or retailers, while food ingredients were sourced fromretailers.

The following mills were used for the grinding experiments

Spex-Type Mill:

Small scale milling experiments were conducted using a vibratory Spex8000D mixer/mill. Twelve ⅜″ stainless steel balls were used as thegrinding media. The powder charge and grinding media were loaded into ahardened steel vial with an internal volume of approximately 75 mL.Following milling, the milled material was discharged from the vial andsieved to remove grinding media.

Attritor-Type Mill:

Small scale attritor milling experiments were performed using a 1HDUnion Process attritor mill with a 110 mL grinding chamber. The grindingmedia consisted of 330 g 5/16″ stainless steel balls. The mill wasloaded through the loading port, with dry materials added initially,followed by the grinding media. The milling process was conducted withthe jacket cooled at 10-20° C. and the shaft rotating at 500 rpm. Uponcompletion of milling, the milled material was discharged from the milland sieved to remove the grinding media.

Medium scale attritor milling experiments were performed using a 1HDUnion Process attritor mill with a 1 L grinding chamber or a 15 UnionProcess attritor mill with a 750 mL grinding chamber. The grinding mediaconsisted of 3 kg of 5/16″ stainless steel balls or 1.5 kg of ⅜″stainless steel balls for the 15 attritor. The 1HD mill was loadedthrough the loading port, with dry materials added initially, followedby the grinding media, while the grinding media was added initially,followed by the dry materials in the 15 attritor mill. The millingprocess was conducted with the jacket cooled at 10-20° C. with the shaftrotating at 350 rpm in the 1HD attritor or 550 rpm in the 15 attritor.Upon completion of milling, the milled material was discharged from themill and sieved to remove the grinding media.

Medium to large scale attritor milling experiments were performed usinga 1S Union Process attritor mill with a ½ gallon grinding chamber. Thegrinding media consisted of 7 kg of ⅜″ stainless steel balls. The millwas loaded through the loading port, with the grinding media addedinitially, followed by the dry powders. The milling process wasconducted with the jacket cooled at 18° C. and the shaft rotating at550-555 rpm. Upon completion of milling, the milled powder wasdischarged from the mill through the bottom discharge port at 77 rpm for5 min.

Large scale attritor milling experiments were performed using a 1S UnionProcess attritor mill with a 1½ gallon grinding chamber. The grindingmedia consisted of 20 kg of ⅜″ stainless steel balls. The mill wasloaded through the loading port, with the grinding media addedinitially, then followed by the dry powders. The milling process wasconducted with the jacket cooled to ambient temperature and the shaftrotating at 300 rpm. Upon completion of milling, the milled powder wasdischarged from the mill through the bottom discharge port at 77 rpm for5 min.

The largest scale attritor millings were done in a 30S Union Processmill with a 25 gallon grinding chamber (Union Process, Akron Ohio, USA).The grinding media consisted of 454 kg of ⅜″ stainless steel balls. Themill was loaded through its split top lid, with the grinding media addedinitially, then followed by the dry powders (25 kg). The milling processwas conducted with the jacket cooled to 10° C. and the shaft rotating at130 rpm. Upon completion of milling, the milled powder was dischargedfrom the mill through the bottom discharge port at 77 rpm for 5 min.

Siebtechnik Mill

Medium scale milling experiments were also performed in a SiebtechnikGSM06 (Siebtechnik, GmbH, Germany) with two 1 L milling chambers. Eachchamber was filled with 2.7 kg stainless steel media with a diameter of⅜″. The media and powder were loaded with the lid off. The mill wasoperated at ambient temperature. The vibration speed was the standardmill settings. Upon completion of the milling the media was separatedfrom the powder by sieving.

Simoloyer Mill

Medium scale milling experiments were performed in a Simoloyer CM01 (ZOZGmbH, Germany) with a 2 L milling chamber. The grinding media consistedof 2.5 kg stainless steel media with a diameter of 5 mm. the media wasloaded though the loading port followed by the dry materials. Themilling vessel was cooled using water at a temperature of about 18° C.The mill speed was operated in cycle mode: at 1300 rpm for two minutesand at 500 rpm for 0.5 min and so forth. Upon completion of the millingthe media was discharged from the mill using a grated valve to retainthe grinding media.

Large scale milling experiments were performed in a Simoloyer CM100 (ZOZGmbH, Germany) with a 100 L milling chamber. The grinding mediaconsisted of 100 kg stainless steel media with a diameter of 3/16″. Thepowder charge (11 kg) was added to the milling chamber, which alreadycontained the grinding media, through a loading port. The millingchamber was cooled to 18° C. and the powder was milled for a total of 20minutes using a cycling mode equivalent to a tip speed at 1300/500 rpmfor 2/0.5 min in the CM-01 type mill. Upon completion of the milling themill was discharged by sucking the powder into a cyclone.

Hicom Mill

Millings performed in a nutating Hicom mill utilized 14 kg of stainlesssteel 0.25″ grinding media together with a powder charge of 480 g. Themill was loaded by pre-mixing media and powder, then adding the mixtureto the grinding chamber through the loading port at the top of the mill.The milling was done at 1000 rpm and the mill discharged by invertingthe mill and emptying through the loading port. The recovered materialwas sieved to separate the grinding media from the powder.

Variations to the milling conditions set out above are indicated in thevariations column in the data tables. The key to these variations isshown in Table A.

Particle Size Measurement:

The particle size distribution (PSD) was determined using a MalvernMastersizer 2000 fitted with a Malvern Hydro 2000S pump unit.Measurement settings used: Measurement Time: 12 seconds, Measurementcycles: 3. Final result generated by averaging the 3 measurements.Samples were prepared by adding 200 mg of milled material to 5.0 mL of1% PVP in 10 mM hydrochloric acid (HCl), vortexing for 1 min and thensonicating. From this suspension enough was added into the dispersant(10 mM HCl) to attain a desired obscuration level. If necessary an extra1-2 minutes of sonication was applied using the internal sonicationprobe in the measurement cell. The refractive index of the activeingredient to be measured was in the range of 1.49-1.73. Any variationsto this general method are summarized in Table B.

XRD Analysis:

Powder X-Ray diffraction (XRD) patterns were measured with aDiffractometer D 5000, Kristalloflex (Siemens). The measurement rangewas from 5-18 degrees 2-Theta. The slit width was set to 2 mm and thecathode ray tube was operated at 40 kV and 35 mA. Measurements wererecorded at room temperature. The recorded traces were subsequentlyprocessed using Bruker EVA software to obtain the diffraction pattern.

TABLE A Variations to milling conditions. Milling Media Media OffloadSpeed size Mass spped Variation # Mill type (rpm) (inch) (kg) (rpm) A1HD 1 L 0.25 B 1S 0.5 gal 5 C 1S 0.5 gal 4 D 1S 0.5 gal 500 E 1S 0.5 gal550-555 F 1S 1.5 gal 316-318 21 G 1S 1.5 gal 500 21 H 1S 1.5 gal 355 21I 1S 1.5 gal 355 18 J 1S 1.5 gal 21 K 1S 1.5 gal 18.4 L 1S 1.5 gal 400 M1S 1.5 gal 21 57 N 1S 1.5 gal 57 O 1S 0.5 gal 400 400 P 1S 0.5 gal 500350 Q HICOM ⅛ R HICOM 11.7 Only conditions reported in the table havechanged as compared to conditions reported above.

TABLE B Variations to particle size measurement conditions. Vari - ationMeasurement Addition # Sample Dispersant Dispersant Method 1 0.1% PVP inDI water Powder 2 0.2% Pluronic L81 DI water addition in DI water 3Saturated glyphosate Powder in DI water addition 4 Saturated glyphosatein DI water Powder addition 5 1% PVP in DI water DI water 6 DI waterPowder addition 7 1% PVP in DI water Saturated creatine in DI water 8 1%PVP in DI water 10 mM HCl 9 0.2% Pluronic L81 Acidified with 1M HCl inDI water 10 1% PVP in DI water 0.1% PVP in DI water 11 1% PVP in DIwater 1% PVP in DI water 12 Filtered before PSD measurement

Abbreviations

HCl: Hydrochloric acid

Nap: Naproxen acid

PSD: Particles size distribution

PVP: Polyvinyl pyrrolidone

RI: Refractive index

Rpm: Revolutions per minute

SLS: Sodium lauryl sulphate

SSB: Stainless Steel Balls

XRD: X-Ray Diffraction

Other abbreviations used in the data tables are listed below in Table C(for actives), Table D (for matrices) and Table E (for surfactants). Inthe data tables single letter with example number abbreviations havebeen used to identify specific sample numbers within the table. The datatables shown in the figures the use of surfactant, matrix areinterchangeable and do not necessarily define the nature of thatmaterial.

TABLE C Abbreviations used for active pharmaceutical ingredients. APIName Abbreviation 2,4-Dichlorophenoxyacetic 2,4D acid Anthraquinone ANTCelecoxib CEL Cilostazol CIL Ciprofloxacin CIP Creatine Monohydrate CRMCyclosporin A CYA Diclofenac Acid DIC Glyphosate GLY Halusulfuron HALIndomethacin IND Mancozeb MAN Meloxicam MEL Metaxalone MTX MetsulfuronMET Naproxen Acid NAA Naproxen Sodium NAS Progesterone PRO SalbutamolSAL Sulfur SUL Tribenuran TRI FOOD Apricot kernel APR Cinnamon GroundCNG Cinnamon Quills CNQ Cocoa Nibs CON Cocoa Powder COP Coffee Beans COFCloves CLO Dehydrated Peas PEA Dehydrated Beans BEA Fenegreek FEN GojiBerry GOJ Green Tea GTE Ground Ginger GIN Lavender LAV Linseed LINMangosteen MST Raspberry Leaf RAS Turmeric TUR

TABLE D Abbreviations used for excipients. Matrix Name AbbreviationCalcium Carbonate CAC Full Cream Milk Powder FCM Glucose GLU LactoseAnhydrous LAA Lactose Monohydrate LAC Lactose Monohydrate Food Grade LFGMalic Acid MAA Maltitol MAL Mannitol MAN Skimmed Milk Powder SMP SodiumBicarbonate SB Sodium Chloride SC Sorbitol SOR Sucrose SUC Tartaric AcidTA TriSodium Citrate Dihydrate TCD Whey Powder WP Xylitol XYL

TABLE E Abbreviations used for surfactants Surfactant Name AbbreviationAerosil R972 Silica AS Benzalkonium Chloride BC Brij700 B700 Brij76 B76Cremophor EL CEL Cremophor RH-40 C40 Dehscofix 920 D920 Docusate SodiumDS Kollidon 25 K25 Kraftsperse 1251 K1251 Lecithin LEC Poloxamer 188P188 Microcrystalline Cellulose MCC Poloxamer 407 P407 PolyethyleneGlycol 3000 P3000 Polyethylene Glycol 8000 P8000 Polyoxyethylene 40Stearate P40S Polyvinyl Pyrrolidone (Kollidon 30) PVP Primellose PMLPrimojel PRI Sodium Deoxycholate SDC Sodium Dodecyl Sulphate SDS SodiumDodecylbenzenesulphonic SDA Acid Sodium N-Lauroyl Sarcosine SNS SodiumOctadecyl Sulphate SOS Sodium Pentane Sulphonate SPS Soluplus HS15 SOLTeric 305 T305 Tersperse 2700 T2700 Terwet 1221 T1221 Terwet 3785 T3785Tween 80 T80

Example 1: Spex Milling

A range of actives, matrices and surfactants in a variety ofcombinations were milled using the Spex mill. The details of thesemillings are shown in FIGS. 1A-1G together with the particle sizedistributions of actives that were milled.

These millings demonstrate that the addition of a small amount ofsurfactant to the milling matrix delivers a smaller particle sizecompared to millings of just an active and a single matrix. Someexamples of this are samples Z and AA compared to sample Y; Sample ABcompared to sample AC; sample AE compared to sample AD; sample AGcompared to sample AF; sample AP compared to sample AO; sample ARcompared to sample AQ, sample AT compared to sample AS; Samples AX, AYand AZ compared to sample AW; sample BC compared to sample BD; sample BIcompared to BH; samples BL-BR compared to sample BK; samples CS-DBcompared to sample DC. This last example is particularly noteworthy asthese millings were undertaken at 45% v/v. This demonstrates the broadapplicability of this invention. Some other examples of surfactantaddition being beneficial for size reduction are samples DD-DG and DI-DKcompared to sample DH; sample DM compared to sample DL. Other samplessuch as samples DY-EC compared to sample DX; sample AV compared tosample AU; samples B-H compared to sample A and samples K-M compared tosample J show this ti be also true when particle size statistics suchthe %<1 micron as used.

Note that this applies to mechanochemcial matrix milling as well. Thisis demonstrated by sample BI where naproxen sodium is milled withtartaric acid and converted to naproxen acid. FIG. 1H shows XRD datathat demonstrates the transformation.

Other samples such as CB-CR show examples were surfactants suitable foruse with IV formulations can be used to manufacture very smallparticles.

It is also noteworthy that samples DS and DT could be sized using asaturated solution of the active (salbutamol) demonstrating that activeswith high water solubility can be measured as long as care is taken whenmeasuring the size.

Two sets of data, samples N-Q and samples R-U, also demonstrate that theinvention described herein is unique. In these samples the active milledwith a matrix and surfactant produces small particles. When milled withmatrix alone the particles sizes are larger, in the case of sample Qthey are not even nanoparticles. When the active is milled with just 1%surfactant the resultant particle size is very large. Even when 80%surfactant is used the size is large.

Example 2: 110 mL Attritor

A range of actives, matrices and surfactants in a variety ofcombinations were milled using the 110 ml stirred attritor mill. Thedetails of these millings are shown in FIG. 2A together with theparticle size distributions of actives that were milled.

These millings also demonstrate that the addition of a small amount ofsurfactant to the milling matrix delivers a smaller particle sizecompared to millings of just an active and a single matrix in a smallscale stirred mill as well as the vibratory Spex mill. Sample F alsodemonstrates that small particles can be achieved at high % actives whena surfactant is present. Sample D and E also show that the addition ofthe surfactant also increased the yield of powder from the mill.

Example 3: Second Matrix

In this example naproxen was milled with a mixture of two matrices usingthe Spex mill. The details of these millings are shown in FIG. 3Atogether with the particle size distributions of actives that weremilled. Samples A and B were milled in a primary matrix of lactosemonohydrate and 20% of second matrix. The particle size of thesemillings is smaller than the same milling with just lactose monohydrate(See example 1 sample No AH, FIG. 1B). The particle size is also smallerthan naproxen milled in the secondary matrices (See example 1 sample NoAl and AJ, FIG. 1B). This shows the mixed matrices have synergytogether.

Samples C-E were milled in anhydrous lactose with 20% of a secondmatrix. All these samples had a particle size much smaller than naproxenmilled in anhydrous lactose alone (See example 1 sample No AK, FIG. 1B).

These millings demonstrate that the addition of a second matrix to theprimary milling matrix delivers a smaller particle size compared tomillings with just a single matrix.

Example 4: 1 L Attritor

Two actives with various combinations of lactose monohydrate and SDSwere milled using the 1 L stirred attritor mill. The details of thesemillings are shown in FIG. 4A together with the particle sizedistributions of actives that were milled.

Sample A and B are millings of meloxicam at 20%. While sample B has aslightly smaller particle size than sample A there is a dramaticdifference in the amount of material recovered from the milling. SampleA, milled with 3% SDS has a high yield of 90% whereas sample B with nosurfactant has practically no yield with all the powder caked in themill.

In samples C-F the milling of 13% indomethacin shows that the use of asecond matrix (tartaric acid) in combination with 1% SDS delivers thebest outcome of a good particle size and high yield. Sample D which hasjust the mixed matrix has very good particle size but poor yield.

These results show that the addition of a small amount of surfactantimproves milling performance.

Example 5: 750 mL Attritor

Two actives with various combinations surfactants were milled using the750 ml stirred attritor mill. The details of these millings are shown inFIG. 5A together with the particle size distributions of actives thatwere milled.

In samples A-C three millings of naproxen are shown. Sample A has just1% SDS as a surfactant. Samples B and C have a second surfactant presentand these samples have a smaller particle size as measured by the %<500nm, %<1000 nm and %<2000 nm.

In samples D-F three millings of indomethacin are shown. Sample D hasjust 1% SDS as a surfactant. Samples E and F have a second surfactantpresent and these samples have a smaller particle size compared tosample D.

These examples demonstrate that the use of combination of surfactantscan be useful to achieve better reduction in particle size.

Example 6: ½Gallon 1S

A range of actives, matrices and surfactants in a variety ofcombinations were milled using the ½ gallon 1S mill. The details ofthese millings are shown in FIGS. 6A-C together with the particle sizedistributions of actives that were milled.

The following examples demonstrate the increased yield obtained whenmilling an active in a ½gallon 1S attritor mill with a surfactant ascompared to no surfactant, with all other factors being identical.Sample C and D (FIG. 6A) shows Naproxen acid milled in Mannitol withyields of 92% and 23%, with and without surfactant. Sample S and AL(FIGS. 6B and C) show the same for glyphosate with yields of 95% and26%, respectively. Sample Al and AJ (FIG. 6B) show Ciprofloxacin yieldsof 94% and 37% with and without surfactant while sample AM an AN (FIG.6C) show Celecoxib yields of 86% and 57% with and without surfactants.Finally, samples AP and AQ (FIG. 6C) shows milling Mancozeb with orwithout surfactants results in yields of 90% and 56%, respectively.

The following examples illustrates that milling an active in a ½gallon1S attritor mill with a surfactant as compared to without surfactant andall other factors identical, leads to smaller particle size aftermilling. Sample C and D (FIG. 6A) shows a D(0.5) of 0.181 and 0.319 withor without surfactant, while sample AM and AN (FIG. 6C) shows D(0.5) of0.205 and 4.775 with and without surfactants.

The series of samples Q-S are timepoints taken from a single glyphosatemilling. The data demonstrates that the size of the actives decreaseswith milling time.

Other samples such as V-AA show examples were surfactants suitable foruse with IV formulations can be used to manufacture very smallparticles.

Some of the particle size data in FIGS. 6A-C was converted to a numberaverage particle size and is shown in the tables. This number wascalculated in the following way. The Volume distribution was transformedto the number distribution using the Malvern Mastersizer software. Foreach size bin the size of the bin was multiplied by the % of particlesin the bin. This numbers were added together and divided by 100 to givethe number average particle size.

Example 7: Metaxalone

Metaxalone was milled with various combinations of matrices andsurfactants using a variety of mills. The details of these millings areshown in FIG. 7A together with the particle size distributions ofactives that were milled. Samples A, B, E, G, H and I were milled in aSpex mill. Samples C, D and F were milled in the 750 ml atrittor. Theremaining samples were milled in the ½ gallon 15 mill.

Samples A compared to sample B and sample H compared to sample Gdemonstrate that the addition of one or more surfactants enables theproduction of smaller active particles. Other millings such as samplesC-F show that metaxalone can be milled small at very high activeloadings. Sample I shows that disintegrant can be added during millingand not effect the production of small active particles. Note that theparticle size in sample I is after filtration through a 10 micronfilter. Sample N shows an alternative way to manufacture a formulationwith small particles and disintegrants. In this example the powder fromsample M was left in the mill and a wetting agent (PVP) and disintegrantwere added. The powder was milled for a further 2 minutes and thenunloaded with a very high yield of 97%.

The series of samples J-M are timepoints taken from a single milling.The data demonstrates that the size of the actives decreases withmilling time.

Example 8: Hicom

A range of actives, matrices and surfactants in a variety ofcombinations were milled using the Hicom mill. The details of thesemillings are shown in FIG. 8A together with the particle sizedistributions of actives that were milled.

The data shows that the invention described herein can be used with theHicom mill with its nutating action. The data in FIG. 8A shows that avariety of actives can be milled small in very short times and give verygood yields at 500 gram scale.

Sample N and O show that cocoa powder can be reduced to very fine sizesin short times using the invention describes here in in combination withthe Hicom nutating mill. Likewise Sample P shows that this is also thecase for cocoa nibs.

Example 9: 1.5 Gallon 1S

A range of actives, matrices and surfactants in a variety ofcombinations were milled using the 1.5 Gallon 1S mill. The details ofthese millings are shown in FIGS. 9A-B together with the particle sizedistributions of actives that were milled.

The following examples demonstrate the increased yield obtained whenmilling an active in a 1.5 gallon 1S attritor mill with a surfactant ascompared to no surfactant, with all other factors being identical.Sample J and N (FIG. 9A) shows yields of 51% and 80%, without and withsurfactant. Sample K and P (FIG. 9A) show yields of 27% and 80%, withoutand with surfactant, while sample L (FIG. 9A) show a yield of 94% withsurfactant and the control without surfactant (sample M, FIG. 9A)resulted in no yield due to caking within the mill.

The following examples illustrates that milling an active in a 1.5gallon 1S attritor mill with a surfactant as compared to withoutsurfactant and all other factors identical, leads to smaller particlesize after milling. Sample F and G (FIG. 9A) shows a D(0.5) of 0.137 and4.94 with or without surfactant, while sample K and P (FIG. 9A) showsD(0.5) of 0.242 and 0.152 without and with surfactants.

The series of samples Al-AL are timepoints taken from a single meloxicammilling. The data demonstrates that the size of the actives decreaseswith milling time.

Other samples such as A-E show examples were surfactants suitable foruse with IV formulations can be used to manufacture very smallparticles.

Sample M was a milling of meloxicam in lactose monohydrate withoutsurfactant. 3 minutes into the milling the mill refused to turn. Themilling was stopped and started again but only ran for another 3 minutesbefore stopping again. At this point the mill was taken apart and noevidence of caking was found. However the powder had a gritty feeling toit and was locking the medium and shaft such that it was not possible toturn. The media was weighed and it as found that 150 grams of powder wason the media indicating that it was sticking to the media and making ithard to move. At this point the mill was re-assembled and the powder andmedia put back in. 30.4 grams of SDS was included in the milling makingit similar to milling L. After the addition of the surfactant the millwas run for another 14 minutes (giving a total of 20 mins) withoutincident. After offloading the powder the media was weighed and theweigh of powder on the media was only 40.5 grams. This indicates theaddition of surfactant has improved the milling performance and abilityto mill the powder.

Some of the particle size data in FIGS. 9A-B was converted to a numberaverage particle size and is shown in the tables. This number wascalculated in the following way. The Volume distribution was transformedto the number distribution using the Malvern Mastersizer software. Foreach size bin the size of the bin was multiplied by the % of particlesin the bin. This numbers were added together and divided by 100 to givethe number average particle size.

Example 10: Large Scale 25/11 kg

Sample A (FIG. 10A) was milled in the Siebtechnik mill for 15 minutes.After this time the powder was completely caked onto the walls of themill and the media. No powder could be removed to measure the particlesize. At this point 0.25 g (1 w/w %) SLS was added to mill chamber andmilling was then undertaken for a further 15 minutes. After the secondperiod of milling in the presence of SLS powder was no longer caked ontothe media and some free powder was also present. The observations madebefore and after the addition of the SLS demonstrate that the additionof the surfactant lessens the problem of caking. With the addition ofsurfactant the caked material could be recovered to become free powderagain with small particle size.

Sample B-E was milled in horizontal Simoloyer mills. The details ofthese millings are shown in FIG. 10A together with the particle sizedistributions of actives that were milled.

The data shows that the invention described herein can be used withSimoloyer mills with their horizontal attritor action. Of particularnote is example E which was milled at 11 kg scale. This demonstrates theinvention described herein is suitable for commercial scale milling.

Sample F was milled in a vertical attritor mill (Union Process S-30).The details of this milling is shown in FIG. 10A together with theparticle size distribution of the active milled.

The data shows that the invention described herein can be used with aS-30 mills with its vertical attritor action. Of particular note is thatthis milling was at 25 kg scale. This demonstrates the inventiondescribed herein is suitable for commercial scale milling.

Example 11: Food SPEX

A range of actives, matrices and surfactants in a variety ofcombinations were milled using the spex. The details of these millingsare shown in FIGS. 11A-C together with the particle size distributionsof actives that were milled.

This millings show that the invention disclosed herein is useful formilling food such as cocoa powder and cocoa nibs and other naturalproducts such as seeds, flowers and berries to a small size.

The milling of dried berries (with some residual moisture) wassuccessfully undertaken in sample AG. In contrast milling the berries onthere own sample AQ resulted is sticky mass that incorporated themilling media. This shows that the invention described herein is usefulfor milling materials with residual water content and achieving a smallparticle size.

Example 12: Food ½Gallon 1S

A range of actives, matrices and surfactants in a variety ofcombinations were milled using the ½ gallon 1S mill. The details ofthese millings are shown in FIG. 12A together with the particle sizedistributions of actives that were milled.

This millings show that the invention disclosed herein is useful formilling food and natural products such as coffee, cocoa powder and cocoanibs.

The milling of coffee (a material with a natural oil content) wassuccessfully undertaken in sample A. In contrast milling the coffee with1% lecithin (sample B) resulted is sticky mass that was caked at the topof the mill (see FIG. 12B). This shows that the invention describedherein is useful for milling materials with natural oil content andachieving a small particle size as well as giving a good yield.

Example 13: Naproxen

Naproxen was milled in mannitol with a range of surfactants using the ½Gallon 1S mill. The details of these millings are shown in FIG. 13Atogether with the particle size distributions of actives that weremilled.

Naproxen acid milled in Mannitol with a surfactant (Sample A, D-J inFIG. 13A) leads to higher yields, as compared to Naproxen acid milled inMannitol without surfactant (Sample K, FIG. 13A). Naproxen acid milledin Mannitol and either microcrystalline cellulose or the disintegrantprimellose (sample L or M, FIG. 13A) leads to small particle size withD(0.5) around 0.25 in both cases.

Example 14: Filtration

Some matrices, milling aids or facilitating agents that are used by thisinvention are not water soluble. Examples of these are microcrystallinecellulose and disintegrants such as croscarmellose and sodium starchglycolate. In order to more easily characterise the particle size of theactive after milling with these materials filtration methods can be usedto remove them allowing a characterisation of the active. In thefollowing examples naproxen was milled with lactose monohydrate andmicrocrystalline cellulose (MCC). The particle size was characterisedbefore and after filtration and the ability of the filters to letthrough the naproxen was demonstrated using HPLC assays. The millingdetails and the particle size are shown in FIG. 14a . Note in this tablethe particle size with milling details is un-filtered. The particle sizein the rows with no milling details is after filtration. The sample thatwas filtered is indicated in the Active material section. The HPLCassays were performed by taking samples before and after filtrationthrough 10 micron poroplast filters. The samples taken were diluted togive a nominal concentration of 100 pg/ml. The HPLC assay data is shownin Table 14

Sample A was milled with 5% MCC. Before filtration the D50 was 2.5 μm,after filtration (sample B) the D50 was 183 nm. When sample B wasassayed the concentration was 94 pg/ml indicating that filtrationprocess retained little naproxen. A second milling (sample C) wasundertaken without MCC. The D50 was 160 nm as would be expected. Afterfiltration (sample D) the particle size was unchanged indicating that ifthe filtration process did remove any naproxen then it was removed in aneven way. Some of sample C was then milled with MCC for 1 minute. Thisis long enough to incorporate the MCC into the powder but not longenough to affect the particle size distribution. Two millings wereundertaken. Sample E incorporated 5% w/w MCC into the powder and SampleF 9% w/w. After incorporation of the MCC the particle size increaseddramatically. These samples where then filtered (Sample E and F) and thesize remeasured. After filtration the particle size is the same asSample C which was the starting material. The assay of samples E-Hindicates that filtration did not remove any naproxen of anysignificance. The combination of particle size and assay data clearlyshows that material such as MCC can easily and successfully be removedallowing the true particle size of the active to be measured.

Samples I and J were millings conducted with 10 and 20% w/w MCC. Theparticle size post filtration is show as sample K and L. Again thefiltration has delivered a reduction in particle size due to the removalof the MCC component. And again the HPLC assay of sample I-L showslittle naproxen was lost during filtration.

This data also demonstrates that MCC can successfully be used as comatrix in the invention disclosed herein.

TABLE 14 The HPLC assay of naproxen before and after filtration ofsamples. Sample No. HPLC Assay (μg/ml) B 94 D 93 E 99 F 96 G 98 H 97 I94 J 89 K 91 L 84

Example 15: Dissolution of Nanoformulation Capsules Example 15(a)Manufacture of Naproxen (200 mg) Nanoformulation Capsules

Nine sublots of naproxen nanoformulation milled powder were combined(Example 9, Sample Z-AH), roller compacted, processed in a Quadro®Comil®, and encapsulated. For each milling sublot, 334 g of naproxen,599 g of mannitol, 9.55 g of povidone K30, and 9.55 g of sodium laurylsulfate were charged into an 8-qt V blender and mixed for 10 minutes,yielding a powder of approximate composition 35% naproxen, 63% mannitol,1% povidone K30, and 1% sodium lauryl sulfate.

The blends were then milled individually and during the millingprocesses, unmilled material and samples were periodically dischargedand their amounts recorded. After completion of each of the individualmillings, an amount of croscarmellose sodium was added to each milling.The amount of croscarmellose sodium added was based on the theoreticalamount of milled powder remaining in the mill, such that the finalconcentration of croscarmellose sodium in the powder would be 5.38% w/wupon addition of the calculated amount. After adding the croscarmellosesodium to the attritor mill, the mill was run for 2 minutes. The milledpowder of approximate final composition 33.11% naproxen, 59.61%mannitol, 0.95% sodium lauryl sulfate, 0.95% povidone K30, and 5.38%croscarmellose sodium was then discharged from the mill.

Materials obtained from Example 9, Samples Z-AH were combined in a 1 cu.ft V-blender and mixed for 20 min. The mixed powder was processed in aFreund Model TF-156 roller compactor (screw speed=13.4, roll speed=4.1,pressure=55 kg/cm²). The powder was processed for approximately 55 min,yielding ribbons of 2.3 to 2.7 mm thickness.

The roller compacted ribbons were manually crushed and fed into thehopper of a Quadro® Comil® 197 equipped with an 1143 micron screen and0.225 inch spacer, operating at 2000 rpm. The net yield of milledgranular material was 4.183 kg.

The milled roller compacted granules were encapsulated into size 00white opaque hard gelatin capsules using a MiniCap 100 Capsule FillingMachine equipped with size 00 change parts. The capsules were filledmanually with a scraper and periodically checked for gross weight,closure integrity, and appearance. The target fill weight was 604 mg,and the average weight of an empty capsule shell was 117 mg. The filledcapsules were then polished in a capsule polishing machine. The netyield of filled, polished capsules was 4,183 g (approximately 6,925capsules).

Example 15(b): Manufacture of Indomethacin (20 mg) NanoformulationCapsules

Indomethacin milled powder (750.0 g, Example 9, Sample T) was chargedinto the bowl of a KG-5 high shear granulator. Separately, a 30%solution of povidone K30 in purified water was prepared by dissolving47.8 g of povidone in 111.6 g of purified water.

The high shear granulator was operated with an impeller speed of 250 rpmand a chopper speed of 2500 rpm. A portion of the povidone solution(80.3 g) was introduced into the granulator over a period ofapproximately 8 minutes using a peristaltic pump. An additional 30 g ofpurified water was then added to the granulation.

After the additions of povidone solution and water were completed, thewet granules were spread on to paper-lined trays to a thickness ofapproximately ½″, and were dried in an oven at 70° C. for approximately1 hour. The granules were then manually screened through a 10 mesh handscreen, and spread on to paper-lined trays for additional drying. Thegranules were dried for a second hour, and then tested for loss ondrying; the LOD value was 1.987%.

The dried granules were processed in a Quadro CoMill (20 mesh screen,0.225 inch spacer) at 2500 rpm, yielding 689.9 g of milled granuleshaving the final composition of 12.60% indomethacin, 62.50% lactosemonohydrate, 20.86% tartaric acid, 0.95% sodium lauryl sulfate, 3.09%povidone K30.

The granules were manually filled into size 4 white opaque hard gelatincapsules using a MiniCap 100 Capsule Filling Machine set up with size 4capsule change parts. The target fill weight of each capsule was 158.7mg and the average empty capsule shell weight was 38 mg. Capsules werefilled manually using a scraper and periodically tested for grossweight. Tamping and vibration were adjusted as necessary to achieve thetarget fill weight. The filled capsules were polished in a CapsulePolishing Machine, yielding a net weight of 803 g of filled capsules(approximately 4,056 capsules).

Example 15(c): Manufacture of Indomethacin (40 mg) NanoformulationCapsules

Two separate granulation sublots were manufactured and combined toproduce Indomethacin Nanoformulation capsules 40 mg.

Granulation sublot A was prepared by charging indomethacin milled powder(750.0 g, Example 9, Sample U) into the bowl of a KG-5 high sheargranulator. Separately, a 30% solution of povidone K30 in purified waterwas prepared by dissolving 47.8 g of povidone in 111.5 g of purifiedwater. The granulator was operated with an impeller speed of 250 rpm anda chopper speed of 2500 rpm. A portion of the povidone solution (80.3 g)was introduced into the granulator over a period of approximately 9minutes, using a peristaltic pump. An additional 20 g of purified waterwas then added to the granulation.

After the additions of povidone solution and water were completed, thewet granules were spread on to paper-lined trays to a thickness ofapproximately ½″.

Granulation sublot B was prepared by charging indomethacin milled powder(731.6 g, Example 9, Sample V and 18.4 g, Example 9, Sample U) into thebowl of a KG-5 high shear granulator. Separately, a 30% solution ofpovidone K30 in purified water was prepared by dissolving 47.8 g ofpovidone in 111.5 g of purified water. The granulator was operated withan impeller speed of 250 rpm and a chopper speed of 2500 rpm. A portionof the povidone solution (80.3 g) was introduced into the granulatorover a period of approximately 10 minutes, using a peristaltic pump. Anadditional 20 g of purified water was then added to the granulation.After the additions of povidone solution and water were completed, thewet granules were spread on to paper-lined trays to a thickness ofapproximately ½″. The wet granules from both sublots were dried in anoven at 70° C. for approximately 2.5 hours. The granules were thenmanually screened through a 10 mesh hand screen, and spread on topaper-lined trays for additional drying. The granules were dried foranother 1.5 hours, until the LOD value was 1.699%.

The dried granules were processed in a Quadro CoMill (20 mesh screen,0.225 inch spacer) at 2500 rpm. The milled granules were then added toan 8 qt V-blender and mixed for 5 minutes, yielding 1390.7 g of granuleswith a final composition of 12.60% indomethacin, 62.50% lactosemonohydrate, 20.86% tartaric acid, 0.95% sodium lauryl sulfate, 3.09%povidone K30.

An IN-CAP® automated capsule filling machine (Dott. Bonapace & C.,Milano, Italy) was set up with size (2) 16 mm dosing disc and size (2)tamping pins. Milled granules were charged into the encapsulator, alongwith size 1 white opaque hard gelatin capsule shells. The target capsulefill weight was 317.7 mg, and the average empty capsule shell weight was75 mg. Tamping pins 1-4 were all set to 9 mm, and the encapsulator wasrun at speed 2. Weight checks, closure checks, and appearance checkswere performed every 15 minutes. Filled capsules were polished in acapsule polishing machine. The net weight of filled, polished capsuleswas 1225.5 g (approximately 3,183 capsules).

Example 15(d): Manufacture of Meloxicam (7.5 mg) NanoformulationCapsules

Milled powder (Example 9, Sample Q) was manually encapsulated using acapsule filling device (Cooper plate and capsule loader) into size “4”white-opaque hard-gelatin capsules. Upon encapsulation, each capsulecontains 7.5 mg active ingredient with a total fill weight of 105 mg.The finished capsules were packaged in 40 cc HDPE bottles (50 counts perbottle) with the bottles being enclosed using an induction seal.

Example 15(e): Manufacture of Diclofenac(18 mg) Nanoformulation Capsules

Diclofenac milled powder (666.2 g, from Example 9, Sample W) was chargedinto the bowl of a KG-5 high shear granulator. Separately, a 30% w/wsolution of povidone K30 was prepared by dissolving 60.0 g of povidoneK30 in 140.0 g of purified water. The granulator was operated at achopper speed of 250 rpm and impeller speed of 2500 rpm. A portion ofthe povidone solution (88.6 g) was introduced into the granulation overa period of approximately 9 minutes with a peristaltic pump. Anadditional 30 g of water was then added to the granulation.

The wet granules were spread on to paper-lined trays and dried in anoven at 70° C. for 2 hours. They were then manually screened through a10 mesh hand screen. After approximately 2.25 hours of drying time, theloss on drying was determined to be 0.559%.

The dried granules were processed in a Quadro CoMill fitted with a 200mesh screen and 0.225 inch spacer, run at 1265 rpm. The process yielded539.0 g of milled, dried granules. The granules were filled into size 4white opaque hard gelatin capsules using an IN-CAP® automated capsulefilling machine (Dott. Bonapace & C., Milano, Italy). The machine wasset up with size 4 change parts and a 10 mm dosing disc. The target fillweight was 124.8 mg, and the average weight of an empty capsule shellwas 38 mg. The machine was run at speed setting #2. Tamping pin #4 wasset to 21 mm; all other tamping pin settings were N/A.

The filled capsules were polished in a capsule polishing machine, andthe net yield of filled capsules was 480.2 g (approximately 2,910capsules).

Example 15(f): Manufacture of Diclofenac(35 mg) Nanoformulation Capsules

Two separate granulation sublots were used for the manufacture ofDiclofenac Nanoformulation Capsules 35 mg. Granulation sublot A: 642.7 gof milled diclofenac powder (Example 9, Sample X) was charged into thebowl of a KG-5 high shear granulator. Separately, a 30% w/w solution ofpovidone K30 was prepared by dissolving 60.0 g of povidone K30 in 140.0g of purified water. The granulator was operated at an impeller speed of250 rpm and a chopper speed of 2500 rpm. A portion of the bindersolution (85.5 g) was introduced into the granulation over a period ofapproximately 8.5 minutes via a peristaltic pump. An additional 30 g ofpurified water was then added to the granulation at the same rate. Thewet granules were spread on to paper-lined trays to a thickness ofapproximately ½″.

Granulation sublot B: 519.6 g of milled diclofenac powder (Example 9,Sample Y) was charged into the bowl of a KG-5 high shear granulator.Separately, a 30% povidone solution was prepared by dissolving 60.0 g ofpovidone K30 in 140.0 g of purified water. The granulator was operatedat an impeller speed of 250 rpm and a chopper speed of 2500 rpm. Aportion of the povidone solution (69.1 g) was added to the granulationover a period of approximately 6.5 minutes. An additional 30 g of waterwas then added at the same rate. The wet granules were spread on topaper-lined trays to a thickness of approximately ½″.

The wet granules from sublots A and B were dried in an oven at 70° C.for approximately 2 hours. They were then manually screened through a 10mesh hand screen and tested for loss on drying. The LOD result was0.316%.

The dried granules were milled in a Quadro CoMill fitted with a 200 meshscreen and 0.225 inch spacer, operated at 2500 rpm. The milled granuleswere charged into an 8 qt V-blender and mixed for 5 minutes, yielding1020.2 g of granules.

The granules were filled into size 3 white opaque hard gelatin capsulesusing a MiniCap Capsule Filling Machine equipped with size 3 changeparts. The target fill weight was 242.7 mg and the average weight of anempty capsule shell was 47 mg. The granules were filled into the capsuleshells manually using a scraper. Vibration and tamping were adjusted toachieve the target fill weight. The filled capsules were polished on acapsule polishing machine, yielding 1149.2 g of filled capsules(approximately 3,922 capsules).

Example 15(g) Manufacture of Metaxalone (100 mg) Nano FormulationCapsules

Milled powder (Example 7, Sample N) was manually encapsulated using acapsule filling device (Profil) into hard-gelatin capsules.

Example 15(h) Dissolution Rate of Milled Naproxen

The Dissolution of milled naproxen (200 mg) capsules (see example 15a),and commercial Naprosyn® 250 mg (naproxen) tablets (RochePharmaceuticals®, Inc., USA) were determined using dissolution equipmentset up as USP Apparatus II (paddles) with a stirrer speed of 50 rpm. Thedissolution media was 900 ml of 0.3% SLS in 0.1 M sodium phosphatebuffer at pH 5. The vessel temperature was 37° C. The capsules whereweighted down with a wire sinker. Six test articles were tested and thedata average for each time point. At each time point a 1 ml sample wastaken from each dissolution vessel, filtered through a 0.45 μm filterand analyzed by HPLC. The data in Table 15a below reports the percentdissolved of the amount of active in each test article, for thespecified time points.

TABLE 15a Dissolution Profiles of Naprosyn ® Tablets 250 mg and NaproxenNano- formulation Capsules 200 mg Percent of Label Claim Dissolved (%)Naproxen Naprosyn Tablets Nanoformulation Capsules Time 250 mg 200 mg 00 0 5 24 19 10 40 53 15 49 77 20 55 90 45 73 98 60 79 99

The results demonstrate that the milled naproxen capsules dissolve morequickly and more completely than the commercial reference naproxen.Those of skill in the art will readily appreciate the advantagesconferred by more rapid dissolution—more active agent is available atany given time point. Put another way, an equal quantity of dissolvednaproxen may be obtained with an initially smaller dosage amount ofmilled naproxen, as opposed to the larger initial dose required for thereference naproxen to reach to the same quantity of dissolved naproxen.Additionally, as the results make clear, the reference naproxen does notachieve complete dissolution even by the final time point, while themilled naproxen achieves greater than 90% dissolution within 20 minutes,and substantially complete dissolution by the 45 minute time point.Again, a smaller dose of milled naproxen yields a quantity of dissolvednaproxen for which a larger dose of reference naproxen would be requiredto equal. Example 15(i): Dissolution rate of milled indomethacin

In this example, dissolution rate is compared between 20 mg and 40 mgnanoformulations of the invention (Example 15(b) and 15(c)), andcommercial reference indomethacin USP 25 mg capsules (MylanPharmaceuticals Inc). The dissolution was performed using Apparatus I(baskets) according to USP <711>. The dissolution medium (900 ml at 37°C.) was 100 mM citric acid buffer (pH 5.5±0.05); The apparatus wasstirred at 100 rpm. Sampling times were 5, 10, 20, 30, 45, and 60 minplus an additional time point at 75 min (250 rpm). Sample of 8 mL weretaken and filtered through a 0.45 μm PVDF filter. The samples were assayby UV-visible spectroscopy with a detection wavelength=319 nm. The datain Table 15b below reports the percent dissolved of the amount of activein each test article, for the specified time points.

TABLE 15b Dissolution Profiles of Indomethacin Capsules USP (25 mg) andIndomethacin Nanoformulation Capsules (20 mg and 40 mg) Percent of LabelClaim Dissolved (%) Indomethacin Indomethacin Indomethacin Time capsulesNanoformulation Nanoformulation (min) USP, 25 mg Capsules 20 mg Capsules40 mg 0 0 0 0 5 20 47 31 10 28 83 66 20 36 99 93 30 40 100 96 45 43 10096 60 46 101 97 75 63 101 97

The results demonstrate that the milled indomethacin capsules dissolvemore quickly and more completely than the commercial referenceindomethacin. Those of skill in the art will readily appreciate theadvantages conferred by more rapid dissolution—more active agent isavailable at any given time point. Put another way, an equal quantity ofdissolved indomethacin may be obtained with an initially smaller dosageamount of milled indomethacin, as opposed to the larger initial doserequired for the reference indomethacin to reach to the same quantity ofdissolved indomethacin. Additionally, as the results make clear, thereference indomethacin does not achieve complete dissolution even by thefinal time point, while the milled indomethacin, in both dosage forms,achieves greater than 90% dissolution within 20 minutes. Again, asmaller dose of milled indomethacin yields a quantity of dissolvedindomethacin for which a larger dose of reference indomethacin would berequired to equal.

Example 15(J): Dissolution Rate of Milled Meloxicam

In this example, dissolution rate is compared between a 7.5 mgnanoformulation of this invention (Example 15(d)), and two commercialreference products Mobicox® 7.5 mg Tablets and Mobic® 7.5 mg Capsules(Both Boehringer Ingelheim). Dissolution was performed using ApparatusII (paddles) according to USP <711>. The dissolution medium was 10 mMphosphate buffer (pH 6.1) with 0.1% w/w sodium lauryl sulfate (500 ml at37° C.). The apparatus was stirred at 50 rpm. Samples were taken atvarious time points from 5 to 60 minutes. For each sample 1 mL wastaken, filtered through a 0.45 μm filter and assayed by HPLC using adetection wavelength of 362 nm. The data in Table 15c below report thepercent dissolved of the amount of active in each test article, for thespecified time points.

TABLE 15C Dissolution profiles of Commercial Meloxicam Tablets andCapsules and Meloxicam Nanoformulation Capsules Percent of Label ClaimDissolved (%) Meloxicam Mobicox ® Mobic ® Capsules Nanoformulation Time(min) Tablets 7.5 mg 7.5 mg Capsules 7.5 mg 0 0 0 0 5 39 19 44 10 50 4368 15 57 52 20 82 30 66 64 86 45 89 60 73 72 93

The results demonstrate that the milled meloxicam capsules dissolve morequickly and more completely than the commercial reference meloxicam.Those of skill in the art will readily appreciate the advantagesconferred by more rapid dissolution—more active agent is available atany given time point. Put another way, an equal quantity of dissolvedmeloxicam may be obtained with an initially smaller dosage amount ofmilled meloxicam, as opposed to the larger initial dose required for thereference meloxicam to reach to the same quantity of dissolvedmeloxicam. Additionally, as the results make clear, the referencemeloxicam does not achieve complete dissolution even by the final timepoint, while the milled meloxicam achieves about 82% dissolution within20 minutes, and reaches over 90% by the 60 minute time point. Again, asmaller dose of milled meloxicam yields a quantity of dissolvedmeloxicam for which a larger dose of reference meloxicam would berequired to equal.

Example 15(K): Dissolution Rate of Milled Diclofenac

In this example, dissolution rate is compared between 18 mg and 35 mgnanoformulations of the invention (Example 15(e) and 15(f)), andcommercial reference diclofenac Voltarol Dispersible Tablets 50 mg(Novartis, U.K) which contain 46.5 mg of diclofenac free acid,equivalent to 50 mg of diclofenac sodium. The dissolution method usedwas Apparatus I (baskets) according to USP <711> with a stirring speedof 100 rpm. The dissolution media was 0.05% sodium lauryl sulfate andcitric acid solution buffered to pH 5.75. The dissolution volume was 900mL and dissolution medium temperature was 37° C. Samples were tested at15, 30, 45, and 60 minutes and at infinity. Infinity was defined as anadditional 15 minutes at a higher rotation speed. A sample of 1 ml wastaken at each time point, filtered and assayed by HPLC with thedetection wavelength set at 290 nm. The data in Table 15d below reportthe percent dissolved of the amount of active in each test article, forthe specified time points.

TABLE 15d Dissolution Profiles for Voltarol ® Dispersible Tablets 50 mg,Diclofenac Nanoformulation Capsules 18 mg, and DiclofenacNanoformulation Capsules 35 mg Percent Label Claim Dissolved (%)Voltarol Diclofenac Diclofenac Dispersible NanoformulationNanoformulation Time Tablets 50 mg Capsules 18 mg Capsules 35 mg 0 0 0 015 52 91 82 30 59 94.0 95 45 63 94 95 60 65 94 95 75 87 94 95

The results demonstrate that the milled diclofenac capsules dissolvemore quickly and more completely than the commercial referencediclofenac. Those of skill in the art will readily appreciate theadvantages conferred by more rapid dissolution—more active agent isavailable at any given time point. Put another way, an equal quantity ofdissolved diclofenac may be obtained with an initially smaller dosageamount of milled diclofenac, as opposed to the larger initial doserequired for the reference diclofenac to reach to the same quantity ofdissolved diclofenac. Additionally, as the results make clear, thereference diclofenac does not achieve complete dissolution even by thefinal time point, while the milled diclofenac achieves about 90%dissolution within 15 minutes. Again, a smaller dose of milleddiclofenac yields a quantity of dissolved diclofenac for which a largerdose of reference diclofenac would be required to equal.

Example 15(I): Dissolution Rate of Milled Metaxalone

The dissolution of milled metaxalone (100 mg) capsules (Example 15(g)),and a portion (equivalent to 100 mg metaxalone) of commercial Skelaxin®800 mg (metaxalone) tablets (King Pharmaceuticals®, Inc., USA) weredetermined using dissolution equipment set up as USP Apparatus II(paddles) with a stirrer speed of 100 rpm. The dissolution media was1000 ml of 0.01 M HCL (pH 2). The vessel temperature was 37° C. Thecapsules were weighted down with a wire sinker. Three to six testarticles were tested and the data averaged for each time point. At eachtime point each dissolution vessel was automatically sampled through a 1μm filter and analyzed in flow through UV/Ms cells. The data in Table15e below report the percent dissolved of the amount of active in eachtest article, for the specified time points.

TABLE 15e Dissolution profiles of Skelaxin Tablets (100 mg portion) andMetaxalone Nanoformulation Capsules 100 mg. Percent of Label ClaimDissolved (%) Metaxalone Nanoformulation Skelaxin Time (min) Capsules100 mg (100 mg portion) 0 0 0 5 4 0 9 43 1 13 75 1 20 88 2 30 93 5 40 937 50 94 9 60 94 11

The results demonstrate that the milled metaxalone capsules dissolvemore quickly and more completely than the commercial referencemetaxalone. Those of skill in the art will readily appreciate theadvantages conferred by more rapid dissolution—more active agent isavailable at any given time point. Put another way, an equal quantity ofdissolved metaxalone may be obtained with an initially smaller dosageamount of milled metaxalone, as opposed to the larger initial doserequired for the reference metaxalone to reach to the same quantity ofdissolved metaxalone. Additionally, as the results make clear, thereference metaxalone does not achieve complete dissolution even by thefinal time point, while the milled metaxalone achieves about 87%dissolution within 20 minutes. Again, a smaller dose of milledmetaxalone yields a quantity of dissolved metaxalone for which a largerdose of reference metaxalone would be required to equal.

Example 16: Materials for Powder Handling Characteristic Testing

Blends of powders with a range of actives were prepared using a varietyof mills for a range of powder handling characteristic testing. Theseare detailed in FIG. 15 along with the particle size of the actives asdetermined by laser diffraction measurement in water based solvents.

Four samples of micronized active were also obtained from commercial APImanufacturers. Two sample of meloxicam (G and H and two samples ofindomethacin (M and N) were also tested. The particle size of theseactives as determined by laser diffraction measurement in water basedsolvents is also shown in FIG. 15.

Three samples were prepared by blending micronized material intolactose/SDS mixture that had been previously been milled in an attritormill. E is a blend of 6.8% w/w micronized meloxicam (G) and 93.2% w/w Dfor a total of 10.0 g. F is a blend of 6.8% w/w micronized meloxicam (H)and 93.2 w/w % D for a total of 10.0 g. These blends were prepared bymixing the respective ingredients. In a SPEX mill for 10 min, withoutthe use of any media. (J) is a blend of powdersize milled lactose (I)and 13% micronized indomethacin (N) prepared by combining I and N in apolyethylene bag and tumbling the bag end over end for a minimum of 10times. The particle size of active in this blend is shown in FIG. 15.

A blend of 13% w/w indomethacin, 1% w/w SDS and 86% w/w lactosemonohydrate was jetmilled (L) in a 10″ Spiral Jet Mill (Powdersize Inc).The particle size of active in this blend is shown in FIG. 15.

The particle size of the blend as a dry powder was measured for aselection of the blends. The measurements were performed on a MalvernMastersizer 2000 with a Scirocco 2000 measurement cell. All measurementswere performed at a pressure of 3 Bar excepting O, P and Q which weremeasured at 4 Bar. Note also that example S and T were passed through a100 micron sieve prior to measurement. The particle size of blendsmeasured in this way is shown in FIG. 16.

Example 17: Content Uniformity of Meloxicam Milled with LactoseMonohydrate

Capsules containing the milled material were obtained using the Profillcapsule filling system, specifically the system using size 4 capsules(100 units). Natural (clear) size 4 capsules (Capsuline) were used inthe process. The empty capsules were loaded onto the equipment and thelids removed as per instructions. The milled material was added to thecapsules by moving powder across the plate with a scraper until thesurface was level. After the capsules were filled in this manner theplate supporting the capsules was tapped lightly (tapped on the side ofthe plate with the plastic scraper), resulting in settling of the powderin the capsules. Powder was then scraped across the capsules anew untilsurface was level. This procedure was repeated a total of three times.The lids of the capsules were repositioned and the capsules closed andremoved from the Profill system.

Content uniformity of the capsules was analyzed using High PerformanceLiquid Chromatography (HPLC). Each sample was run according to theMeloxicam USP method and results obtained using the following formula:

$\left\lbrack {\frac{Ru}{Rs} \times C \times D\; {il} \times \frac{100}{LC}} \right\rbrack = {\% \mspace{14mu} {LC}}$

Where:

Ru=Peak Response (Area) of Meloxicam in Test Solution

Rs=Average Peak Response (Area) of Meloxicam obtained from all StandardSolution injections

C=Concentration of Meloxicam in Standard (mg/mL)

Dil=Dilution factor (mL)

LC=Label Claim (7.5 mg, desired level in final product)

Example 17(a)

Powder of A (Example 16) was capsulated on Profill size 4 equipment (Atotal of 100 capsules produced). Content uniformity (by HPLC) measuredand the results summarized in Table 16.

TABLE 16 Assay of 10 individual Meloxicam capsules. Sample # 1 2 3 4 5 67 8 9 10 Weight (mg) 148.3 150.8 142.6 152.1 146.2 146.4 151.6 147.1152.0 143.9 Assay (% LC) 98.9 100.3 94.0 102.9 98.8 99.6 106.1 99.5105.6 98.1 Weight Corrected 98.2 97.9 97.0 99.6 99.5 100.1 103.0 99.6102.3 100.3 (% LC) Note: Weight includes gelatin capsule.

A test of fill weight consistency was performed on 100 capsules byweighing each capsule individually and subtracting the gelatin capsuleweight. The data is shown in Table 17.

TABLE 17 Weight distribution of 100 size 4 capsules filled on Profillsystem. Weight distribution No. of Capsules 110 mg ±5 mg 78 capsules 110mg ±5-10 mg 21 capsules 110 mg ± >10 mg  1 capsule

Example 17(b)

Sample B (Example 16) powder was capsulated on Profill size 4 equipment(A total of 600 capsules produced). Content uniformity (by HPLC) wasmeasured and the results summarized in Table 18.

TABLE 18 Assay of 10 individual Meloxicam capsules. Sample # 1 2 3 4 5 67 8 9 10 Weight (mg) 138.1 143.3 139.0 141.9 144.1 143.4 133.7 137.5147.9 142.7 Assay (% LC) 93.6 96.8 92.2 91.5 98.6 96.7 88.1 90.7 102.194.7 Weight Corrected 99.4 99.0 97.2 94.5 100.3 98.9 96.6 97.1 101.297.3 (% LC) Note: Weight includes gelatin capsule.

A test of fill weight consistency was performed on 100 capsules byweighing each capsule individually. This data is shown in Table 19.

TABLE 19 Weight distribution of 100 size 4 capsules filled on Profillsystem. Weight distribution No. of Capsules 140 mg ±5 mg 84 capsules 140mg ±5-10 mg 16 capsules 140 mg ± >10 mg  0 capsule Note: Weight includesgelatin capsule.

Subtracting the capsule weight the following weight distributions werefound:

Average fill weight of powder=104.1 mg

Average fill weight of Meloxicam=7.10 mg

Average % Label Claim of Meloxicam=94.6%

Example 17(c)

Sample C (Example 16) powder was capsulated on Profill size 4 equipment(A total of 600 capsules produced) Content uniformity (by HPLC) measuredand the results summarized in Table 20.

TABLE 20 Assay of 10 individual Meloxicam capsules. Sample # 1 2 3 4 5 67 8 9 10 Weight (mg) 144.3 144.4 154.2 143.5 136.5 149.4 138.2 137.3144.5 133.0 Assay (% LC) 97.6 96.7 106.6 97.7 91.2 102.8 90.8 91.6 96.087.3 Weight Corrected 99.2 98.2 101.3 99.8 97.9 100.9 96.3 97.8 97.496.2 (% LC) Note: Weight includes gelatin capsule.

A test of fill weight consistency was performed on 52 capsules byweighing each capsule individually. The data is shown in Table 21.

TABLE 21 Weight distribution of 52 size 4 capsules filled on Profillsystem. Weight distribution No. of Capsules 140 mg 5 mg 44 capsules140mg ±5-10 mg  6 capsules 140mg ± >10 mg  2 capsule Note: Weightincludes gelatin capsule.

Subtracting the capsule weight the following weight distributions werefound:

Average fill weight of powder=105.1 mg

Average fill weight of Meloxicam=7.15 mg

Average % Label Claim of Meloxicam=95.3%

The above example illustrates that milling Meloxicam in lactosemonohydrate results in a homogenous mixture upon completion, asindicated by the content uniformity results. Furthermore, the simplehand-filling of size 4 capsules on Profill equipment, using standardhard gelatine capsules, results in a narrow weight distribution range ofthe filled capsules, indicating excellent flow properties of the milledpowder obtained in this process. This indicates that nanoparticles ofmeloxicam have been made by the process outlined herein with improvedpowder handling characteristics. Such improved powder handlingcharacteristics will be highly beneficial in a commercial scaleformulation process.

Example 18: Content Uniformity after Segregation

Seven materials from example 16 were subjected to a segregation study.The blends were placed into 15 ml narrow plastic tubes and placed on aroller table for 16 hours. The roller table was placed on a gentleincline in order to promote segregation. After doing this the powderswere visibly segregated into coarse and fine particles. The tubes wereprepared with three holes drilled at fixed levels and samples were takenfrom these and assayed by HPLC. Samples were taken at the top, middleand bottom positions. An assay was also taken of the blend prior tosegregation. Each assay was the average of three injections. The % thateach sample deviated from the assay of material before segregation isshown in Table 22. Blends that have superior content uniformity aftersegregation will have small % deviations, while blends that have large %deviations that vary with sample position indicate stratification of theactive across the levels of the tube, that is bad content uniformity.The data shows that all blends produced by this invention (B, C, K)retain uniformity after segregation. The blends of micronized active andattritor milled lactose (D, E, J) all show very poor content uniformityafter segregation. The blend of active and excipients (L) that was jetmilled also have superior content uniformity. This is because theparticle size of the active and excipients are very similar meaning thatlittle or no segregation has occurred. However as the following examplesshow this blend has many other power handling characteristics that arevery poor.

TABLE 22 Shows the deviation of the assay (from before segregation) ofactive present invarious blends at three positions in a tube that theblends have segregated in. % Deviation of assay from unsegregated blendSample # Top Middle Bottom B 1.4 0.8 0.8 C 0.4 0.4 0.6 E 10.4 7.0 1.7 F8.5 5.4 11.5 J 10.3 36.3 1.4 K 0.5 0.4 1.5 L 0.5 0.8 0.5

Example 19: Powder Adherence Measurements

Powder Adherence to material surfaces was measured using three differentmedia; Stainless steel, Polypropylene and Glass as detailed below.Samples B,C,D,E,G,H,J,K,L and M from Example 16 were tested.

Stainless steel: A tared stainless steel spatula was used to scoop aportion of each blend and deposit the sample back into the container bya consistent action of inverting the spatula through 360°. The residualmass of the powder remaining of the spatula was recorded. Threemeasurements were performed for each sample. The average of the massmeasured and the RSD between the three measurements are shown in FIG.16. In FIG. 17 some images of the residual powder on the spatula areshown. Images A (sample M), B (sample E) and C (Sample L), conventionalactive/blends, clearly show more residual powder than D (sample K) whichis a blend made by this invention.

Polypropylene: The sample was loaded into a preweighed polypropylenecentrifuge tube, which was rolled on a roller table for 5 minutes andsubsequently inverted by a consistent action. The residual mass on thetube was recorded The average of the mass measured and the % RSD betweenthe three measurements are shown in FIG. 16. In FIG. 18 some images ofthe residual powder on the plastic tubes are shown. Images B (sample E),C (sample G) and D (Sample L) are conventional active/blends and showvarying degrees of powder clumped onto the tube. Image A (sample B), ablend made by this invention has only a fine coating of residual powder.

Glass: Each sample was loaded into a preweighed glass tube, rolled on aroller table for 5 minutes and subsequently inverted by a consistentaction. The residual mass on the glass tube was recorded. Only onemeasurement was performed for each sample. The data is shown in FIG. 16.In FIG. 19 some images of the residual powder on the glass tubes areshown. Images A (sample G), B (sample M) and C (sample F) areconventional active/blends and show varying degrees of powder clumpedonto the tube. Image D (Sample B), a blend made by this invention hasvery little residual powder.

Overall the data of residual masses shown in FIG. 16 indicates thatblends made by this invention show less adherence to these threematerials compared to actives and blends made by conventionaltechniques.

Example 20: Angle of Repose Measurements

Angle of repose measurements were made on three indomethacin blends andone micronized active from Example 16. Measurements were made using aplastic column (diameter 23 mm) supported on paper. The column wasloaded with the powder sample (15-20 g). The powder was deposited fromthe column by a consistent slow upward raising of the column. The angleof repose was calculated from the measurement of the height and theaverage radius of the powder deposit. The measurement was repeated 4-7times for each sample. The angle of repose and % RSD across themeasurements are shown in FIG. 16. The data shows that the blendproduced with this invention (sample K) has a lower angle of reposecompared to the blend of active with attritor milled lactose (Sample J)and the micronized indomethacin (Sample M) indicating powder withsuperior flow. The blend that was jetmilled (Sample L) had a low angleof repose but this was because the powder had agglomerated to form largeballs of powder. This is not a desirable power handling characteristic.

Example 21: Bulk and Tap Bulk Density

Bulk and tap bulk density measurements were made on a number of theactives/blends from example 16. The measurements were performedaccording to USP <616>. The data from these measurements is shown inFIG. 20.

Example 22: Powder Rheology

Powder Rheology measurements were made on three indomethacin blends andone micronized active from Example 16. The measurements were conductedon Freeman Technology FT4 powder rheometer. The analysis was conductedaccording to the standard operating procedures of the instrument. Thedata from these measurements, Basic Flow Energy (FBE), Specific Energy(SE), Pressure Drop (PD15) and Compressibility (CPS18) are shown in FIG.20. BFE is the energy (mJ) needed to displace a conditioned andstabilized powder at a given flow pattern (−5° helix) and flow rate (100mm/s). The BFE was taken at the seventh test. The lower the BFE the moresuperior the powder rheology. The data shows that the blend made by thisinvention (Sample K) is superior to the active (Sample N) and two otherblends (Sample J, L) made using conventional approaches. The SE is ameasure of the energy per unit mass (mJ/g) needed to displace aconditioned powder where the rheometer blade is used in an upwardlifting mode of displacement. The SE is a measure of cohesivity. Thehigher the SE the more cohesive a powder is. The data shows that theblend made by this invention (Sample K) is less cohesive than the active(Sample N) and two other blends (Sample J, L) made using conventionalapproaches. PD15 is the pressure drop (mBar) across the powder bed witha normal stress of 15 kPa applied. The air velocity across the bed was2.0 mm/s. A highly permeable powder has a low pressure drop and is adesirable powder handling characteristic. The data shows that the blendmade by this invention (sample K) has a lower pressure drop than theactive (sample N) and two other blends (Sample J, L) made usingconventional approaches. CPS18 measures the percentage (%) by which thebulk density has increased with a normal stress of 18 kPa applied. Alower compressibility is an indication of superior powder flowproperties. The data shows that the blend made by this invention (sampleK) has a lower compressibility than the active (Sample N) and two otherblends (Sample J, L) made using conventional approaches.

Example 23: Aerodynamic Particle Size

Two blends of 1% salbutamol (albuterol) where prepared according toExample 16 sample S and T. These two blends where then passed through a100 micron sieve prior to measurement. The two blends were then testedfor aerodynamic particle size.

Example 23(a): Aerosizer Measurements

The two samples were measured on a TSI Aerosizer with a Aerodisperserset to a medium shear force and feed rate. Deagglomeration was set tonormal and pin vibration was on. The particle size statistics (volumedistribution) for these measurements are shown in Table 23.

TABLE 23 Volume distribution particle size from Aerosizer measurements.Mean D[50] D[4.3] Sample name (μm) (μm) (μm) Example 16 S 16.8 18.9 19.0Example 16 T 19.7 21.9 21.9

Example 23(b): Next Generation Impactor Measurements

The two blends of 1% salbutamol (Example 16 S, T) as well as acommercial blend (Ventolin Rotocaps (200 μg), Allen and Hanburys) wereall tested in triplicate on a Next Generation Impactor (NGI).Approximately 20 mg of two 1% salbutamol blends were filled intogelatine capsules to give a similar nominal dose of 200 μg. The datafrom these measurements is shown in Table 24. The mean of the threemeasurements and RSD (%) are shown. One key finding is that the powderflow properties of the two blends made using this invention (S, T) aresuperior to the commercial blend. In the table the amount of materialleft in the capsule and device after testing (Residual inCapsule+Device) was high in the commercial sample compared to the othertwo blends. Another way of expressing this result was the percentdelivered. This is the % of the total recovered dose that was deliveredto the testing device. For the two blends made with this invention thepercentage delivered was about 97% while the commercial blend onlydelivered 82%. All three blends delivered active into the Fine ParticleFraction (FPF) size range. This is the range needed for a blend to beuseful as an inhaled formulation. The fact that the two blends made withthis invention could deliver active into the FPF range and that the MMADof the active was 5 micron or less indicates that the invention hereinis useful for formulating inhaled pharmaceutical medicaments.

TABLE 24 Data from the NGI measurements on the two blends from Example16 and the commercial blend. Ventolin Example 16S Example 16T SampleMass (μg) RSD Mass (μg) RSD Mass (μg) RSD Induction Port 33.7 13.5 32.66.1 29.8 0.0 Pre-separator 86.0 4.7 104.3 2.7 111.6 1.5 Stage 1 14.7 9.018.1 9.9 14.2 4.3 Stage 2 (6.1 μm) 18.2 12.5 11.2 7.6 10.6 35.5 Stage 3(3.4 μm) 21.8 8.9 6.0 3.8 5.7 10.0 Stage 4 (2.2 μm) 23.3 10.3 3.8 5.33.9 8.3 Stage 5 (1.3 μm) 12.3 11.7 1.7 6.9 2.8 22.3 Stage 6 (0.7 μm) 3.024.0 1.0 6.0 1.1 23.6 Stage 7 (0.4 μm) 1.4 27.7 0.4 25.0 0.4 0.0 MOF(0.2 μm) 0.3 45.8 0.1 0.0 0.2 34.6 Residual in Capsule + Device 45.710.4 5.5 3.8 3.3 4.7 Total recovered dose 260.5 1.7 184.7 2.0 183.4 2.2Delivered dose (DD) 214.7 3.4 179.1 2.1 180.1 2.3 Percent delivered 82.42.3 97.0 0.2 98.2 0.1 FPD (μg <5 μm) 74.6 6.7 20.2 3.7 20.9 17.4 FPF (%<5 μm relative to DD) 34.7 5.2 11.3 1.6 11.6 15.1 MMAD (μm) 2.6 6.0 5.22.2 4.6 2.5

Example 23(c): Content Uniformity

One of the blends measured S (Example 16) was also tested for contentuniformity before NGI testing. Ten samples were taken from the blend andeach was assayed. The data from those assays is shown in Table 25. Thedata shows that the blend has excellent uniformity even at this lowactive loading. It should be noted that the blend was manufactured inAustralia and transported to the USA for testing and the fact that thecontent uniformity has been retained is strong testament to theexcellent properties of material made with this invention.

TABLE 25 Content uniformity data for sample S (Example 16). Sample No. 12 3 4 5 6 7 8 9 10 Ave RSD (%) w/w % Salbutamol 0.92 0.91 0.90 0.90 0.910.91 0.90 0.90 0.90 0.90 0.91 0.54

Example 24: SEM

For two of the blends in Example 16 S and R SEM images were taken andare shown in FIGS. 21-27. For sample S images are shown for a sampletaken at the 20 minute time point of this milling and at the end of themilling at 30 mins. For sample R the images are taken for the sampletaken at 20 minutes. The images at low magnification show the compositeparticles which are or order 5-30 micron. The images at highmagnification show that the composite particles are made up of particlesof order 200 nm or less.

1. A method for producing nanoparticle and/or microparticle biologicallyactive material with powder handling characteristics superior to powdersmade by conventional size reduction processes, wherein the said methodcomprises the steps of: dry milling a solid biologically active materialand a millable grinding matrix in a mill comprising a plurality ofmilling bodies, for a time period sufficient to produce particles of thebiologically active material dispersed in an at least partially milledgrinding material.
 2. A method for producing a blend containingnanoparticle and/or microparticles of biologically active material withpowder handling characteristics superior to a blend made by conventionalmethods, wherein the said method comprises the steps of: dry milling asolid biologically active material and a millable grinding matrix in amill comprising a plurality of milling bodies, for a time periodsufficient to produce particles of the biologically active materialdispersed in an at least partially milled grinding material.
 3. Themethod of claim 2, wherein the blend has a median particle size,determined on a particle volume basis, equal or greater than a sizeselected from the group consisting of: 20,000 nm, 15,000 nm, 10,000 nm,8000 nm, 6000 nm, 5000 nm, 4000 nm, 3000 nm and 2000 nm.
 4. The methodof claim 2, wherein the blend has a volume weighted mean (D4,3) equal orgreater than a size selected from the group consisting of: 40,000 nm,30,000 nm, 20,000 nm, 15,000 nm, 10,000 nm, 8000 nm, 6000 nm and 5000nm.
 5. The method of claim 2, wherein the percentage of particles in theblend, on a particle volume basis, is selected from the group consistingof: greater than 2 micron (%>2 micron) is selected from the group 50%,60%, 70%, 80%, 85%, 90% and 95%; greater than 10 micron (%>10 micron) isselected from the group 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 85%, 90%and 95%; equal to or less than 20 micron (%<20 micron) is selected fromthe group 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95% and 100%. 6.The method of claim 1, wherein the average particle size of thebiologically material, determined on a particle number basis, is equalto or less than a size selected from the group consisting of: 10,000 nm,8000 nm, 6000 nm, 5000 nm, 4000 nm, 3000 nm, 2000 nm, 1900 nm, 1800 nm,1700 nm, 1600 nm, 1500 nm, 1400 nm, 1300 nm, 1200 nm, 1100 nm, 1000 nm,900 nm, 800 nm, 700 nm, 600 nm, 500 nm, 400 nm, 300 nm, 200 nm and 100nm.
 7. The method of claim 1, wherein the particles of the biologicallyactive material have a median particle size, determined on a particlevolume basis, equal or less than a size selected from the groupconsisting of: 20,000 nm, 15,000 nm, 10,000 nm, 8000 nm, 6000 nm, 5000nm, 4000 nm, 3000 nm, 2000 nm, 1900 nm, 1800 nm, 1700 nm, 1600 nm, 1500nm, 1400 nm, 1300 nm, 1200 nm, 1100 nm, 1000 nm, 900 nm, 800 nm, 700 nm,600 nm, 500 nm, 400 nm, 300 nm, 200 nm and 100 nm.
 8. The method ofclaim 7, wherein the percentage of particles, on a particle volumebasis, is selected from the group consisting of: 50%, 60%, 70%, 80%,90%, 95% and 100% less than: a. 20,000 nm (%<20,000 nm); b. 10,000 nm(%<10,000 nm); c. 5,000 nm (%<5,000 nm); d. 2,000 nm (%<2,000 nm); or e.1,000 nm (%<1,000 nm); or is selected from the group consisting of: 0%,10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95% and 100% less than: f.500 nm (%<500 nm); g. 300 nm (%<300 nm); or h. 200 nm (%<200 nm).
 9. Themethod of claim 7, wherein the Dx of the particle distribution, asmeasured on a particle volume basis, is selected from the groupconsisting of less than or equal to 10,000 nm, 5000 nm, 3000 nm, 2000nm, 1900 nm, 1800 nm, 1700 nm, 1600 nm, 1500 nm, 1400 nm, 1300 nm, 1200nm, 1100 nm, 1000 nm, 900 nm, 800 nm, 700 nm, 600 nm, 500 nm, 400 nm,300 nm, 200 nm, and 100 nm; wherein x is greater than or equal to 90.10. The method of claim 1, wherein the milling time period is a rangeselected from the group consisting of: between 10 minutes and 2 hours,between 10 minutes and 90 minutes, between 10 minutes and 1 hour,between 10 minutes and 45 minutes, between 10 minutes and 30 minutes,between 5 minutes and 30 minutes, between 5 minutes and 20 minutes,between 2 minutes and 10 minutes, between 2 minutes and 5 minutes,between 1 minutes and 20 minutes, between 1 minute and 10 minutes, andbetween 1 minute and 5 minutes.
 11. The method of claim 1, wherein thedry milling is undertaken in a mechanically agitated attritor mill(horizontal or vertical), vibratory mill or nutating mill, wherein themilling medium is steel balls having a diameter selected from the groupconsisting of: between 1 and 20 mm, between 2 and 15 mm and between 3and 10 mm.
 12. The method of claim 1, wherein the biologically activematerial is selected from the group consisting of: fungicides,pesticides, herbicides, seed treatments, cosmeceuticals, cosmetics,complementary medicines, natural products, vitamins, nutrients,nutraceuticals, pharmaceutical actives, biologics, amino acids,proteins, peptides, nucleotides, nucleic acids, additives, foods andfood ingredients and analogs, homologs and first order derivativesthereof.
 13. The method of claim 1, wherein the biologically activematerial is selected from the group consisting of: indomethacin,diclofenac, naproxen, meloxicam, metaxalone, cyclosporin A, progesteronecelecoxib, cilostazol, ciprofloxacin, 2,4-dichlorophenoxyacetic acid,anthraquinone, creatine monohydrate, glyphosate, halusulfuron, mancozeb,metsulfuron, salbutamol, sulphur, tribenuran and estradiol or any saltor derivative thereof.
 14. The method of claim 1, wherein the grindingmatrix is a single material or is a mixture of two or more materials inany proportion wherein the single material or a mixture of two or morematerials is selected from the group consisting of: mannitol, sorbitol,Isomalt, xylitol, maltitol, lactitol, erythritol, arabitol, ribitol,glucose, fructose, mannose, galactose, anhydrous lactose, lactosemonohydrate, sucrose, maltose, trehalose, maltodextrins, dextrin,Inulin, dextrates, polydextrose, starch, wheat flour, corn flour, riceflour, rice starch, tapioca flour, tapioca starch, potato flour, potatostarch, other flours and starches, milk powder, skim milk powders, othermilk solids and derivatives, soy flour, soy meal or other soy products,cellulose, microcrystalline cellulose, microcrystalline cellulose basedco blended materials, pregelatinized (or partially) starch, HPMC, CMC,HPC, citric acid, tartaric acid, malic acid, maleic acid fumaric acid,ascorbic acid, succinic acid, sodium citrate, sodium tartrate, sodiummalate, sodium ascorbate, potassium citrate, potassium tartrate,potassium malate, potassium ascorbate, sodium carbonate, potassiumcarbonate, magnesium carbonate, sodium bicarbonate, potassiumbicarbonate and calcium carbonate. dibasic calcium phosphate, tribasiccalcium phosphate, sodium sulfate, sodium chloride, sodiummetabisulphite, sodium thiosulfate, ammonium chloride, Glauber's salt,ammonium carbonate, sodium bisulfate, magnesium sulfate, potash alum,potassium chloride, sodium hydrogen sulfate, sodium hydroxide,crystalline hydroxides, hydrogen carbonates, ammonium chloride,methylamine hydrochloride, ammonium bromide, silica, thermal silica,alumina, titanium dioxide, talc, chalk, mica, kaolin, bentonite,hectorite, magnesium trisilicate, clay based materials or aluminiumsilicates, sodium lauryl sulfate, sodium stearyl sulfate, sodium cetylsulfate, sodium cetostearyl sulfate, sodium docusate, sodiumdeoxycholate, N-lauroylsarcosine sodium salt, glyceryl monostearate,glycerol distearate glyceryl palmitostearate, glyceryl behenate,glyceryl caprylate, glyceryl oleate, benzalkonium chloride, CTAB, CTAC,Cetrimide, cetylpyridinium chloride, cetylpyridinium bromide,benzethonium chloride, PEG 40 stearate, PEG 100 stearate, poloxamer 188,poloxamer 338, poloxamer 407 polyoxyl 2 stearyl ether, polyoxyl 100stearyl ether, polyoxyl 20 stearyl ether, polyoxyl 10 stearyl ether,polyoxyl 20 cetyl ether, polysorbate 20, polysorbate 40, polysorbate 60,polysorbate 61, polysorbate 65, polysorbate 80, polyoxyl 35 castor oil,polyoxyl 40 castor oil, polyoxyl 60 castor oil, polyoxyl 100 castor oil,polyoxyl 200 castor oil, polyoxyl 40 hydrogenated castor oil, polyoxyl60 hydrogenated castor oil, polyoxyl 100 hydrogenated castor oil,polyoxyl 200 hydrogenated castor oil, cetostearyl alcohol, macrogel 15hydroxystearate, sorbitan monopalmitate, sorbitan monostearate, sorbitantrioleate, Sucrose Palmitate, Sucrose Stearate, Sucrose Distearate,Sucrose laurate, Glycocholic acid, sodium Glycholate, Cholic Acid,Soidum Cholate, Sodium Deoxycholate, Deoxycholic acid, Sodiumtaurocholate, taurocholic acid, Sodium taurodeoxycholate,taurodeoxycholic acid, soy lecithin, phosphatidylcholine,phosphatidylethanolamine, phosphatidylserine, phosphatidylinositol,PEG4000, PEG6000, PEG8000, PEG10000, PEG20000, alkyl naphthalenesulfonate condensate/Lignosulfonate blend, Calcium DodecylbenzeneSulfonate, Sodium Dodecylbenzene Sulfonate, Diisopropylnaphthaenesulphonate, erythritol distearate, Naphthalene SulfonateFormaldehyde Condensate, nonylphenol ethoxylate (poe-30),Tristyrylphenol Ethoxylate, Polyoxyethylene (15) tallowalkylamines,sodium alkyl naphthalene sulfonate, sodium alkyl naphthalene sulfonatecondensate, sodium alkylbenzene sulfonate, sodium isopropyl naphthalenesulfonate, Sodium Methyl Naphthalene Formaldehyde Sulfonate, sodiumn-butyl naphthalene sulfonate, tridecyl alcohol ethoxylate (poe-18),Triethanolamine isodecanol phosphate ester, Triethanolaminetristyrylphosphate ester, Tristyrylphenol Ethoxylate Sulfate,Bis(2-hydroxyethyl)tallowalkylamines.
 15. The method of claim 14,wherein the concentration of the single material or the major componentin a mixture of two or more materials is selected from the groupconsisting of: 5-99% w/w, 10-95 w/w, 15-85% w/w, of 20-80% w/w, 25-75%w/w, 30-60% w/w, 40-50% w/w and the concentration of the second orsubsequent material is selected from the group consisting of: 5-50% w/w,5-40% w/w, 5-30% w/w, of 5-20% w/w, 10-40% w/w, 10-30% w/w, 10-20% w/w,20-40% w/w, or 20-30% w/w or if the second or subsequent material is asurfactant or water soluble polymer the concentration is selected from0.1-10% w/w, 0.1-5% w/w, 0.1-2.5% w/w, of 0.1-2% w/w, 0.1-1%, 0.5-5%w/w, 0.5-3% w/w, 0.5-2% w/w, 0.5-1.5%, 0.5-1% w/w, of 0.75-1.25 w/w,0.75-1% and 1% w/w.
 16. The method of claim 1, wherein the grindingmatrix is selected from the group consisting of: (a) lactose monohydrateor lactose monohydrate combined with at least one material selected fromthe group consisting of: xylitol; lactose anhydrous; microcrystallinecellulose; sucrose; glucose; sodium chloride; talc; kaolin; calciumcarbonate; malic acid; trisodium citrate dihydrate; D,L-Malic acid;sodium pentane sulfate; sodium octadecyl sulfate; Brij700; Brij76;sodium n-lauroyl sacrosine; lecithin; docusate sodium;polyoxyl-40-stearate; Aerosil R972 fumed silica; sodium lauryl sulfateor other alkyl sulfate surfactants with a chain length between C5 toC18; polyvinyl pyrrolidone; sodium lauryl sulfate and polyethyleneglycol 40 stearate, sodium lauryl sulfate and polyethylene glycol 100stearate, sodium lauryl sulfate and PEG 3000, sodium lauryl sulphate andPEG 6000, sodium lauryl sulphate and PEG 8000, sodium lauryl sulphateand PEG 10000, sodium lauryl sulfate and Brij700, sodium lauryl sulfateand Poloxamer 407, sodium lauryl sulfate and Poloxamer 338, sodiumlauryl sulfate and Poloxamer 188; Poloxamer 407, Poloxamer 338,Poloxamer 188, alkyl naphthalene sulfonate condensate/Lignosulfonateblend; Calcium Dodecylbenzene Sulfonate (Branched); Diisopropylnaphthalenesulphonate; erythritol distearate; linear and brancheddodecylbenzene sulfonic acids; Naphthalene Sulfonate FormaldehydeCondensate; nonylphenol ethoxylate, POE-30; Phosphate Esters,Tristyrylphenol Ethoxylate, Free Acid; Polyoxyethylene (15)tallowalkylamines; sodium alkyl naphthalene sulfonate; sodium alkylnaphthalene sulfonate condensate; sodium alkylbenzene sulfonate; sodiumisopropyl naphthalene sulfonate; Sodium Methyl Naphthalene; FormaldehydeSulfonate; sodium salt of n-butyl naphthalene sulfonate; tridecylalcohol ethoxylate, POE-18; Triethanolamine isodecanol phosphate ester;Triethanolamine tristyrylphosphate ester; Tristyrylphenol EthoxylateSulfate; Bis(2-hydroxyethyl)tallowalkylamines (b) lactose anhydrous orlactose anhydrous combined with at least one material selected from thegroup consisting of: lactose monohydrate; xylitol; microcrystallinecellulose; sucrose; glucose; sodium chloride; talc; kaolin; calciumcarbonate; malic acid; trisodium citrate dihydrate; D,L-Malic acid;sodium pentane sulfate; sodium octadecyl sulfate; Brij700; Brij76;sodium n-lauroyl sacrosine; lecithin; docusate sodium;polyoxyl-40-stearate; Aerosil R972 fumed silica; sodium lauryl sulfateor other alkyl sulfate surfactants with a chain length between C5 toC18; polyvinyl pyrrolidone; sodium lauryl sulfate and polyethyleneglycol 40 stearate, sodium lauryl sulfate and polyethylene glycol 100stearate, sodium lauryl sulfate and PEG 3000, sodium lauryl sulphate andPEG 6000, sodium lauryl sulphate and PEG 8000, sodium lauryl sulphateand PEG 10000, sodium lauryl sulfate and Brij700, sodium lauryl sulfateand Poloxamer 407, sodium lauryl sulfate and Poloxamer 338, sodiumlauryl sulfate and Poloxamer 188; Poloxamer 407, Poloxamer 338,Poloxamer 188, alkyl naphthalene sulfonate condensate/Lignosulfonateblend; Calcium Dodecylbenzene Sulfonate (Branched); Diisopropylnaphthalenesulphonate; erythritol distearate; linear and brancheddodecylbenzene sulfonic acids; Naphthalene Sulfonate FormaldehydeCondensate; nonylphenol ethoxylate, POE-30; Phosphate Esters,Tristyrylphenol Ethoxylate, Free Acid; Polyoxyethylene (15)tallowalkylamines; sodium alkyl naphthalene sulfonate; sodium alkylnaphthalene sulfonate condensate; sodium alkylbenzene sulfonate; sodiumisopropyl naphthalene sulfonate; Sodium Methyl Naphthalene; FormaldehydeSulfonate; sodium salt of n-butyl naphthalene sulfonate; tridecylalcohol ethoxylate, POE-18; Triethanolamine isodecanol phosphate ester;Triethanolamine tristyrylphosphate ester; Tristyrylphenol EthoxylateSulfate; Bis(2-hydroxyethyl)tallowalkylamines. (c) mannitol or mannitolcombined with at least one material selected from the group consistingof: lactose monohydrate; xylitol; lactose anhydrous; microcrystallinecellulose; sucrose; glucose; sodium chloride; talc; kaolin; calciumcarbonate; malic acid; trisodium citrate dihydrate; D,L-Malic acid;sodium pentane sulfate; sodium octadecyl sulfate; Brij700; Brij76;sodium n-lauroyl sacrosine; lecithin; docusate sodium;polyoxyl-40-stearate; Aerosil R972 fumed silica; sodium lauryl sulfateor other alkyl sulfate surfactants with a chain length between C5 toC18; polyvinyl pyrrolidone; sodium lauryl sulfate and polyethyleneglycol 40 stearate, sodium lauryl sulfate and polyethylene glycol 100stearate, sodium lauryl sulfate and PEG 3000, sodium lauryl sulphate andPEG 6000, sodium lauryl sulphate and PEG 8000, sodium lauryl sulphateand PEG 10000, sodium lauryl sulfate and Brij700, sodium lauryl sulfateand Poloxamer 407, sodium lauryl sulfate and Poloxamer 338, sodiumlauryl sulfate and Poloxamer 188; Poloxamer 407, Poloxamer 338,Poloxamer 188, alkyl naphthalene sulfonate condensate/Lignosulfonateblend; Calcium Dodecylbenzene Sulfonate (Branched); Diisopropylnaphthalenesulphonate; erythritol distearate; linear and brancheddodecylbenzene sulfonic acids; Naphthalene Sulfonate FormaldehydeCondensate; nonylphenol ethoxylate, POE-30; Phosphate Esters,Tristyrylphenol Ethoxylate, Free Acid; Polyoxyethylene (15)tallowalkylamines; sodium alkyl naphthalene sulfonate; sodium alkylnaphthalene sulfonate condensate; sodium alkylbenzene sulfonate; sodiumisopropyl naphthalene sulfonate; Sodium Methyl Naphthalene; FormaldehydeSulfonate; sodium salt of n-butyl naphthalene sulfonate; tridecylalcohol ethoxylate, POE-18; Triethanolamine isodecanol phosphate ester;Triethanolamine tristyrylphosphate ester; Tristyrylphenol EthoxylateSulfate; Bis(2-hydroxyethyl)tallowalkylamines. (d) Sucrose or sucrosecombined with at least one material selected from the group consistingof: lactose monohydrate; lactose anhydrous; mannitol; microcrystallinecellulose; glucose; sodium chloride; talc; kaolin; calcium carbonate;malic acid; tartaric acid; trisodium citrate dihydrate; D,L-Malic acid;sodium pentane sulfate; sodium octadecyl sulfate; Brij700; Brij76;sodium n-lauroyl sacrosine; lecithin; docusate sodium;polyoxyl-40-stearate; Aerosil R972 fumed silica; sodium lauryl sulfateor other alkyl sulfate surfactants with a chain length between C5 toC18; polyvinyl pyrrolidone; sodium lauryl sulfate and polyethyleneglycol 40 stearate, sodium lauryl sulfate and polyethylene glycol 100stearate, sodium lauryl sulfate and PEG 3000, sodium lauryl sulphate andPEG 6000, sodium lauryl sulphate and PEG 8000, sodium lauryl sulphateand PEG 10000, sodium lauryl sulfate and Brij700, sodium lauryl sulfateand Poloxamer 407, sodium lauryl sulfate and Poloxamer 338, sodiumlauryl sulfate and Poloxamer 188; Poloxamer 407, Poloxamer 338,Poloxamer 188, alkyl naphthalene sulfonate condensate/Lignosulfonateblend; Calcium Dodecylbenzene Sulfonate (Branched); Diisopropylnaphthalenesulphonate; erythritol distearate; linear and brancheddodecylbenzene sulfonic acids; Naphthalene Sulfonate FormaldehydeCondensate; nonylphenol ethoxylate, POE-30; Phosphate Esters,Tristyrylphenol Ethoxylate, Free Acid; Polyoxyethylene (15)tallowalkylamines; sodium alkyl naphthalene sulfonate; sodium alkylnaphthalene sulfonate condensate; sodium alkylbenzene sulfonate; sodiumisopropyl naphthalene sulfonate; Sodium Methyl Naphthalene; FormaldehydeSulfonate; sodium salt of n-butyl naphthalene sulfonate; tridecylalcohol ethoxylate, POE-18; Triethanolamine isodecanol phosphate ester;Triethanolamine tristyrylphosphate ester; Tristyrylphenol EthoxylateSulfate; Bis(2-hydroxyethyl)tallowalkylamines. (e) Glucose or glucosecombined with at least one material selected from the group consistingof: lactose monohydrate; lactose anhydrous; mannitol; microcrystallinecellulose; sucrose; sodium chloride; talc; kaolin; calcium carbonate;malic acid; tartaric acid; trisodium citrate dihydrate; D,L-Malic acid;sodium pentane sulfate; sodium octadecyl sulfate; Brij700; Brij76;sodium n-lauroyl sacrosine; lecithin; docusate sodium;polyoxyl-40-stearate; Aerosil R972 fumed silica; sodium lauryl sulfateor other alkyl sulfate surfactants with a chain length between C5 toC18; polyvinyl pyrrolidone; sodium lauryl sulfate and polyethyleneglycol 40 stearate, sodium lauryl sulfate and polyethylene glycol 100stearate, sodium lauryl sulfate and PEG 3000, sodium lauryl sulphate andPEG 6000, sodium lauryl sulphate and PEG 8000, sodium lauryl sulphateand PEG 10000, sodium lauryl sulfate and Brij700, sodium lauryl sulfateand Poloxamer 407, sodium lauryl sulfate and Poloxamer 338, sodiumlauryl sulfate and Poloxamer 188; Poloxamer 407, Poloxamer 338,Poloxamer 188, alkyl naphthalene sulfonate condensate/Lignosulfonateblend; Calcium Dodecylbenzene Sulfonate (Branched); Diisopropylnaphthalenesulphonate; erythritol distearate; linear and brancheddodecylbenzene sulfonic acids; Naphthalene Sulfonate FormaldehydeCondensate; nonylphenol ethoxylate, POE-30; Phosphate Esters,Tristyrylphenol Ethoxylate, Free Acid; Polyoxyethylene (15)tallowalkylamines; sodium alkyl naphthalene sulfonate; sodium alkylnaphthalene sulfonate condensate; sodium alkylbenzene sulfonate; sodiumisopropyl naphthalene sulfonate; Sodium Methyl Naphthalene; FormaldehydeSulfonate; sodium salt of n-butyl naphthalene sulfonate; tridecylalcohol ethoxylate, POE-18; Triethanolamine isodecanol phosphate ester;Triethanolamine tristyrylphosphate ester; Tristyrylphenol EthoxylateSulfate; Bis(2-hydroxyethyl)tallowalkylamines. (f) Sodium chloride orsodium chloride combined with at least one material selected from thegroup consisting of: lactose monohydrate; lactose anhydrous; mannitol;microcrystalline cellulose; sucrose; glucose; talc; kaolin; calciumcarbonate; malic acid; tartaric acid; trisodium citrate dihydrate;D,L-Malic acid; sodium pentane sulfate; sodium octadecyl sulfate;Brij700; Brij76; sodium n-lauroyl sacrosine; lecithin; docusate sodium;polyoxyl-40-stearate; Aerosil R972 fumed silica; sodium lauryl sulfateor other alkyl sulfate surfactants with a chain length between C5 toC18; polyvinyl pyrrolidone; sodium lauryl sulfate and polyethyleneglycol 40 stearate, sodium lauryl sulfate and polyethylene glycol 100stearate, sodium lauryl sulfate and PEG 3000, sodium lauryl sulphate andPEG 6000, sodium lauryl sulphate and PEG 8000, sodium lauryl sulphateand PEG 10000, sodium lauryl sulfate and Brij700, sodium lauryl sulfateand Poloxamer 407, sodium lauryl sulfate and Poloxamer 338, sodiumlauryl sulfate and Poloxamer 188; Poloxamer 407, Poloxamer 338,Poloxamer 188, alkyl naphthalene sulfonate condensate/Lignosulfonateblend; Calcium Dodecylbenzene Sulfonate (Branched); Diisopropylnaphthalenesulphonate; erythritol distearate; linear and brancheddodecylbenzene sulfonic acids; Naphthalene Sulfonate FormaldehydeCondensate; nonylphenol ethoxylate, POE-30; Phosphate Esters,Tristyrylphenol Ethoxylate, Free Acid; Polyoxyethylene (15)tallowalkylamines; sodium alkyl naphthalene sulfonate; sodium alkylnaphthalene sulfonate condensate; sodium alkylbenzene sulfonate; sodiumisopropyl naphthalene sulfonate; Sodium Methyl Naphthalene; FormaldehydeSulfonate; sodium salt of n-butyl naphthalene sulfonate; tridecylalcohol ethoxylate, POE-18; Triethanolamine isodecanol phosphate ester;Triethanolamine tristyrylphosphate ester; Tristyrylphenol EthoxylateSulfate; Bis(2-hydroxyethyl)tallowalkylamines. (g) xylitol or xylitolcombined with at least one material selected from the group consistingof: lactose monohydrate; lactose anhydrous; mannitol; microcrystallinecellulose; sucrose; glucose; sodium chloride; talc; kaolin; calciumcarbonate; malic acid; tartaric acid; trisodium citrate dihydrate;D,L-Malic acid; sodium pentane sulfate; sodium octadecyl sulfate;Brij700; Brij76; sodium n-lauroyl sacrosine; lecithin; docusate sodium;polyoxyl-40-stearate; Aerosil R972 fumed silica; sodium lauryl sulfateor other alkyl sulfate surfactants with a chain length between C5 toC18; polyvinyl pyrrolidone; sodium lauryl sulfate and polyethyleneglycol 40 stearate, sodium lauryl sulfate and polyethylene glycol 100stearate, sodium lauryl sulfate and PEG 3000, sodium lauryl sulphate andPEG 6000, sodium lauryl sulphate and PEG 8000, sodium lauryl sulphateand PEG 10000, sodium lauryl sulfate and Brij700, sodium lauryl sulfateand Poloxamer 407, sodium lauryl sulfate and Poloxamer 338, sodiumlauryl sulfate and Poloxamer 188; Poloxamer 407, Poloxamer 338,Poloxamer 188, alkyl naphthalene sulfonate condensate/Lignosulfonateblend; Calcium Dodecylbenzene Sulfonate (Branched); Diisopropylnaphthalenesulphonate; erythritol distearate; linear and brancheddodecylbenzene sulfonic acids; Naphthalene Sulfonate FormaldehydeCondensate; nonylphenol ethoxylate, POE-30; Phosphate Esters,Tristyrylphenol Ethoxylate, Free Acid; Polyoxyethylene (15)tallowalkylamines; sodium alkyl naphthalene sulfonate; sodium alkylnaphthalene sulfonate condensate; sodium alkylbenzene sulfonate; sodiumisopropyl naphthalene sulfonate; Sodium Methyl Naphthalene; FormaldehydeSulfonate; sodium salt of n-butyl naphthalene sulfonate; tridecylalcohol ethoxylate, POE-18; Triethanolamine isodecanol phosphate ester;Triethanolamine tristyrylphosphate ester; Tristyrylphenol EthoxylateSulfate; Bis(2-hydroxyethyl)tallowalkylamines. (h) Tartaric acid ortartaric acid combined with at least one material selected from thegroup consisting of: lactose monohydrate; lactose anhydrous; mannitol;microcrystalline cellulose; sucrose; glucose; sodium chloride; talc;kaolin; calcium carbonate; malic acid; trisodium citrate dihydrate;D,L-Malic acid; sodium pentane sulfate; sodium octadecyl sulfate;Brij700; Brij76; sodium n-lauroyl sacrosine; lecithin; docusate sodium;polyoxyl-40-stearate; Aerosil R972 fumed silica; sodium lauryl sulfateor other alkyl sulfate surfactants with a chain length between C5 toC18; polyvinyl pyrrolidone; sodium lauryl sulfate and polyethyleneglycol 40 stearate, sodium lauryl sulfate and polyethylene glycol 100stearate, sodium lauryl sulfate and PEG 3000, sodium lauryl sulphate andPEG 6000, sodium lauryl sulphate and PEG 8000, sodium lauryl sulphateand PEG 10000, sodium lauryl sulfate and Brij700, sodium lauryl sulfateand Poloxamer 407, sodium lauryl sulfate and Poloxamer 338, sodiumlauryl sulfate and Poloxamer 188; Poloxamer 407, Poloxamer 338,Poloxamer 188, alkyl naphthalene sulfonate condensate/Lignosulfonateblend; Calcium Dodecylbenzene Sulfonate (Branched); Diisopropylnaphthalenesulphonate; erythritol distearate; linear and brancheddodecylbenzene sulfonic acids; Naphthalene Sulfonate FormaldehydeCondensate; nonylphenol ethoxylate, POE-30; Phosphate Esters,Tristyrylphenol Ethoxylate, Free Acid; Polyoxyethylene (15)tallowalkylamines; sodium alkyl naphthalene sulfonate; sodium alkylnaphthalene sulfonate condensate; sodium alkylbenzene sulfonate; sodiumisopropyl naphthalene sulfonate; Sodium Methyl Naphthalene; FormaldehydeSulfonate; sodium salt of n-butyl naphthalene sulfonate; tridecylalcohol ethoxylate, POE-18; Triethanolamine isodecanol phosphate ester;Triethanolamine tristyrylphosphate ester; Tristyrylphenol EthoxylateSulfate; Bis(2-hydroxyethyl)tallowalkylamines. (i) microcrystallinecellulose or microcrystalline cellulose combined with at least onematerial selected from the group consisting of: lactose monohydrate;xylitol; lactose anhydrous; mannitol; sucrose; glucose; sodium chloride;talc; kaolin; calcium carbonate; malic acid; tartaric acid; trisodiumcitrate dihydrate; D,L-Malic acid; sodium pentane sulfate; sodiumoctadecyl sulfate; Brij700; Brij76; sodium n-lauroyl sacrosine;lecithin; docusate sodium; polyoxyl-40-stearate; Aerosil R972 fumedsilica; sodium lauryl sulfate or other alkyl sulfate surfactants with achain length between C5 to C18; polyvinyl pyrrolidone; sodium laurylsulfate and polyethylene glycol 40 stearate, sodium lauryl sulfate andpolyethylene glycol 100 stearate, sodium lauryl sulfate and PEG 3000,sodium lauryl sulphate and PEG 6000, sodium lauryl sulphate and PEG8000, sodium lauryl sulphate and PEG 10000, sodium lauryl sulfate andBrij700, sodium lauryl sulfate and Poloxamer 407, sodium lauryl sulfateand Poloxamer 338, sodium lauryl sulfate and Poloxamer 188; Poloxamer407, Poloxamer 338, Poloxamer 188, alkyl naphthalene sulfonatecondensate/Lignosulfonate blend; Calcium Dodecylbenzene Sulfonate(Branched); Diisopropyl naphthalenesulphonate; erythritol distearate;linear and branched dodecylbenzene sulfonic acids; Naphthalene SulfonateFormaldehyde Condensate; nonylphenol ethoxylate, POE-30; PhosphateEsters, Tristyrylphenol Ethoxylate, Free Acid; Polyoxyethylene (15)tallowalkylamines; sodium alkyl naphthalene sulfonate; sodium alkylnaphthalene sulfonate condensate; sodium alkylbenzene sulfonate; sodiumisopropyl naphthalene sulfonate; Sodium Methyl Naphthalene; FormaldehydeSulfonate; sodium salt of n-butyl naphthalene sulfonate; tridecylalcohol ethoxylate, POE-18; Triethanolamine isodecanol phosphate ester;Triethanolamine tristyrylphosphate ester; Tristyrylphenol EthoxylateSulfate; Bis(2-hydroxyethyl)tallowalkylamines. (j) Kaolin combined withat least one material selected from the group consisting of: lactosemonohydrate; xylitol; lactose anhydrous; mannitol; microcrystallinecellulose; sucrose; glucose; sodium chloride; talc; kaolin; calciumcarbonate; malic acid; tartaric acid; trisodium citrate dihydrate;D,L-Malic acid; sodium pentane sulfate; sodium octadecyl sulfate;Brij700; Brij76; sodium n-lauroyl sacrosine; lecithin; docusate sodium;polyoxyl-40-stearate; Aerosil R972 fumed silica; sodium lauryl sulfateor other alkyl sulfate surfactants with a chain length between C5 toC18; polyvinyl pyrrolidone; sodium lauryl sulfate and polyethyleneglycol 40 stearate, sodium lauryl sulfate and polyethylene glycol 100stearate, sodium lauryl sulfate and PEG 3000, sodium lauryl sulphate andPEG 6000, sodium lauryl sulphate and PEG 8000, sodium lauryl sulphateand PEG 10000, sodium lauryl sulfate and Brij700, sodium lauryl sulfateand Poloxamer 407, sodium lauryl sulfate and Poloxamer 338, sodiumlauryl sulfate and Poloxamer 188; Poloxamer 407, Poloxamer 338,Poloxamer 188, alkyl naphthalene sulfonate condensate/Lignosulfonateblend; Calcium Dodecylbenzene Sulfonate (Branched); Diisopropylnaphthalenesulphonate; erythritol distearate; linear and brancheddodecylbenzene sulfonic acids; Naphthalene Sulfonate FormaldehydeCondensate; nonylphenol ethoxylate, POE-30; Phosphate Esters,Tristyrylphenol Ethoxylate, Free Acid; Polyoxyethylene (15)tallowalkylamines; sodium alkyl naphthalene sulfonate; sodium alkylnaphthalene sulfonate condensate; sodium alkylbenzene sulfonate; sodiumisopropyl naphthalene sulfonate; Sodium Methyl Naphthalene; FormaldehydeSulfonate; sodium salt of n-butyl naphthalene sulfonate; tridecylalcohol ethoxylate, POE-18; Triethanolamine isodecanol phosphate ester;Triethanolamine tristyrylphosphate ester; Tristyrylphenol EthoxylateSulfate; Bis(2-hydroxyethyl)tallowalkylamines. (k) Talc combined with atleast one material selected from the group consisting of: lactosemonohydrate; xylitol; lactose anhydrous; mannitol; microcrystallinecellulose; sucrose; glucose; sodium chloride; kaolin; calcium carbonate;malic acid; tartaric acid; trisodium citrate dihydrate; D,L-Malic acid;sodium pentane sulfate; sodium octadecyl sulfate; Brij700; Brij76;sodium n-lauroyl sacrosine; lecithin; docusate sodium;polyoxyl-40-stearate; Aerosil R972 fumed silica; sodium lauryl sulfateor other alkyl sulfate surfactants with a chain length between C5 toC18; polyvinyl pyrrolidone; sodium lauryl sulfate and polyethyleneglycol 40 stearate, sodium lauryl sulfate and polyethylene glycol 100stearate, sodium lauryl sulfate and PEG 3000, sodium lauryl sulphate andPEG 6000, sodium lauryl sulphate and PEG 8000, sodium lauryl sulphateand PEG 10000, sodium lauryl sulfate and Brij700, sodium lauryl sulfateand Poloxamer 407, sodium lauryl sulfate and Poloxamer 338, sodiumlauryl sulfate and Poloxamer 188; Poloxamer 407, Poloxamer 338,Poloxamer 188, alkyl naphthalene sulfonate condensate/Lignosulfonateblend; Calcium Dodecylbenzene Sulfonate (Branched); Diisopropylnaphthalenesulphonate; erythritol distearate; linear and brancheddodecylbenzene sulfonic acids; Naphthalene Sulfonate FormaldehydeCondensate; nonylphenol ethoxylate, POE-30; Phosphate Esters,Tristyrylphenol Ethoxylate, Free Acid; Polyoxyethylene (15)tallowalkylamines; sodium alkyl naphthalene sulfonate; sodium alkylnaphthalene sulfonate condensate; sodium alkylbenzene sulfonate; sodiumisopropyl naphthalene sulfonate; Sodium Methyl Naphthalene; FormaldehydeSulfonate; sodium salt of n-butyl naphthalene sulfonate; tridecylalcohol ethoxylate, POE-18; Triethanolamine isodecanol phosphate ester;Triethanolamine tristyrylphosphate ester; Tristyrylphenol EthoxylateSulfate; Bis(2-hydroxyethyl)tallowalkylamines.
 17. The method of claim1, wherein a milling aid or combination of milling aids is used wherethe milling aid is selected from the group consisting of: colloidalsilica, a solid or semi solid surfactant, a liquid surfactant, asurfactant that can be manufactured into a solid or semisolid, apolymer, a stearic acid and derivatives thereof.
 18. The method of claim17, wherein the surfactant is selected from the group consisting of:polyoxyethylene alkyl ethers, polyoxyethylene stearates, poloxamers,sarcosine based surfactants, polysorbates, alkyl sulfates and othersulfate surfactants, ethoxylated castor oil, polyvinylpyrrolidones,deoxycholate based surfactants, trimethyl ammonium based surfactants,lecithin and other phospholipids and bile salts.
 19. The method of claim17, wherein the surfactant is selected from the group consisting of:sodium lauryl sulfate, sodium docusate, sodium deoxycholate,N-lauroylsarcosine sodium salt, benzalkonium chloride, cetylpyridiniumchloride, cetylpyridinium bromide, benzethonium chloride, PEG 40stearate, PEG 100 stearate, poloxamer 188, Brji 72, Brji 700, Brji 78,Brji 76, Cremophor EL, Cremophor RH-40, Dehscofix920, Kollidon 25,Kraftsperse 1251, Lecithin, Poloxamer 407, polyethyleneglycol 3000,polyethyleneglycol, 8000, polyvinylpyrrolidone, sodiumdodecylbenzenesulphonic acid, sodium octadecyl sulphate, sodium pentanesulphonate, soluplus HS15, Teric305, Tersperse 2700, Terwet 1221, Terwet3785, Tween 80 and polysorbate
 61. 20. The method of claim 17, whereinthe milling aid has a concentration selected from the group consistingof: 0.1-10% w/w, 0.1-5% w/w, 0.1-2.5% w/w, of 0.1-2% w/w, 0.1-1%, 0.5-5%w/w, 0.5-3% w/w, 0.5-2% w/w, 0.5-1.5%, 0.5-1% w/w, of 0.75-1.25% w/w,0.75-1% and 1% w/w. 21.-47. (canceled)